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7ABSTRACT
Obesity is a major health problem and is increasing rapidly both in developed and developing
countries worldwide. Treatment of obesity is difficult, expensive and often fails. Obesity increases
the likelihood for many diseases, such as type 2 diabetes, coronary heart disease, metabolic
syndrome, hyperlipidemia and some types of cancer. We still lack a meaningful understanding of
the factors behind this complex disease and therefore any proper means to battle it. Only lately,
adipose tissue and especially its mitochondria have been recognized as important contributors to
whole-body energy balance and the development of obesity.
This thesis investigates the biological pathways in adipose tissue that lead to the development of
metabolic complications in early-onset obesity in young healthy twins. The aim was to study how
acquired obesity affects adipose tissue and adipocyte function and how these link to whole body
metabolism. The rare weight-discordant monozygotic (MZ) co-twin setting used in this study, is
uniquely positioned to disentangle acquired and inherited metabolic pathways to disease in obesity.
MZ twin pairs discordant for obesity enable controlling for genetic background, age, sex and early
environmental influences. As MZ twins are fully identical at the level of genome sequence, the
observed differences between co-twins can be assumed to be acquired. This is a major strength of
our study regarding a polygenic and multifactorial trait as obesity.
Adipocyte hypertrophy in adipose tissue is one of the main features of obesity. The first study of the
thesis investigated adipose tissue hypertrophy and hyperplasia in acquired obesity and its
associations with whole body metabolism and gene expression pathways of the adipose tissue. We
showed a high within-pair resemblance in adipocyte size and number suggesting that the adipocyte
phenotype is genetic or due to shared environmental factors. Hypertrophy and low number of
adipocytes in acquired obesity was related to metabolic dysfunction in obesity and associated with
the disturbances in mitochondrial function and with increased cell death within the adipose tissue.
In the second study we investigated how transcriptional pathways of subcutaneous adipose tissue
and the liver fat associate with “metabolically healthy obesity” – a phenomenon where some of the
obese individuals stay free from the metabolic complications usually associated with weight gain.
We showed for the first time in twins that the amount of liver fat is a key clinical determinant of
metabolic health and that low liver fat associates with maintenance of high mitochondrial
transcription and lack of inflammation in subcutaneous adipose tissue.
In further investigations we addressed mitochondrial biogenesis and oxidative metabolism in detail.
The third and fourth studies concentrated on mitochondrial biogenesis in adipose tissue and in
adipocytes, respectively. The novel findings in the third study were that obesity is related to reduced
mitochondrial mass and oxidative metabolic activity in subcutaneous adipose tissue, both on the
nuclear and on the mitochondrial transcription level, as well as to decreased protein levels in the
OXPHOS system, especially OXPHOS complex subunits I and IV. The mitochondrial ‘dysfunction’
paralleled whole body insulin resistance and low-grade systemic inflammation. Remarkably, these
changes were seen already in the early stages of acquired obesity. In the fourth study, we showed
that the global downregulation of mitochondrial transcriptional signature in acquired obesity
originates at least partly from the adipocyte cells of adipose tissue.
8This research resulted in better understanding of the factors behind metabolic complications in
acquired obesity. Development of obesity seems to associate with mitochondrial dysfunction in
adipose tissue. The decreased function of mitochondria was evident at the level of both nuclear gene
expression level and mitochondrial gene expression, as well as mitochondrial protein levels. These
changes associated with metabolic disturbances of obesity. With rare obesity-discordant MZ twins
we  have  been  able  to  show  that  these  changes  are  not  genetic  but  result  from  acquired  factors.
However, as there was a remarkable similarity of adipocyte size and especially number between the
co-twins, responses to obesity may have a partial genetic basis. With low capacity to adipocyte
hypertrophy,  excess  fat  may  accumulate  to  liver  and  other  tissues.  Liver  fat  content  is  a  clear
determinant of metabolic health in acquired obesity. The results of my thesis as a whole suggest that
obesity-associated metabolic disturbances might be halted by improving mitochondrial activity in
adipose tissue.
TIIVISTELMÄ (in Finnish)
Lihavuus on nykyisin yksi merkittävimpiä kehittyneiden maiden kansanterveydellisiä ongelmia ja
lisääntymässä nopeasti. Lihavuuden lääketieteellinen hoito on vaikeaa, kallista ja epäonnistuu usein.
Lihavuus aiheuttaa metabolisia häiriöitä, kuten insuliiniresistenssiä, tyypin 2 diabetesta,
sydänsairauksia, metabolista syndroomaa, ja veren kohonneita rasva-arvoja. Lihavuuden syistä ei
ole edelleenkään kokonaisvaltaista ymmärrystä. Vasta viime vuosina on huomattu, että rasvakudos
ja erityisesti sen mitokondrioiden toiminta ovat keskeisessä asemassa koko kehon
aineenvaihdunnassa ja lihavuuden kehittymisessä.
Väitöskirjani käsittelee nuorten terveiden kaksosten rasvakudoksen varhaisia
aineenvaihduntamuutoksia ja insuliiniresistenssiä hankitussa lihavuudessa. Mielenkiinnon kohteena
on, kuinka lihavuus vaikuttaa rasvakudoksen ja rasvasolujen toimintaan ja koko kehon metaboliaan.
Näitä muutoksia tutkitaan harvinaisten identtisten mutta eripainoisten kaksosten avulla. Tässä
asetelmassa voidaan ainutlaatuisesti kontrolloida geneettinen tausta, ikä, sukupuoli ja aikaiset
rasvakudokseen vaikuttavat ympäristötekijät ja näin erottaa hankitut ja periytyvät syyt lihavuuden
aiheuttamien ongelmien synnyssä. Eroavaisuudet geeneiltään identtisten kaksosten välillä voidaan
olettaa ympäristötekijöistä johtuviksi. Tarkoitukseen käytettävä suomalainen kaksosaineisto on
kansainvälisesti merkittävä ja ainutlaatuinen. Kaksosasetelma on myös suuri vahvuus
monitekijäisen sairauden, kuten lihavuuden, tutkimisessa.
Lihavuudessa erityisesti rasvakudoksen solujen koko kasvaa (hypertrofia). Ensimmäisessä
väitöskirjan osatutkimuksessa selvitimme miten rasvasolujen suuri koko on yhteydessä
rasvakudoksen geenien toimintaan ja koko kehon aineenvaihduntaan. Lihavuudessa havaittu
rasvasolujen hypertrofia ja hypoplasia eli suuri koko ja pieni rasvasolumäärä olivat geneettisesti
säädeltyjä ja yhdistyivät aineenvaihdunnan ongelmiin ja geenireitteihin, jotka liittyivät
heikentyneeseen mitokondrioiden toimintaan ja lisääntyneeseen rasvakudoksen solukuolemaan.
Toisessa osatutkimuksessa selvitimme kehon rasvavarastojen ja rasvakudoksen geenireittien
merkitystä ”metabolisesti terveillä” lihavilla, joille ei näytä ilmaantuvan lihavuuteen liittyviä
metabolisia ongelmia. Havaitsimme ensimmäisinä, että maksan rasvamäärä voi olla merkki
9metabolisten ongelmien kehittymisestä lihavuudessa. Mitokondrioiden aktiivisuus ja vähäinen
rasvakudoksen tulehdus olivat yhteydessä matalaan maksan rasvapitoisuuteen ja ”metabolisesti
terveeseen” lihavuus – ilmiöön.
Väitöskirjan kolmas ja neljäs osatyö käsittelivät tarkemmin rasvakudoksen ja rasvasolujen
mitokondrioiden toiminnan häiriötä lihavuudessa ja mitokondrioiden toiminnan yhteyttä kehon
aineenvaihduntamuutoksiin. Mitokondriot ovat solun energiatehtaita, jotka tuottavat solun
tarvitseman energian ATP-yhdisteen muodossa. Mitokondriot tuottavat myös solun kasvuun,
jakautumiseen ja erilaistumiseen tarvittavat yhdisteet ja niillä on oma pieni genominsa, jolla ne
koodaavat osan omista rakenneosistaan. Kolmannessa työssämme näytimme ensimmäistä kertaa,
että hankittu lihavuus vähentää mitokondrioiden massaa ja hengitysketjun toimintaa
rasvakudoksessa. Mitokondrioiden toiminnan vähentyminen oli näkyvissä niin tuman koodaamien
mitokondriaalisten geenien ja niitä säätelevien geenien ilmentymisenä, mitokondrion genomin
kopiolukumäärän pienenemisenä, mitokondrion omien geenien ilmentymisen vähemenisenä kuin
mitokondrion hengitysketjun proteiinien vähentyneinä määrinä. Näytimme myös ensimmäistä
kertaa hengitysketjun komponenttien I ja IV vähentyneet määrät lihavuudessa. Mitokondrion huono
toiminta yhdistyi aineenvaihdunnan ongelmiin, insuliiniresistenssiin ja tulehdusmerkkiaineiden
suurentuneisiin pitoisuuksiin veressä. Sama mitokondriaalisen toiminnan väheneminen ja sen yhteys
kehon huonontuneeseen rasva- ja sokeriaineenvaihduntaan oli nähtävissä väitöskirjan neljännessä
osatyössä myös rasvasoluissa. Huomattavaa oli, että muutokset mitokondrioiden toiminnassa ja
kehon metaboliassa olivat näkyvissä jo lihavuuden aikaisessa vaiheessa, nuorilla ja terveillä lihavilla
kaksosilla.
Lihavuuden kehittyminen näyttää olevan yhteydessä rasvakudoksen mitokondrioiden toiminnan
häiriintymiseen. Häiriintynyt toiminta näyttäytyy sekä tuman koodaamien mitokondrioon liittyvien
geenien ilmentymisen kuin mitokondrion omien geenien toiminnan ja rakenneosasten määrän
tasolla yhdistyen koko kehon insuliiniresistenssiin, tulehdukseen ja rasvakudoksen varhaisiin
epäedullisiin aineenvaihdunnan muutoksiin. Harvinaisten identtisten mutta eripainoisten kaksosten
avulla olemme voineet osoittaa, että muutokset geenien ilmenemisessä ja aineenvaihdunnassa
johtuvat hankitusta lihavuudesta eivätkä geneettisistä tekijöistä. Geneettistä näyttää puolestaan
olevan se, miten keho reagoi lihomiselle. Osa kaksosista kasvatti lihotessaan rasvasolun kokoa,
toiset taas pystyivät lisäämään koon lisäksi rasvasolujensa määrää. Suuri rasvasolun koko ja
vähäinen kapasiteetti lisätä niiden lukumäärää rasvakudoksessa näyttää aiheuttavan liian rasvan
kertymistä maksaan ja muualle sisäelimiin. Maksan rasvapitoisuuden perusteella voidaan
väitöskirjani mukaan mahdollisesti erottaa lihavat, jotka ovat alttiita lihomisen aiheuttamille
komplikaatioille ja insuliiniresistenssille. Väitöskirjani tuloksien perusteella lihavuuteen yhdistyviä
metabolisia häiriöitä voidaan mahdollisesti estää lisäämällä ja parantamalla mitokondrioiden
toimintaa rasvakudoksessa.
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1. INTRODUCTION
Obesity  is  a  major  health  problem  that  is  increasing  rapidly  all  over  the  world.  Obesity  causes
metabolic disturbances including insulin resistance and dyslipidemia. We still know very little of
the molecular causes and consequences of obesity. The contribution of genes versus environmental
factors to the development of metabolic complications in obesity is not known. Furthermore, not all
obese individuals (10-40%) develop these metabolic disturbances (1, 2) and the underlying
mechanisms are still unclear.
The enlarged adipocyte size or mitochondrial dysfunction in adipose tissue has been suggested to
play a role in the metabolic problems of obesity (3-5). Mitochondria are needed for the anabolic
functions of the cell and are essential for adipocyte differentiation (6). It has been proposed that
adipose tissue dysfunction and the impairment in metabolic health in obesity (7, 8) would be due to
the reduced oxygen consumption in obese adipose tissue (9), mediated by its mitochondria (10).
Many cross-sectional studies (11-15), although not all (16), have shown that body composition with
less visceral fat,  and less ectopic fat accumulation in liver (16) and skeletal muscle (12, 16), would
underlie a more metabolically healthy obese phenotype. The obese that accumulate metabolic
problems have been suggested to have limited capacity of adipose tissue expandability, impaired
adipocyte differentiation and thus limited capacity to store excess fat in adipose tissue, leading to
accumulation of fat in internal organs and other ectopic sites (17, 18). Adipocyte hypertrophy,
inflammation in adipose tissue and adipocyte dysfunction can be possible manifestations or
mechanisms behind this. These functions may be genetically determined. The reason for the
metabolic problems has however still remained unclear.
The TwinFat- study investigates the early gene expression differences in adipose tissue of young
healthy monozygotic twin pairs discordant for obesity and the relation of these changes to metabolic
alterations in glucose, insulin, lipids and other metabolic markers, body composition, inflammatory
cytokines and mitochondrial biogenesis between the co-twins. The specific aim of this thesis was to
study the gene expression pathways and the status of mitochondrial oxidative metabolism associated
with obesity.
In this thesis, rare MZ obesity-discordant co-twins are used to disentangle acquired and genetic
factors behind these pathways. Differences in investigated traits that correlate to weight-differences
between  the  co-twins  can  be  assumed  to  derive  from  acquired  factors  while  extreme  similarity
between the twins is taken as evidence of genetic effect. We have previously shown significant
differences in the global transcriptomic profiles of fat between the obese and non-obese identical
co-twins. We have also shown that in obese individuals, mitochondrial DNA copy-number is
downregulated, the expression of mitochondrial gene pathways reduced and inflammatory pathways
up-regulated in acquired obesity (4, 19). This defective function of oxidative pathway components
in mitochondria and the early phase of metabolic dysregulation in mitochondria seem to be key
components associated with the development of metabolic complications in obesity and adipose
tissue dysfunction. In addition to previous suggestions (4, 6, 20), the studies in this thesis have
provided evidence that the metabolic problems of obesity begin with adipose tissue dysfunction
including downregulation of mitochondrial biogenesis and function, and increased inflammation,
conditions which are closely linked to fatty liver, insulin resistance and other metabolic
complications.
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This thesis describes biological pathways in adipose tissue that lead to the development of metabolic
complications in obesity. The MZ twin co-twin setting, with twins of identical genome sequence,
gave a unique possibility of detecting differences between the co-twins, which can be assumed to be
acquired by obesity. Large adipocyte size and low adipocyte number in an individual associated
with the metabolic unhealthy profile in obese co-twins. The extreme similarity between the co-twins
in adipocyte number of the body suggested that adipocyte number and thus the expansion capacity
of adipose tissue is genetically determined. The expandability of adipose tissue in turn relates to
increase in liver fat amount and to the metabolic complications of obesity. Twins who had high liver
fat content and large adipocytes were metabolically unhealthier than twins with low liver fat content
and many small adipocytes in their adipose tissue. The increase in adipocyte volume, especially in
the metabolically unhealthy twins was related to the downregulation of mitochondrial transcriptional
pathways. The downregulation of mitochondria-related gene expression pathways, reduced
mitochondrial DNA amount, downregulation of mitochondrial DNA transcripts and reduced levels
of oxidative phosphorylation (OXPHOS) protein subunit levels in adipose tissue and adipocytes in
obesity confirmed a widespread downregulation of mitochondrial biogenesis in obesity, associating
with the metabolic derangements of acquired obesity.
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2. REVIEW OF THE LITERATURE
2.1. Obesity – prevalence, complications and current treatment
Obesity is a major global health problem. In a large study conducted between 1980 and 2008, the
prevalence of obesity doubled in every region of the world (21). In 2008, about 1.5 billion people
were estimated to be overweight (BMI body mass index over 25 kg/m2), 500 million of which were
obese  (BMI  over  30  kg/m2)  (21).  In  2012,  52%  of  European  adults  (OECD  Health  at  a  glance,
Europe 2012) and 68% of adults in United States (22) could be characterized as overweight or obese.
Childhood obesity has tripled in the last 30 years leading to health problems already at a young age
(23). The rapid increase in the prevalence of obesity is mainly due to changing lifestyle factors; diet,
eating behaviors (24, 25) and diminished exercise (26). Other factors linked to the development of
obesity include genetic features (27), lack of sleep, psychosocial stress, viral and bacterial infections,
fetal overnutrition, increasing gravida age (28) and gut microbiota (29).
Excess adiposity is associated with various disorders. Metabolic syndrome, insulin resistance, type
2 diabetes, hypertension, hyperlipidemias, atherosclerosis and cardiovascular diseases are major
consequences of obesity (WHO: Obesity and overweight, Fact sheet N°311, Updated January 2015),
(30). Metabolic syndrome often accompanies obesity and precedes type 2 diabetes and other
complications of obesity including insulin resistance of the tissues, hypertension and dyslipidemia
(31). Obesity-associated type 2 diabetes develops, when insulin secretion from pancreas is no longer
sufficient for the needs of the insulin resistant tissues (32, 33). Obese individuals show an impaired
blood vessel endothelial function (34, 35), linking obesity to the development of arterial stiffness
and atherosclerosis. A chronic systemic and local low-grade inflammation is perceived in obesity
and related to other undesirable metabolic changes (36). Stroke, congestive heart failure, pulmonary
embolism, asthma, gallbladder disease (37) and gout are more common in obese than in lean persons.
In addition, obesity increases the risk of breast, ovarian, endometrial, colorectal, esophageal, kidney,
pancreatic and prostate cancers (WHO: Obesity and overweight, Fact sheet N°311, Updated January
2015) (30, 37). Excess weight gain can also lead to mechanical problems like obstructive sleep apnea
(38), chronic pain and osteoarthritis (37). Psycho-social problems, increased probability of
depression (39) and eating disorders may reduce the quality of life in obesity. Many of these factors
are also linked to reduced life expectancy or premature death.
Treatment of obesity is difficult. Dietary and lifestyle modifications and exercise can be effective in
the treatment, but changes in them can also be difficult to maintain. There is still a large need for an
effective therapy to reverse the obese and diabetic phenotypes without side effects.
The diets generally used to combat obesity include low-caloric, low-fat, low-carbohydrate and very-
low-calorie diets (40). However, when comparing all four diets no differences in the total weight
loss after two years have been found (41). Generally, it is believed that the diet best suitable for the
obese patient’s taste is the best diet to that individual person. Exercise has proven important in
maintaining weight loss achieved through caloric restriction (42), even though exercise alone seems
to result in only very modest weight loss (43). Obesity surgery has proven beneficial and has helped
patients with BMI ≥ 35 kg/m2, but here too the results have sometimes been difficult to predict: while
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some obese acheived significant weight loss, some did not lose enough weight and then there were
some who continued to lose weight until anorexia.
Currently there are three drugs approved in Europe to treat obesity; orlistat, which inhibits pancreatic
and gastric lipases that break triclycerides; glucagon-like peptide 1 receptor (GLP1R) agonist
liraglutide, which increases insulin secretion and inhibits hyperglycaemia; and a combination of
naltrexone–bupropion, which works by antagonizing the opioid system. Although these compounds
have resulted in 3-12% weight loss, they also have various negative side effects and do not benefit
all patients (44).
2.2. Fundamentals of adipose tissue and adipocytes
2.2.1. Adipose tissue in health and disease
Previously, white adipose tissue was thought to be a mere repository for the excess energy in the
form of triglycerides. In recent decades, adipose tissue has been shown to be an important endocrine
organ functioning in the regulation of whole-body metabolism, energy intake and fat storage and is
thus also a major contributor in the metabolic consequences of obesity (45). Adipocyte lipid uptake
and storage as triglycerides allows for expansion of adipose tissue and is an adaptive response to
overnutrition, protecting other tissues from excess lipids. Beyond their role in nutrient handling and
metabolism, adipocytes are highly active secretory cells producing hormones, adipokines and
chemokines that contribute to immunity, inflammation, vascular growth and matrix remodeling (46).
Adipose tissue is one of the largest organs in the body. Obesity causes excess fat accumulation into
adipose tissue, testing the limits of its storage capacity. A general assumption is that when adipose
tissue storing capacity is exceeded, fat starts to accumulate in internal organs, causing metabolic
problems in the whole body (17, 47).
2.2.2. White adipose tissue distribution
White adipose tissue is divided into different depots, mainly subcutaneous and visceral adipose
tissue (omental, mesenteric, retroperitoneal, pericardial and gonadal fat) as well as ectopic (intra-
hepatic, intra-muscular, intra-pancreatic) fat, all of which have different characteristics and
contributions to whole-body metabolism. Subcutaneous adipose tissue (SAT) is the largest body fat
reserve and in total over 4-5 times larger than visceral adipose tissue (48, 49). Subcutaneous fat is
divided between upper and lower body in a sex-specific manner (50) and both compartments
contribute differently to the metabolic function of the body (51-53). Subcutaneous adipose tissue
stores ~80-90% of the total body fat, mainly in the abdominal (around the waist), subscapular (on
the upper back), gluteal and femoral (thigh) areas (48, 54). A smaller portion of the body fat (10-
20% depending on sex and the individual) resides viscerally in the abdominal cavity (49).
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2.2.3. Characteristics of white adipose tissue
White adipose tissue represents around 10%-20% of total body-weight in lean adults, but can
achieve over 50% or even up to 70% in obese persons (55). Approximately 75% of the adipose tissue
weight consists of lipids (56). The rest is an adipose tissue matrix, which includes collagen, blood
vessels and lymphatic vessels as well as endothelial cells, smooth muscle cells, pericytes, immune
cells (macrophages, lymphocytes and other inflammatory cells), fibroblast-like preadipocytes and
adipocyte mesenchymal stem cells (ASCs) that together constitute the stromal vascular fraction
(SVF) of the adipose tissue (53, 57). Adipose stem cells commit to preadipocytes – adipose precursor
cells. (58-60). These cells are responsible for the maintenance, renewal and expansion potential of
white adipose tissue in the normal and in the excess energy state (60). In response to energy needs,
adipose tissue expands by increasing the cell size (hypertrophy) or the cell number (hyperplasia) in
the tissue. 95% (61) of an adipocyte consists of triglycerides, which are stationed as one large lipid
droplet inside the cell. The rest of an adipocyte is a small cytoplasm with all the cell organelles and
an adipocyte cell membrane spanning around the cytoplasm and the lipid droplet. The fat stored is
composed primarily of triglycerides and cholesteryl esters. Adipocyte mitochondria reside in the
cytoplasm.
Figure 1: Adipocyte structure
Figure 1: Adipocyte structure. Triglycerides are stationed as one large lipid droplet inside the cell.
Nucleus and other cell organelles are packed into a small space at the cell boundary. The cell
membrane spans around the cytoplasm and the lipid droplet. Adipocyte mean size often ranges from
60 to 120 μm, but can be larger or smaller depending on the individual and the body fat mass.
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2.2.4. Other types of adipose tissue
White adipose tissue is the most prevalent and largest adipose tissue depot. However, also other
types of adipose tissue exist. Brown adipocytes have different morphological and functional features
than white adipocytes. They are smaller in size, with only ~50% of the cell volume occupied by
lipids, which are divided into several small droplets inside the cell (62). Brown adipocytes in humans
reside in small areas around the large blood vessels, especially in the supraclavicular region (62).
Brown adipocytes do not store energy but dissipate it by producing heat. Their activity is regulated
by the sympathetic nervous system (63). New research has also established a “beige” or “brite”
adipocyte population that has characteristics of both white and brown adipocytes. These cells have
thought to be in transition state between white and brown adipocytes and have the capacity to turn
into either of them (62).
2.3.  Fundamentals of mitochondria
2.3.1. Adipose tissue mitochondria in health and disease
The role of mitochondria in adipocytes was long neglected, perhaps because of their low abundance
in these cells. Recent evidence has however shown that mitochondria in adipocytes are at the core
of the energy metabolism of the cell, in healthy state actively controlling lipid turnover, producing
ATP and substrates for cell metabolism as well as controlling the generation of new adipocytes,
apoptosis and other essential functions of the cell (6, 64). Excess fat accumulation in obesity has
been associated with mitochondrial dysfunction and impaired glucose and lipid metabolism in
adipose tissue (6, 64, 65). In obese mice, a decrease in mitochondrial mass and function has been
observed (66), as well as decrease in mitochondrial DNA (mtDNA) amount (67). Lower oxygen
consumption rates in obese human preadipocytes compared with lean subjects have been recorded
(68), and a reduced mitochondrial DNA copy-number in obese co-twins compared with their leaner
counterparts (4). In healthy as well as in diseased state adipose tissue and its mitochondria have an
important role in whole body metabolism.
2.3.2. Characteristics of mitochondria
Mitochondria in humans are organelles essential for the cell function, regulating many metabolic
pathways by which chemical energy (from carbohydrates, lipids and proteins) is converted into
energy-substrate ATP. Pyruvate oxidation, tricarboxylic acid (TCA) cycle, fatty acid β-oxidation
and oxidative phosphorylation (OXPHOS) take place in mitochondria (69).
Mitochondria have two membranes; the outer membrane and the inner membrane, which is folded
into cristae. These membranes divide mitochondria into the intermembrane space and an inner
matrix subcompartments. The folded inner membrane houses the respiratory chain complexes (I-
IV) and the ATP-synthase (complex V), which comprise the essential units of OXPHOS dependent
energy production in the cell. The OXPHOS pathway consists of circa 90 protein subunits that are
assembled into five complexes; Complex I (NADH dehydrogenase, 45 subunits), complex II
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(succinate dehydrogenase, 4 subunits), complex III (cytochrome bc 1, 11 subunits), complex IV
(cytochrome oxidase, COX, 13 subunits), and complex V (ATP synthase, 17 subunits) (70). In
addition to the OXPHOS complexes, the respiratory chain has two mobile electron shuttles,
ubiquinone (Coenzyme Q, CoQ), and cytochrome c (cyt c), a heme-containing small polypeptide.
Mitochondria possess their own multicopy genome, a 16.6 kb circular mitochondrial DNA (mtDNA)
residing in the inner matrix. A special feature of this mtDNA is that it is inherited maternally. The
mtDNA encodes two ribosomal RNAs (12S and 16S), 22 transfer RNAs, and 13 polypeptides (71).
The two mtDNA-encoded rRNAs are constitutents of mitochondrial ribosomes; 12S RNA in the
small 28S subunit and 16S RNA in the large 39S subunit of a mitochondrial ribosome (72, 73). In
addition, 78 other structural proteins of mitochondrial ribosomes are encoded in the nucleus. The
mitochondrial ribosomes are assembled in the mitochondria from nuclear-encoded proteins and the
mitochondria-encoded RNAs. Mitochondrial ribosomes translate the mtDNA-encoded transcripts
into the protein subunits of the OXPHOS complexes in the inner mitochondrial membrane (72).
The 13 mtDNA-encoded proteins are the core catalytic components of the OXPHOS complexes I,
III,  IV,  and V (74).  The remaining OXPHOS proteins are  encoded in the nucleus.  Complex II  is
solely nuclear-encoded. Also, about 1500 other mitochondrial proteins that are encoded in the
nucleus —involving approximately 8% of all nuclear genes—act in mitochondrial maintenance,
transcription and as structural components (75). These proteins are synthesized on cytoplasmic
ribosomes and imported into mitochondria, where they are sorted into different compartments (76,
77). The nuclear-encoded subunits of the OXPHOS complexes translocate across the mitochondrial
membrane (78) and are assembled into complexes with the mtDNA-encoded subunits. The
OXPHOS complexes then bond together into larger “supercomplexes” (79) that facilitate the
oxidative phosphorylation process and stabilize the complexes (80, 81). Mitochondrial ribosomes
and  the  OXPHOS  system  are  the  only  cellular  entities  that  are  encoded  by  both  nuclear  and
mitochondrial genomes.
2.3.3. Functions of mitochondria
Mitochondria are required for both catabolic and anabolic functions in the cell (Figure 2). Energy
production through an oxidative phosphorylation process (OXPHOS) is the best known function of
mitochondria. Oxidative phosphorylation transforms the energy from digested carbohydrates, amino
acids and fatty acids into ATP compounds for the cell to use. Oxidation of the energy substrates
happens through the electron transport chain in the inner mitochondrial membrane. Complexes I, III
and IV generate a potential difference across the inner mitochondrial membrane. Electrons derived
from reducing agents of NADH and FADH2 from the TCA cycle or fatty-acid oxidation are shuttled
through complexes I–IV to oxygen while forming water. The energy derived from this electron flux
is used to pump protons (H+) from the mitochondrial matrix to the intermembrane space (82). This
proton gradient is released by complex V (ATP-synthase) through a flow of electrons from NADH
or FADH2 to oxygen and energy is generated by phosphorylation of ADP into ATP (83, 84). The
complexes I, III and IV regulate the electron flux (85). The rate of ATP production is constrained
by the cellular need for ATP. The generated membrane potential is used for the essential functions
of mitochondria like protein import (76), fatty acid oxidation, generation of intermediary
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metabolites, and to trigger changes to alter mitochondrial behavior. While working, complexes I and
III  generate  reactive  oxygen  species  (ROS)  that  can  damage  cellular  proteins,  nucleic  acids  and
lipids (86). Disrupted electron flux leads both to energy depletion and to increased production of
reactive oxygen species (ROS) (87).
In detail, complex I (NADH ubiquinone oxidoreductase) catalyzes the oxidation of NADH by
Coenzyme Q (ubiquinone, CoQ). Complex I is the largest complex in the OXPHOS system (88).
Seven of its subunits are encoded by the mitochondrial genome. Complex II is the smallest
respiratory chain complex with four subunits, all encoded by nuclear genes. Complex III (ubiquinol–
cytochrome c reductase) catalyzes the electron transfer from reduced coenzyme QH2, (ubiquinol)
to cytochrome c. Complex III consists of 11 subunits (89) of which cytochrome b is encoded by the
mtDNA. Complex IV (cytochrome c oxidase, COX), is the terminal component of mitochondrial
respiratory chain and transfers electrons from reduced cytochrome c to molecular oxygen. COX is
composed of 13 subunits (90), of which three are mtDNA-encoded. Complex V (ATP synthase)
dissipates the proton electrochemical gradient generated by the respiratory chain across the inner
mitochondrial membrane to produce ATP. It comprises of a membrane-bound cylindrical rotor-like
structure, the F0 particle and a matrix-facing F1 particle, the catalytic ATP synthase domain (83).
All five subunits of F1 and all except two subunits of F0 are nuclear-encoded.
The mitochondrial tricarboxylic acid cycle (TCA) /citric acid cycle (Figure 3) in the mitochondrial
matrix generates the reducing equivalents NADH and FADH2, which donate electrons to the
electron transport chain, and energy compounds (ATP/GTP) for the cell to use. As its intermediate
products TCA creates substrates that are used for carbon skeletons of many non-essential amino
acids, needed for the synthesis of hemoglobin, myoglobin and various cytochromes, used for fatty-
acid synthesis and production of cholesterol (Acetyl-CoA), and exported from mitochondria to be
used in adipogenesis (citrate) in adipose tissue and gluconeogenesis in liver (oxaloacetate) (91).
Breakdown of excess amino acids and conversion of excess nitrogen into urea take place in
mitochondria. Fatty-acid β-oxidation in mitochondria converts dietary long chain fatty-acids to
Acetyl-CoA to be used in energy production (92). Mitochondria control many biosynthetic pathways
like steroid synthesis (93), Fe-S synthesis (94) and heme synthesis (95). They have an important role
in programmed cell death, also known as apoptosis (96). Mitochondrial also store calcium,
functioning as the calcium buffer of the cell, controlling cellular calcium signals and Ca2+ flux from
the plasma membrane and the endoplasmic reticulum (97).
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Figure 2: Mitochondrial functions in adipose tissue
Figure 2: Mitochondria have various functions in the cell. Amino acid (Aa) and branched-chain
amino acid (BCAA) catabolism and long-chain fatty acid oxidation occur in the mitochondrial
matrix. These together with cytoplasmic glycolysis produce Acetyl-CoA and other substrates for the
TCA cycle. TCA cycle generates energy for the cell in the form of ATP as well as reducing
equivalents (NADH, FADH2) for the electron transport chain. The electron transport chain in the
inner mitochondrial matrix transfers electrons from one complex to another and finally to complex
IV, which reduces oxygen to water. The transfer of electrons is coupled to the pumping of protons
into the intermembrane space by complexes I, III and IV. The resulting proton gradient is harnessed
by complex V, whereby the force driven by the flow of protons into the matrix is used to phosphylate
ADP to ATP. Mitochondrial DNA (mtDNA) transcription produces mRNAs and rRNAs, which are
structural parts of mitochondrial ribosomes and the OXPHOS complexes. A large number of
mitochondrial structural and functional proteins are however encoded in the nucleus and
transported into mitochondria. Mitochondria control Ca2+ signaling in the cell and cell apoptosis.
CI-CV = complexes 1-5 of oxidative phosphorylation (OXPHOS).
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Figure 3: TCA cycle
Figure 3: Tricarboxylic acid (TCA) cycle. Energy substrates converted into Acetyl-CoA enter the
TCA cycle. In intermediate steps, Acetyl-CoA is converted into different substrates and in due
course, reducing equivalents (NADH, FADH2), CO2 and energy (ATP, GTP) are generated.
2.3.4. Regulation of mitochondrial number and function in the cell
Mitochondria constantly remodel themselves by biogenesis, fusion and fission as well as by
travelling in the cell (98, 99). The cell regulates the function of its mitochondria based on its energy
needs. Pancreatic β-cells and muscle cells in a nutrient-rich environment have morphologically
fragmented mitochondria, but in starvation their mitochondria elongate (100, 101). In muscle studies
starvation increases mitochondrial ATP synthesis capacity (100) and increase in mitochondrial mass
and OXPHOS activity are observed after endurance exercise (102). Adipose tissue in nutrient excess
is suggested to be characterized by a decrease in mitochondrial function, biogenesis or content (103-
105). It has, however, remained controversial if there is a reduction in all or in only some of these
features.
The energy status information in the cell is transmitted through NAD+:NADH ratio, the AMP:ATP
ratio and Acetyl-CoA levels, which sense the signals of mitochondrial activity. Two key cellular
energy sensors are the AMP-activated protein kinase (AMPK) and a NAD+-dependent deacetylase
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SIRT1 (106, 107). AMPK enhances oxidative phosphorylation and other catabolic functions of the
cell, while suppressing cell proliferation and growth (108). SIRT1 regulates mitochondrial mass,
nutrient oxidation, and ATP production. Together, they act through the transcription cofactor,
peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α). By changing the
function, morphology, number, organization and distribution of the mitochondria within the cell, the
cell adapts to different energy demands, cell growth, cell death and differentiation (109).
Mitochondrial biogenesis needs an orchestrated induction of transcriptional regulators, activated by
energy demands (110). PGC-1α is one of the main inducers of mitochondrial oxidative metabolism
(111). PGC-1α interacts with various mitochondria-related transcription factors and hormone
receptors (112) to fine-tune mitochondrial metabolism, and has a major role both in adipogenesis
and mitochondrial biogenesis. The activity of PGC-1α is regulated by acetylation. In a normal state,
PGC-1α is acetylated and silenced. However, in nutrient excess, SIRT1 activates PGC-1α and
mitochondrial activity is enhanced (113). PGC-1α regulates the functions of TFAM, which controls
the transcription of mitochondrial proteins (114) and NRF-1, which is needed in the induction of
mitochondrial biogenesis (115). PGC-1α also targets estrogen-related receptor α (ERRα) and
GABPα to regulate the OXPHOS complexes including cytochrome c and ATP synthase (116, 117).
The transcription factor Forkhead box O 1, FOXO1, is another important mitochondrial regulator,
which enhances the expression of genes involved in mitochondrial lipid oxidation and oxidative
stress protection (118).
2.4. Functions of adipose tissue and its mitochondria
2.4.1. Adipogenesis and adipocyte turnover in adipose tissue
Adipose tissue enlarges by increasing adipocyte size (adipocyte hypertrophy), by recruitment of new
adipocyte cells in adipogenesis (hyperplasia), or both. Increase in the number of adipocytes
(hyperplasia) or turnover of the old cells is thought to happen throughout life by preadipocyte
differentiation (119, 120). A study on adipocyte turnover in white adipose tissue used C14 detection
to suggest that approximately 10% of the body's fat cells are regenerated each year at all adult ages
and levels  of  body mass index and that  the formation of  adipocytes  is  a  lifelong and a regulated
process (120). This study compared the levels of C14 in atmosphere versus in adipose tissue in
persons with different BMIs, born before and after the nuclear bomb tests of 1955, which caused a
rise  in  C14 in the atmosphere.  The levels  of  C14 have since decreased due to diffusion from the
atmosphere. Comparing the levels of atmospheric C14 at the time point when the persons were born
to the current C14 levels in their adipose tissue gave indication how many cells had been renewed
since  the  individuals  were  born.  The  number  of  adipocytes  in  adipose  tissue  seem  to  be  largely
determined by the ability of the limited number of preadipocytes to undergo the differentiation
process as well as the amount of mesenchymal stem cells that are available for differentiation into
new preadipocytes when necessary (121).
Adipocytes are believed to originate from mesenchymal stem cells, but the early steps leading the
mesenchymal  stem cells  to  commit  to  adipocyte  lineage  and  form the  adipocyte  precursor  cells,
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preadipocytes, have remained unknown (122). The cells that are capable of differentiating into full
mature adipocytes (adipose stem cells and preadipocytes) reside in the adipose stroma (59). The
adipocyte stem cells may originate from perivascular cells, at least partly, through transforming into
mural cells and then to a progenitor population (123, 124). However, not all adipose tissue originates
from the mesoderm. Mouse embryonic stem cells have been shown to be able to commit to adipocyte
lineage (125). Some recent studies in humans raise the possibility that hematopoietic stem cells from
bone-marrow (126) might give rise to a certain subset of adipocytes and also neuroepithelial cells
seem to have the capacity of generating adipocytes (127).
Adipogenesis means the differentiation of mesenchymal stem cells into fibroblast-like
preadipocytes, which then differentiate into mature lipid-rich adipocytes (128). In the first step of
the differentiation, the pluripotent stem cell commits to unipotent preadipocyte lineage, where it has
lost the capacity to differentiate into other cell types. In the second step called terminal
differentiation, preadipocytes undergo marked changes in their gene expression and morphology
and acquire the phenotype and characteristics of mature adipocytes. When adipocytes are fully
mature, they are incapable of differentiation and of cell division.
The maturation of stem cells into preadipocytes is dependent on the expression of extracellular
factors like transforming growth factor β (TGFβ), the bone morphogenetic proteins (BMPs), insulin-
like growth factor 1 (IGF1), interleukin 17 (IL17), activin, fibroblast growth factor 1 (FGF1), and
FGF2 (129). Silencing of Wnt signaling (130) and Hedgehog signaling (131) pathways are important
for the differentiation to proceed.
Changes from preadipocytes to adipocytes include becoming sensitive to insulin, expressing fatty-
acid-binding protein (422/aP2), lipoprotein lipase (LPL), adipsin and GLUT4 on the cell surfaces
and beginning the uptake of glucose, induced by insulin (132). This terminal differentiation step is
dependent primarily on the transcription factors PPARγ (115, 133), its activator PGC-1α, as well as
transcription factor C/EBPα (134), sterol regulatory element-binding protein-1 (SREBP1) (135),
mTORC (136) and the forkhead transcription factor FOXO1 (137), the latter of which may link the
effects of insulin to the differentiation process. Low levels of these factors are found in
preadipocytes, but during adipocyte differentiation their expression increases (133). PGC-1α and
mTORC1 (138), enhance adipogenesis through their effect on PPARγ, but also independently by
enhancing insulin sensitivity of the differentiating preadipocytes (139).
Mitochondria have been recognized as essential effectors in adipocyte differentiation and
adipogenesis (6). The first microscopic observations on changes in mitochondrial number and
morphology during adipogenesis were made already in 1962 (140, 141). The increased oxygen
consumption of preadipocytes during the differentiation process was thought to be evidence of
increased mitochondrial biogenesis (66, 142, 143). A 20- to 30-fold increase in the concentration of
mitochondrial proteins during adipose differentiation and marked changes in mitochondrial
morphology have been recorded (66).
Coordination between adipogenesis and mitochondrial biogenesis is supported by the fact that the
same transcription factors are needed in both processes. PPARγ, C/EBPα, CREB, (133), estrogen-
related receptor α (ERRα) (144) and PGC-1α are all major regulators of mitochondrial biogenesis,
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adipogenesis and body energy balance (145). The link between mitochondrial biogenesis and
adipogenesis was demonstrated by treatment of adipocytes with rosiglitazone, a PPARγ agonist,
which caused marked alterations in mitochondrial morphology and density (142), suggesting that
the nuclear-encoded mitochondria-related genes are under major control of PPARγ, a strong inducer
of adipogenesis (133).
Mitochondria, or their dysfunction, may also inhibit adipogenesis. Mitochondrial reactive oxygen
species (ROS) production by complexes I and the ATP-synthase inhibit proliferation of 3T3-L1
mouse preadipocytes (146) and prevent adipocyte differentiation in mice (147). However, ROS
levels are also believed to play an important role in signalling during the differentiation (148). Thus
it seems that the amount and the duration of ROS effect are critical in the initiation of normal versus
pathological responses in adipocyte differentiation. Normal mitochondrial function is needed to
enable  and  drive  adipogenesis  in  adipose  tissue  and  defects  in  this  might  thus  affect  the
differentiation capacity and possibly the expansion potential of the tissue.
Figure 4: Adipogenesis
Figure 4: Mesenchymal stem cells differentiate into preadipocytes. This is initiated and enhanced
by IL17, FGF1 and 2, TGFβ, bone morphogenic proteins (BMPs) and activin. Silencing of Wnt
signaling and Hedgehog signaling is needed. Preadipocytes differentiate into lipid-laden
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adipocytes. Here, PGC-1α, FOXO1, C/EBPα, KLF5, SREBP-1, mTORC and C/EBPβ function as
main regulators and enhancers.
2.4.2. Lipogenesis and lipolysis
The key function of adipose tissue is to, depending on the body energy state, expand and store excess
energy in the form of triglycerides (lipogenesis), or release them into circulation and other tissues
as free fatty acids (FFA) (lipolysis) when needed. 1000g of fat contains 800g of triglycerides and
circa 7000 kcal of energy. An average life span of an adipocyte in subcutaneous white fat is 9.5
years, during which time its lipid storage is replaced six times on average (120). In obese state there
is increased lipid storage and decreased lipid removal compared to lean persons meaning an overall
increased lipid turnover rate (120).
Lipogenesis refers to the FFA or glucose uptake into adipocytes and their subsequent synthesis into
triglycerides  (TAG’s)  (149).  Activation  of  adipose  tissue  lipoprotein  lipase  (LPL)  is  crucial  for
lipogenesis. LPL is synthesized by adipocytes and transferred into the capillary endothelial lumen,
where it liberates FFA’s from circulating chylomicron particles. The FFAs diffuse through capillary
endothelium, where they are taken up into adipocytes by fatty acid translocases (150). Two enzymes,
Acetyl-CoA carboxylase and fatty-acid synthase, use Acetyl-CoA and malonyl-CoA from glucose,
pyruvate or other carbon precursors to generate palmitate. This palmitate and the FFAs can then be
modified to produce multiple lipid species.
Mitochondria are essential in generating the intermediary metabolites needed in lipogenesis (6). The
generation of Acetyl-CoA for fatty acid activation and synthesis before their esterification into
triglycerides requires active mitochondria. Interventions that reduce mitochondrial ATP-generation
(151) or the uncoupling of the electron transport chain (152) are shown to decrease the rate of
lipogenesis in mice studies and thus fatty acid deposition into adipocytes. The activation of medium-
sized fatty acids for lipogenesis happens in the mitochondrial matrix. Long-chain fatty acids are
activated both in mitochondrial matrix and endoplasmic reticulum. Mitochondria are also an
important site for phospholipid synthesis and thus control the structure of the cell membrane (153).
Insulin is the key regulator of fatty acid uptake and metabolism in adipocytes. Insulin increases the
recruitment of glucose transporters (GLUT4) to the adipocyte membrane and activates lipogenic and
glycolytic enzymes. Insulin stimulates PPARγ, an important lipogenic and adipogenic enhancer. In
the long-term, insulin promotes lipogenesis by enhancing the transcription of lipogenic genes trough
regulatory factor SREBP-1 (149). SREBPs are transcription factors that coordinate fatty acid and
cholesterol metabolism and mediate the lipogenic action of hormones and nutrients. In addition to
insulin, lipogenesis is promoted by acyl-stimulating protein ASP and prostaglandins whereas growth
hormone and leptin inhibit lipogenesis (149).
During fasting, adipose tissue releases FFA by lipolysis. Triglyceroles are hydrolyzed into di- and
monoglyceroles and glycerol, and transported from adipose tissue into circulation for liver, muscle
and other tissues. Lipolysis requires structural reorganization in the lipid droplets to enable the
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hydrophilic lipases to access the hydrophobic lipid inside the droplets. Perilipin moves away from
the droplet surface to allow the enzymes in (154). The hormone-sensitive lipase (HSL) and its
regulation  is  the  rate-limiting  step  of  lipolysis  (155).  HSL  liberates  two  fatty  acids  from  the
triglycerol backbone by hydrolysis. Adipose triglyceride lipase (ATGL) (156) has recently been
characterized as another lipase in this initial hydrolysis step. 2-monoacylglycerol (MAG) lipase then
catalyzes the liberation of the remaining fatty acid and glycerol. FFAs can be transported out of the
cell or re-esterified back to new triglycerides. The glycerol produced in adipose tissue however
cannot be used as energy source there, because adipose tissue has only a limited activity of glycerol
kinase. Glycerol from adipose tissue is thus transported to the liver for gluconeogenesis.
The regulation of lipolysis is sensitive to the energy status of the adipocyte (the ATP levels of the
cell), maintained by its mitochondria. Lipolysis and mitochondrial ATP synthesis were shown to be
coupled already in 1975, when inhibitors of the electron transport chain function shut down
catecholamine-induced lipolysis (157). Mitochondrial energy sensor cyclic adenosine
monophosphate (cAMP) works as the main second messenger of ATP levels in the cell during
lipolysis. Its high levels enhance the protein kinase A (PKA) activity and lipolysis. Catecholamines
and  glucagon  stimulate  lipolysis  in  the  fasting  state,  and  insulin  and  AMPK  inhibit  it  in  energy
excess (158).
Only a small fraction of the FFAs released as a result of adipose tissue lipolysis are oxidized for
energy needs. Instead, the majority are re-esterified back into triglycerides in adipose and other
tissues. In adipose tissue the FFA re-esterification by de novo lipogenesis is generally low (159) but
occurs during low glucose supply or fasting (160, 161). The amount of re-esterification, independent
of the metabolic state, is up to 75% and during fasting, adipose tissue accounts for 20-30% and liver
for circa 50% of this amount (161).
2.4.3. Fatty acid oxidation
Inside the adipocyte, FFAs are esterified, metabolized or β-oxidized in mitochondria. In fatty acid
oxidation, the long-chain fatty-acids are transported into the mitochondrial matrix. Carnitine
palmitoyltransferases (CPTs; CPT1, CACT, CPT2) (162) facilitate this step. As the result of the β-
oxidation Acetyl-CoA is generated and enters the tricarboxylic acid (TCA) cycle for cellular
respiration and ATP production. Malonyl-CoA from glucose metabolism and lipogenesis regulates
fatty acid oxidation by inhibiting the function of CPT1. AMP-activated protein kinase AMPK
inhibits ATP-consuming processes and activates catabolic pathways. AMPK thus increases β-
oxidation by decreasing the flux of substrates in the anabolic pathway of fatty acid synthesis (163).
In consequence, Malonyl-CoA levels in the cell drop leading to an increase in CPT1 activity and to
fatty acid β-oxidation.
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2.4.4. BCAA oxidation
Adipose tissue is nowadays recognized as one of the main sites of mitochondrial branched-chain
amino acid (BCAAs; including leucine, isoleucine and valine - three of the nine essential amino
acids) catabolism (164, 165). In contrast to the other 17 amino acids which are metabolized in the
liver, BCAA’s are only poorly metabolized there. In circulation, they continue to peripheral tissues
and act as nutrient signals of amino acid intake, regulate protein synthesis and degradation, impact
insulin secretion and act in the neural control of food intake and energy balance (166, 167). Adipose
tissue was already earlier suggested to be the main site of excess BCAA conversion into fat (168)
and estimated second only to skeletal muscle in metabolizing BCAAs, the metabolism in liver being
6-7 fold less than in these two tissues (164, 169). However, the two first enzymes of the BCAA
oxidation pathway across many tissues, BCAT2 and BCKD, were found to be less active in adipose
tissue than in other tissue depots (170). Thus, the quantitative role of adipose tissue in BCAA
catabolism remained unclear. In 2010 Herman et al demonstrated that adipose tissue is an important
site  of  BCAA catabolism and indeed has the capacity to regulate  levels  of  circulating BCAAs in
vivo (165).
The first step in BCAA catabolism is a reversible transamination reaction by branched-chain amino-
acid  aminotransferase  (BCAT)  to  form  their  respective  α-ketoacids.  There  are  two  mammalian
BCAT enzymes: a cytosolic (BCATc, BCAT1) and a mitochondrial (BCATm, BCAT2) isoenzyme
(171). The second step in BCAA metabolism is an irreversible oxidative decarboxylation reaction
of the branched-chain α-keto acids (BCKAs) and catalyzed by the mitochondrial branched-chain α-
ketoacid dehydrogenase (BCKD) complex. After additional steps the metabolic pathway produces
substrates that are used in the TCA cycle in mitochondria.
When mitochondrial mass is elevated in adipogenesis, the expression of enzymes involved in BCAA
catabolism increases (172). Mitochondrial metabolism of BCAAs stimulates adipocyte growth and
differentiation by activating rapamycin signaling (173) and a decrease in BCAA catabolism reduces
the substrates for this pathway. While adipose tissue BCAA catabolism decreases, plasma BCAA
levels rise (165). Until now, it has not been known if decreased catabolism of BCAAs could be one
factor behind impaired adipocyte differentiation.
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Figure 5: BCAA catabolism
Figure 5: Branched chain amino acids (BCAAs) valine (Val), isoleucine (Ile) and leucine (Leu)
enter the cell through L-transporter in the plasma membrane. In the cytosol the BCAA
aminotransferase BCAT1 and BCAT2 in the mitochondria initiate the BCAA catabolism by
converting the BCAAs to branched-chain α keto-acids (BCKAs). The branched-chain alpha-keto
acid dehydrogenase complex (BCKD), with additional enzymes, catalyzes the conversion of the
BCKAs to Acetoacetic-acid, Succinyl-CoA and Acetyl-Coa, which can be further metabolized in the
cell or can enter the TCA cycle in mitochondria for energy generation.
2.4.5. Glucose metabolism
In the fed state, insulin binds to its receptors on the adipocyte surface and signals the translocation
of GLUT4 glucose-transporters to the membrane (174). This allows for the glucose to enter the
adipocyte. In glycolysis, glucose is metabolized into Acetyl-CoA and ATP in the cell cytosol.
Glucose is also converted into glycerol-3-phosphate, which serves as the basis of adipocyte
triglyceride synthesis. Circa 20-25% of the glucose taken up by adipocytes is used for triglyceride
synthesis and storage (175).  Adipocytes lack the enzyme glycerol kinase. Thus, they cannot convert
the glycerol that is formed in lipolysis into glycerol-3-phosphate (176).  Therefore, glucose uptake
into adipocytes and its modification into glycerol-3-phosphate is essential for adipocyte lipid
packaging. When glucose levels are low however, adipocytes can use non-carbohydrate substrates
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like lactate or amino acids to generate glycerol-3-phosphate by glyceroneogenesis (177). If insulin
receptor is knocked out in mice, glucose uptake and triglyceride synthesis in adipose tissue are
reduced and the mice become resistant to diet-induced obesity (178).
2.4.6. Adipokine secretion
Adipose tissue has only lately been shown to secrete a huge variety of adipocytokines that play a
role in energy intake and energy expenditure, body weight, glucose and lipid metabolism, insulin
sensitivity and inflammation (179, 180). These adipokines also function in the formation of new
preadipocytes (181) and regulate the migration of the cells in adipose tissue (182). Many of these
adipocytokines act as hormones (endocrine action), or in autocrine or paracrine fashion within the
adipose tissue and its cells.
Adipocytokines are defined either as factors secreted by adipocytes or factors secreted by any cells
present in adipose tissue. The latter definition includes also the SVF cells (183, 184). Main
adipocytokines include the energy intake regulator leptin, energy regulator and anti-inflammatory
factor adiponectin, acute phase proteins like plasminogen activator inhibitor-1 (PAI-1), blood vessel
vasoconstrictor angiotensinogen, transforming growth factor-β (TGF-β), prostaglandins, acylation
stimulating protein (ASP-1), adipophilin, and factors affecting adipose tissue proliferation,
heterogeneity and distribution like insulin-like growth factor I (IGF-I), glucocorticoids and sex
steroids (185). Adipose tissue also secretes regulators of lipoprotein metabolism; apolipoprotein E
(apoE), lipoprotein lipase (LPL) and cholesteryl ester transfer protein (CETP) (185). Many
cytokines, chemokines and inflammatory-related factors are secreted by adipocytes. These include
resistin, osteopontin, TNF-α, IL-6, IL-8, IL-10, IL-1α, monocyte chemoattractant protein-1 (MCP-
1), interferon-γ-inducible protein 10 (IP-10), macrophage inflammatory protein-1β, granulocyte
colony stimulating factor (G-CSF) and alkaline phosphatase (ALP) (133, 185, 186).
Leptin and adiponectin are exclusively secreted from adipocytes. Leptin is a 167 amino-acid long
protein and hormone that regulates energy intake, energy expenditure and whole-body energy
balance, but also cytokine secretion, phagocytosis, angiogenesis and reproduction (53). Leptin
works as a general signal on energy reserves (187). Leptin increases food intake and decreases
energy consumption by acting both on hypothalamic cells and target tissues. Thus it indirectly
increases insulin sensitivity (188, 189). Leptin stimulates lipolysis by increasing cyclic adenosine
monophosphate cAMP concentrations in the cell (190). Leptin can also activate inflammatory
cytokine secretion (191) and inflammatory cytokines TNF-α and IL-6 in adipose tissue stimulate the
production of leptin (192).
Adiponectin is a 244-amino-acid long protein that has four regions; a globular part, a region with
similarity to collagen proteins, a signal sequence region important in the secretion of adiponectin
from the adipocyte and a region which varies between species. Adiponectin signals through
ADIPOR1 and ADIPOR2 receptors (193). Adiponectin stimulates fatty-acid oxidation, improves
glucose metabolism and insulin sensitivity in adipose tissue, and decreases plasma FFA levels (194)
by inhibiting lipolysis in adipose tissue (195). Adiponectin also enhances whole-body insulin
sensitivity by reducing hepatic glucose production and increasing fatty-acid oxidation in adipose
tissue, liver and muscle (194). Adiponectin works as an anti-inflammatory molecule. In mouse
30
preadipocytes, inhibition of both lipolysis and inflammatory response were observed after
administration of adiponectin (196). In mice with induced adiponectin deficiency, plasma and
adipose  tissue  TNF-α levels  rise,  decreasing  with  adiponectin  treatment  (197).  A  link  between
adiponectin and mitochondrial function was shown by Koh et al 2007 who demonstrated that a
decrease or an increase in mitochondrial biogenesis directly inhibited or enhanced adiponectin
secretion and synthesis in adipocytes (198). In addition, animal studies have indicated that
adiponectin increases mitochondrial biogenesis and oxidative capacity in skeletal muscle (199, 200).
This happens through triggering Ca2+ influx in the cell by ADIPOR1 receptor and resulting in
enhanced AMPK and PGC-1α activity and increased mitochondrial biogenesis (200). Adiponectin
also promotes cellular survival and mitochondrial proliferation by stimulating ceramidase activity
through ADIPOR1 and ADIPOR2 receptors (201). This leads to reduced levels of ceramide (202),
which is metabolically harmful for the cells, as well as to the formation of anti-apoptotic metabolites
sphingosine and sphingosine-1-phosphate (201).
2.5. The role of adipose tissue and its mitochondria in the pathogenesis of
obesity-related metabolic disturbances
2.5.1. Adipocyte hypertrophy and hyperplasia in obesity
Adipose tissue enlarges by hypertrophy, hyperplasia or both. Increased adipocyte size (hypertrophy)
is associated with insulin resistance (203-205) dyslipidaemia and hepatic steatosis (206), and
predicts the onset of type 2 diabetes (5, 207). Large adipocyte size has been linked to cell death (208,
209) and suggested to be the determining factor of inflammatory macrophage infiltration in adipose
tissue (208).
Hyperplasia in turn is thought to be a mechanism that could protect (210) from the metabolic
complications of obesity. Hyperplastic changes seem to retain insulin sensitivity (204, 211) and a
favorable secretion of signaling molecules in adipose tissue (212). A reduced total number of
adipocytes (less hyperplasia) in adipose tissue however is associated with type 2 diabetes (213). It
has been thought that failure of adipocyte proliferation, differentiation and new preadipocyte
recruitment results in excess adipocyte hypertrophy and this in turn to insulin-resistant adipocytes
(210). Hyperplasia has been associated with preferential accumulation of subcutaneous adipose
tissue and a “pear” shaped more healthy fat phenotype (214-216), while adipocyte hypertrophy is
commonly connected with visceral fat accumulation, the “apple” shaped body image and metabolic
complications (215, 216). Recent evidence suggests that rather than the anatomical position, the
different characteristics and expandability of visceral and subcutaneous adipose tissue determine
their effect on metabolism (217, 218). However, even though subcutaneous fat has a better
adipogenic potential than visceral fat (219-221), both adipose tissue depots are capable of
hypertrophy and hyperplasia during weight gain (221, 222). While there are sex- (223) and depot-
specific differences in body fat accumulation (220, 221), the acquired or genetic nature of the
individual differences in the hypertrophic and hyperplastic capacity of adipose tissue have still
remained unclear.
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Figure 6: Adipocyte hypertrophy and hyperplasia
Figure 6: Adipose tissue enlarges by increase in the size of the existing cells (hypertrophy), by
recruitment of new adipocytes (hyperplasia), or by both. Genetic and environmental factors affect
these capacities. With increasing weight gain adipose hyperplasia with adipose hypertrophy seem
to retain the metabolic function of the cells. Adipose hypertrophy with only little hyperplasia in the
tissue in turn is related to worsened metabolic parameters, insulin resistance, inflammation,
impaired adipokine secretion and possibly to the limited expansion capacity of the adipose tissue
and the accumulation of ectopic fat. The genetic and environmental determinants and the
interindividual differences in the hypertrophic/hyperplastic capacities have remained unknown.
Arner et al demonstrated that after bariatric surgery, subjects with the largest reduction in adipocyte
size gained most in insulin sensitivity (205). Indeed, smaller adipocytes have been thought to be
more insulin-sensitive (49) and are reported in the visceral fat of insulin sensitive obese individuals
(14) and individuals characterized as “metabolically healthy” obese (224). Insulin and its increased
concentrations in the circulation stimulate adipocyte hypertrophy (225), but not hyperplasia, because
preadipocytes exhibit only low levels of insulin receptor (226). Interestingly, two studies have
presented that insulin resistance (227), and also adipokine secretion (186), may depend on the cell-
size distribution of large and small cells in adipose tissue, rather than only the mean cell size.
In addition to adipose tissue insulin resistance, hypertrophied adipocytes (by mean and maximal cell
diameters or volume) have been associated with elevated levels of circulating inflammatory markers,
and an increased number of macrophages in adipose tissue (186, 228). Studies with mice models of
obesity have linked adipocyte hypertrophy with cell death (208, 209, 229). Morphologically dying
32
or dead adipocytes are surrounded by infiltrated inflammatory macrophages and so called crown-
like structures (CLS), found in obese adipose tissue and increasing over time (208). In rodents, large
adipocytes secrete more inflammatory TNF-α (230), and the expression and secretion of
proinflammatory adipokines such as IL-6, TNF-α, IL-8, MCP-1, CRP, chemerin, progranulin and
granulocyte colony stimulating factor have been related to adipocyte hypertrophy (186, 231, 232)
and to the insulin resistant obesity state (14). Large adipocytes also release more FFA that can
activate the TNF-α inflammatory secretion from macrophages (233). Adipocyte apoptosis has also
been suggested as a key event that contributes to macrophage infiltration into adipose tissue and
subsequent insulin resistance (234).
Mitochondria are essential in adipocyte differentiation and adipogenesis (6). Thus, they do have an
important  role  in  the  hyperplastic  capacity  of  adipose  tissue.  How  adipocyte  size  relates  to
mitochondrial biogenesis and function has thus far been unknown. There is still very little evidence
if smaller adipocytes have more active mitochondria, or contain more mitochondria than larger cells.
Two recent studies did not find differences in the respiration capacities of large and small adipocytes
(10, 235), but the relationship of cell size, adipocyte dysfunction and mitochondrial biogenesis still
needs further studies.
2.5.2. Adipose tissue dysfunction in obesity
Adipose tissue dysfunction has been recognized as an important contributor to the obesity-related
disorders (7, 8). Excess adipose tissue is associated with marked changes in the adipose tissue
function and secretion, with the development of low-grade inflammation and an increased risk for
developing insulin resistance, type 2 diabetes, dyslipidemia, hypertension, metabolic syndrome,
coronary heart disease, stroke and vascular complications (236, 237). Pro-atherogenic, pro-
diabetogenic and pro-inflammatory cytokines are secreted, accompanied by a decreased production
of protective adiponectin (237).
The ability of adipocytes to expand their lipid content, while maintaining insulin sensitivity, has a
protective and adaptive role in whole body metabolism (238). If the storage capacity is exceeded,
lipids spill over to ectopic sites in liver, muscle and pancreas causing dysfunction and insulin
resistance (47). A general assumption is that at a certain adipocyte hypertrophy level the cells begin
exhibiting signs of stress. The ultimate expansion limit of subcutaneous adipose tissue however
remains unknown, if any. Also, the underlying causes for the adipocyte stress have until now
remained unanswered. Mechanical stress for the adipocyte membrane, mitochondrial dysfunction
(6), endoplasmic reticulum (ER) stress (239), increased hypoxia of the cells (240, 241), insulin
resistance, increased production of reactive oxygen species (ROS) by mitochondria (242), altered
adipokine signalling, increased inflammation in the tissue (228) as well as increased possibility for
apoptosis (234) have all been suggested as contributing factors for adipose tissue dysfunction. The
relationship and timetable of these changes is yet largely unknown. What is known however, is that
if  adipose  tissue  mitochondria  are  stressed,  they  release  more  ROS,  which  can  damage  the
mitochondria and other cellular entities, as well as reduced mitochondrial function may hinder many
of the basic functions of an adipocyte (242). If the mitochondria are not able to cope with increased
demand for FFA oxidation in obesity (65), incomplete β-oxidation products (243), and increased
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endoplasmic reticulum stress in mitochondria and adipocytes may lead to a deterioration of insulin
sensitivity and to other complications (244). The ultimate causality between all the contributing
factors has remained unanswered.
Figure 7: Adipose tissue dysfunction and metabolic health
Figure 7: Long term excess energy intake causes weight gain and adipocyte hypertrophy. Adipose
hypertrophy is related to impaired adipocyte function, with impaired lipid handling and impaired
secretion of adipokines, with a shift towards a pro-inflammatory state. The secreted adipokines
further boost the infiltration of resident and circulating macrophages and inflammatory cells into
adipose tissue. The inflammatory cytokines produced further impair preadipocyte recruitment and
differentiation. Increased inflammatory secretion and impairments in the lipid metabolism cause
insulin resistance in adipose tissue. Increased FFA (free fatty acid) spillover to other tissues,
adipose tissue insulin resistance and dysfunction, and altered inflammatory and adipokine secretion
from adipose tissue is thought to lead to FFA accumulation in ectopic sites and to whole-body
metabolic complications. In muscle and liver increased lipid content and insulin resistance is
observed, together with insulin resistant adipose tissue contributing to the rise in blood glucose. In
pancreas, increased glucose concentrations cause β-cell overfunction and subsequently, exhaustion.
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2.5.3. Mitochondria in obese adipose tissue
Several  animal  studies  using  genetic  or  dietary  models  of  obesity  have  shown  a  reduction  in
mitochondrial oxidative capacity in white adipose tissue (66, 104). Mitochondrial number is shown
to be reduced by 50%, and the transcription of genes encoding mitochondrial proteins decreased in
white epididymal adipocytes obtained from ob/ob mice when compared with lean mice (142). When
these cells were treated with rosiglitazone, a PPARγ agonist and insulin sensitizer, they displayed
markedly enhanced oxygen consumption and increased palmitate oxidation as well as increase in
the expression of half of the previously downregulated mitochondria-related transcripts (142). In
another study on mice, impaired mitochondrial function induced endoplasmic reticulum stress.
Treatment with rosiglitazone resulted in enhanced mtDNA content, expression of mitochondrial
proteins, fatty acid oxidation, and oxygen consumption (198). In both db/db diabetic mice and obese
high-fat fed mice the mtDNA amount and the expression of genes involved in mitochondrial ATP
production and genes encoding mitochondrial ribosomal proteins and mitochondrial heat-shock
proteins were downregulated compared with non-diabetic or lean mice, respectively (67). Also an
increase in mitochondrial mass, modifications in mitochondrial structure and enhanced expression
of mitochondrial inductor PGC-1α were observed after treatment with rosiglitazone. In mice fed
with high fat diet, a decrease in citrate synthase activity, reduced expression of PGC-1α and a
decrease in the abundance of several proteins in the mitochondrial respiratory chain or matrix,
without a change in mitochondrial mtDNA amount or basal oxygen consumption has been reported,
suggesting downregulation of mitochondrial activity at the nuclear level (245).
The improvements in mitochondrial respiration after insulin sensitizer in mice studies speak for a
relationship between mitochondrial function and insulin sensitivity. A study in 3T3-L1 mouse
preadipocytes linked mitochondrial function to insulin signaling in adipose tissue by demonstrating
that reduction in mtDNA levels and respiratory chain activity enhanced insulin signaling, but caused
impaired insulin responsiveness by decreasing the glucose transport (GLUT4 translocation on the
cell surface) in adipose tissue (246). Recently, another study however showed that respiratory
capacity measured by cell respirometer in subcutaneous and visceral fat would be reduced in murine
obesity, independent of insulin resistance (247).
Only few studies have investigated the effects of obesity or type 2 diabetes on the oxidative capacity
of mitochondria or vice versa in human adipose tissue. Diverse mitochondrial parameters like
structure, function and number vary between insulin resistant and insulin sensitive individuals,
suggesting that low mitochondrial function is related and may contribute to insulin resistance (248).
Obesity is thought to lead to mitochondrial dysfunction and impaired glucose and lipid metabolism
in adipose tissue in humans (6, 64, 65). The expression of the main mitochondrial regulator PGC-
1α has been shown to be decreased in morbidly obese versus lean subjects (202). Chattopadhyay et
al 2011 showed that  the activities of the respiratory complexes I-IV, mitochondrial membrane
potential and inorganic phosphate utilization were reduced in subcutaneous adipose tissue in obese
patients, and that the reduction was similar in obese versus obese diabetic patients (249). These
results suggest that obesity per se relates to impaired mitochondrial function. Reduction of
respiration was more pronounced in visceral than in subcutaneous fat. Flachs et al found that n-3-
polyunsaturated fatty acids, known to prevent obesity and insulin resistance, upregulated
mitochondrial biogenesis in adipose tissue in humans (250). Reduced mtDNA levels have been
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observed in identical obese twins compared with their leaner counterparts (4), emphasizing that
environmental acquired effects contribute to the regulation of mitochondrial mass and biogenesis.
MtDNA copy-number correlates with lipogenesis in adipose tissue and the mitochondria have an
active role in the cell enlargement and the adipocyte energy deposition process (251, 252).
The mechanisms responsible for the reduced mitochondrial oxidative capacity in adipose tissue in
obesity are not yet known. It has been suggested that they involve reduced mitochondrial biogenesis
and impaired mitochondrial dynamics, increased inflammation, damage caused by excess ROS in
mitochondrial metabolism and ER stress, among others (253). The causality of the changes in
mitochondria and the relationship to the development of the metabolic complications of obesity has
also remained unclear. In adipose tissue, high-fat-fed mice displayed mitochondrial dysfunction that
was observed as a secondary feature after the development of insulin resistance (105, 254). In rodent
studies TNF-α has impaired mitochondrial biogenesis and function in adipose tissue (253). Also in
humans, treatment of preadipocytes with the inflammatory cytokine TNF-α reduced the expression
of OXPHOS genes in healthy individuals, suggesting a role for inflammation in the development of
mitochondrial dysfunction (255). However, other studies speak for the mitochondria as the
underlying mechanism behind insulin resistance and inflammation. High levels of FFAs and glucose
have been reported to directly stimulate mitochondrial dysfunction in 3T3-L1 adipocytes (256).
TNF-α and other inflammatory cytokines can also be secreted because of the dysfunctional
mitochondria. As mitochondria are the site of phospholipid synthesis of the adipocyte cell membrane
(153), and that adipocyte cell membrane lipid modifications have been shown to recruit
inflammatory cells to adipose tissue (19), mitochondria and their dysfunction may be suggested to
lie behind the changes in the cell membrane and the inflammatory processes of the adipose tissue.
The causality of the various changes in mitochondria in obesity has remained to be determined. Also
it is not yet known how the “dysfunction” in mitochondria manifests; is there a reduced number of
mitochondria in obesity, downregulation of mitochondrial oxidative metabolism, downregulation of
mitochondrial biogenesis, other functions, or all, and which of these contribute to the dysfunction
of the adipocyte cell?
2.5.4.  Mitochondria in obese adipocytes
Adipose tissue includes both adipocytes and stromal vascular fraction cells and thus many of the
changes seen in obese adipose tissue may be derived from other cells than adipocytes. It is not yet
known, how much adipocytes contribute to the mitochondrial dysfunction and metabolic
disturbances in obese adipose tissue and which part of the observed mitochondria-related changes
derive from adipocyte mitochondria. Although there is no consensus yet, it generally appears that
mitochondrial amount and/or function are decreased in adipocyte cells.
The studies on adipocyte mitochondria are still sparse. Reduction of mitochondrial biogenesis by
deletion of mitochondrial transcription factor A altered the expression of electron transport chain
proteins, decreased complex I activity and enhanced reactive oxygen production in mouse
adipocytes (257); however, endogenous uncoupling, β-oxidation and basal and insulin-stimulated
glycolysis were increased. In humans, preadipocytes differentiated in vitro from human
subcutaneous adipose tissue of obese persons had lower oxygen consumption rates after beta-
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adrenergic stimulation compared with preadipocytes from lean subjects (68). Another recent study
in humans has shown that both mitochondrial oxygen consumption rates and the levels of OXPHOS
complexes CI and CIV were reduced in adipocytes in obesity, independent of the adipocyte cell size
(235). Both Fischer et al and previously Yin et al have reported reduced mitochondrial oxygen
consumption in obese adipocytes (10, 235) and proposed that the perceived reduced oxidative
capacity of mitochondria in obesity is not due to adipocyte cell size, but rather related to overall
adiposity. The above-mentioned studies are performed in obese and lean unrelated individuals. Even
though previous studies have indicated a reduction in the number of mitochondria and/or
mitochondrial respiratory capacity, controversy remains if there is reduction in both or only one of
these factors in obese adipose tissue. Although adipose hypertrophy associates with an unhealthy
metabolic obese profile (231) it is not yet known if mitochondrial biogenesis and oxidative pathways
associate with adipocyte hypertrophy or to worsening of the metabolic profile in obesity in general
and whether there are interindividual differences in the mitochondria-related metabolic responses to
obesity.
2.5.5. Mitochondrial oxidative metabolism in obesity
Mitochondrial fatty acid oxidation has been suggested to be compromised in obesity (65). Obese
individuals seem to have decreased fatty acid oxidation at least in their subcutaneous adipose tissue;
however in visceral adipose tissue a study by Auguet et al found no differences between the lean
and the obese groups (258). Increased fatty-acid oxidation and increased lipolysis in adipocytes have
been shown to improve insulin sensitivity and reduce inflammatory signaling (259). Targeting
PPARγ, a master regulator of mitochondrial biogenesis and adipogenesis by thiazolidinediones, has
proven effective in the treatment of diabetes (142, 260), although some of the effect may also come
from PPARγ independent direct actions of thiazolidinediones on mitochondria (261). The exact role
of fatty acid oxidation in relation to whole-body metabolism in obesity, however, remains to be
determined.
Adipose mitochondria are important in the BCAA oxidation and studies have demonstrated
downregulation in the expression of adipose tissue BCAA metabolizing enzymes in insulin-resistant
state and obesity (166, 262). In turn, after gastric bypass and related weight loss, the adipose tissue
BCAA oxidation enzymes increase and circulating BCAA levels decline. BCAAs in circulation
correlate positively with insulin resistance (263) and type 2 diabetes (264). Increased levels of
BCAAs have also been linked to cardiovascular disease and metabolic syndrome (265, 266).
However, some controversy exists, because BCAA-rich diets in mice have been associated with
positive effects on glucose homeostasis and body weight (267). Furthermore, a knock-out of
mitochondrial BCAA transferase in mice was associated with elevated levels of BCAAs in
circulation but with improved insulin sensitivity and increased energy expenditure (268). One
hypothesis for the role of BCAAs in the development of insulin resistance is that the increase in
BCAAs in the cell could promote the accumulation of mitotoxic metabolites and thus pancreatic β-
cell dysfunction, stress signaling and apoptosis (167). In contrast however, insulin resistance is
shown to cause impairment in protein degradation of the tissues (167) and may as a result increase
the levels of amino acids and BCAAs in the circulation. The causal role of BCAAs in the
development of type 2 diabetes and metabolic diseases has thus remained unanswered. It has been
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proposed that the BCAAs could as markers reflect the insulin resistance and the obese state of the
tissues, resulting from an altered appearance and clearance of these metabolites (167).
2.5.6.  AT oxygen deprivation and mitochondrial respiration
Excess adipocyte hypertrophy has been suggested to cause adipose tissue oxygen deprivation,
because the adipocytes enlarge beyond the oxygen diffusion limit of circa 100μm (269). Adipose
tissue hypoxia and oxygen deprivation of the cells may in turn be a factor contributing to the adipose
tissue dysfunction and the inflammatory response of the adipose tissue in obesity (241, 270). The
view of hypoxia as one of the inducers of inflammation in obese adipose tissue has been backed up
by studies where human obese adipose tissue SVF cells cultured in hypoxic conditions secreted more
inflammatory markers and harbored an increased inflammatory cell infiltrate (271). However, the
role of mitochondria in this low oxygen supply milieu is not yet clear.
Partial oxygen pressure (pO2) is the difference between O2 delivery and O2 consumption in the
tissue. Human abdominal subcutaneous adipose tissue pO2 lies between ~3 and 11% O2 (~23–
84 mmHg) (213, 272) and blood flow in the tissue is an important determinant of pO2. Adipose
tissue blood flow is shown to be lower in obese compared with lean individuals (272, 273). In rodent
models of obesity, rapid weight gain was accompanied with increased expression of genes related
to hypoxia, lower partial oxygen pressure and increase in hypoxic areas in adipose tissue (274, 275).
In human obesity, studies are still rare and controversial. Pasarica et al reported that oxygen pressure
in adipose tissue was reduced in obese versus lean individuals (213), however a study by Goossens
et al found an increased oxygen pressure in obese adipose tissue (272). The latter study was matched
for age, gender, presence of type II diabetes and ethnicity. Recently, in a study by Hodson et al no
significant differences were found between obese and lean persons in relation to secretion of adipose
tissue hypoxic markers lactate and pyruvate (276). Based on the controversial results it has been
suggested that the metabolic rate of the adipose tissue may be reduced in obesity, rendering higher
adipose tissue partial oxygen pressure despite the lower blood supply (9). In mouse models of
obesity and type 2 DM,  mitochondrial biogenesis, mass and oxygen consumption were reduced in
adipose tissue of obese mice and enhanced by rosiglitazone (67, 142), supporting the idea of  lower
oxygen consumption in obese adipose tissue. Also in humans, metabolic pathways related to
mitochondria have been shown to be downregulated and inflammatory pathways upregulated in
subcutaneous fat (4), and in both subcutaneous and visceral fat (277) of obese individuals. These
studies speak for the role of low mitochondrial oxidative metabolism behind the low oxygen
consumption and high partial O2 in adipose tissue. However, the mechanisms behind the low
mitochondrial respiration in obesity are still to be studied.
2.5.7. Adipose tissue angiogenesis
Enlarging adipose tissue needs new blood vessels. The blood vessel formation, angiogenesis, is
crucial for tissue growth, repair and expansion (278). The changes in the production of angiogenic
factors and inhibitors like vascular endothelial growth factor A (VEGFA), adiponectin, fibroblast
growth factor (FGF) and thrombospondin 1 (279) result in an angiogenic phenotype in the tissue. In
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growing adipose tissue angiogenesis contributes to adipogenesis by supplying more nutrients,
growth factors and oxygen in the blood (280). Endothelial cells in new blood vessels have been
shown to have stem-cell-like properties that allow them to differentiate into new preadipocytes
(123). New vessels also enable the infiltration of macrophages and monocytes into the tissue, the
amount of which is observed as increased in obese individual’s adipose tissue (281). The changes in
the vasculature may alter blood perfusion in adipose tissue, which may control the number and sizes
of adipocytes, thus leading to expansion or shrinkage of certain adipose depots.
While angiogenesis is required for normal maintenance and enlargement of the tissue, in obesity it
may also be pathological. In obesity, alterations of the vascular endothelium in adipose tissues
include impaired vasodilation, a possible hypoxia-induced angiogenesis, and inflammation-induced
vascular damage (282). The possible hypoxia in adipose tissue of obese individuals has been
suggested to have a causal role in switching on inflammation and angiogenesis in the tissue. Hypoxia
induces hypoxia-inducible transcription factor 1 (HIF1) and HIF2, which both increase the
expression of angiogenesis-related factors and downregulate the inhibitors of angiogenesis (279).
However,  the  connection  of  impaired  angiogenesis  and  hypoxia  in  obese  adipose  tissue  is  still
debated, because based on most recent controlled studies on adipose tissue oxygen tension (272,
276), there is no hypoxia in obese adipose tissue.
Impaired vascular function has been suggested to lead to alterations of lipid metabolism and the
development of insulin resistance in tissues and in whole body, and contribute to the development
of type 2 diabetes (283). While angiogenesis is also needed for energy expenditure (280, 284), recent
discussion has focused on the issue, if increasing or decreasing adipose tissue angiogenesis might
have beneficial effects on treating obesity.
2.5.8. Cell death
Controlled cell death, apoptosis, is both beneficial and necessary for the tissue, playing an important
role in tissue homeostasis and development. Cell death can also be disrupted and harmful, at least if
uncontrolled. In apoptosis, there are two principal pathways, the intrinsic or mitochondria-mediated
pathway and the extrinsic, death-receptor-mediated pathway (96). Mitochondria are essential in
activating the cell death apoptotic pathway and their own mitophagy (mitochondrial apoptosis) upon
increased cellular and mitochondrial stress (285).
Some studies have supported the model in which adipocyte apoptosis in obesity would result from
inability of adipose tissue enlargement and precede the adipose tissue macrophage infiltration and
along with it, insulin resistance, dyslipidemia and other metabolic abnormalities (234). Autophagy,
the  controlled  cell  death,  has  been  shown to  be  increased  in  adipose  tissue  samples  from human
obese and type 2 diabetic subjects, particularly in those individuals that had a greater degree of
insulin resistance (286, 287). Adipocyte hypertrophy and the degree of obesity correlated with the
increased expression of autophagy-related regulatory genes (286). In murine obesity, frequency of
adipocyte cell death increases with increasing obesity (209). This cell death has been thought to
result in the formation of “crown-like structures”, characterized by dead adipocytes surrounded by
macrophages – a feature that has been described in adipose tissue from both obese mice and humans
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(208, 209). On the other hand, in a study by Fischer-Posovszky et al, targeted deletion and apoptosis
of adipocytes in mice was sufficient to lead to a large increase in infiltration of macrophages to
adipose tissue. However, these cells had an anti-inflammatory phenotype contrary to the
inflammatory phenotype that is usually activated in obesity. The authors thus suggest that at least
controlled apoptosis is a healthy process in adipose tissue, and other mechanisms are needed to
activate the inflammatory phenotype of obese adipose tissue (288).
In obesity, multiple factors including insulin resistance, inflammation and oxidative stress are
simultaneously present in adipose tissue and it is not known if the increased autophagy or cell death
are a general response to the adipocyte stress and inability of adipose tissue to enlarge in obesity, or
dependent primarily on some of these or other factors. In obesity, mitochondrial stress may lead to
increased ROS, which further impair mitochondrial and cell function (242), predisposing to cell
death and consequently to increased immune cell infiltration (208).
2.5.9. Altered cytokine secretion and low-grade inflammation  in obese adipose tissue
Several pieces of evidence support the view that obesity and metabolic syndrome are chronic low-
grade inflammation states  (289).  Obesity is  often characterized by a  slight  increase in circulating
inflammatory markers but with no visible clinical signs of inflammation (290). Modestly elevated
levels of circulating inflammation markers including TNF-α, IL-6, IL-8, with disturbed secretion of
plasminogen activator inhibitor-1 (PAI-1), angiotensin-II, leptin, and decreased levels of protective
adiponectin (270, 291) have been recorded in obese adults.
Already in the 1970’s infectious states such as sepsis were noticed to induce whole-body insulin
resistance (292). In obesity, the chronic low-grade inflammation is thought to play a central role in
the development of whole-body insulin resistance (36) and other complications of obesity (293).
The increased infiltration of immune cells into adipose tissue and the increased secretion of
proinflammatory cytokines by adipocytes and inflammatory cells has been proposed as a link
between excess adiposity and the development of AT and systemic insulin resistance (294).
In obesity, immune cell populations in several tissues (liver, muscle, pancreas and adipose tissue)
shift towards a pro-inflammatory state with production of inflammatory cytokines (289). In adipose
tissue, the dysfunction of adipocytes has been suggested to initiate the changes (289). In a normal
non-obese condition adipose tissue has resident inflammatory cells that function in tissue
maintenance and various other tasks (295), but with excessive fat accumulation, their amount and
functions change. Obese adipose tissue is characterized by accumulation of macrophages,
lymphocytes, mast cells and neutrophils (228, 296). Two types of macrophages reside in adipose
tissue; type M1 inflammatory macrophages that are capable of secreting TNF-α and IL-6 and type
M2 macrophages that are anti-inflammatory. In obese adipose tissue there is a switch from an M2-
anti-inflammatory milieu toward an M1-proinflammatory state (289).
Obesity alters adipokine secretion in adipose tissue. The secretion of proinflammatory adipokines
and leptin are upregulated and the anti-inflammatory adiponectin is downregulated (297). In normal
concentrations, adiponectin represses the inflammatory pathways in adipose and other tissues, but
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in obesity, this effect is blunted (237). Despite high leptin concentrations, a state of leptin resistance
emerges, where the increased leptin no longer signals on excess adiposity (298). Inflammatory
cytokines are secreted both from adipocytes and the resident macrophages in adipose tissue.
Macrophage-derived TNF-α has been shown to activate the adipocytes in humans, induce their
lipolysis and upregulate the expression of inflammatory genes like ICAM-1, IL-6 and macrophage
chemo attractant protein-1 (MCP-1) (294, 299). ICAM-1 and MCP-1 are capable of inducing
monocyte migration from circulation into adipose tissue and enhance their differentiation into
macrophages. Obese adipocytes secrete more TNF-α in rodents (230), and IL-6, TNF-α, IL-8, MCP-
1 are expressed and secreted in humans in adipocyte hypertrophy (186, 231). Large fat cells also
release more FFA that can bind to macrophage receptors, activate inflammatory pathways and
induce TNF-α secretion from macrophages (300). Increased TNF-α secretion from obese adipocytes
first provided evidence for a functional link between obesity and inflammation (301).
The dysfunctional secretion of adipocytokines and inflammatory factors from adipose tissue is seen
to play a role in the development of insulin resistance and systemic metabolic disorders (302, 303).
Inflammatory cytokines secreted by adipocytes and immune cells inhibit insulin signaling (301, 304,
305). TNF-α induces lipolysis (306), decreases preadipocyte differentiation (307), induces insulin
resistance by decreasing GLUT4 on the adipocyte surface (307) and decreasing the phosphorylation
of the insulin receptor (305). TNF-α downregulates PPARγ, the main inducer of adipogenesis and
mitochondrial function (308). Ruan et al have shown that the changes in lipogenesis and in altered
inflammatory gene expression of adipocytes can be reversed when the effect of TNF-α is removed
(309).
Inflammatory gene expression on the whole is increased in obese adipose tissue (4, 296). It has
however been controversial if this increase derives from adipocytes, from other cells of the tissue,
or both. Some studies have suggested that the increased release of interleukins and other
inflammatory cytokines from adipose tissue in obesity would be because of the non-fat cells of the
tissue (310). However, also adipocytes are known secretors of IL-6, IL-8, TNF-α and other
inflammatory adipokines (311). Until now, the contribution of adipocytes to the inflammatory milieu
of adipose tissue has remained unanswered.
The causality of the inflammatory changes in adipose tissue is only partly clear. It has been suggested
that the increase in proinflammatory molecule secretion by dysfunctional adipocytes in the long term
would trigger the recruitment of circulating immune cells from macrophages to T-cells and B-cells
and reinforce the inflammation to systemic level (303). Membrane lipid alterations in obese
adipocytes may be at least one initial factor triggering the recruitment of inflammatory cells into the
adipose tissue (19). As mitochondria are an important site of membrane lipid generation (153),
changes in their function may lie behind the cell membrane plasticity.
In summary, obesity induced inflammation in adipose tissue seems to be chronic, low-grade,
nutrient-induced and creating a proinflammatory state in the tissue, with an influence on whole-body
metabolic status.
41
2.5.10. Insulin resistance and the development of type II diabetes
The dysfunction of obese adipose tissue is thought to be a major factor in the development of whole-
body insulin resistance (7). Insulin resistance is a state, where the response of the tissues to insulin
stimulation is attenuated and where a higher dose of insulin is needed to produce the same response
as in insulin sensitive state (312). Insulin resistance was first believed to be due to low affinity of
insulin to its  receptor  or  diminished insulin receptor  number in the target  tissues (313).  It  is  now
established that the resistance is caused by several defects in the insulin-signaling cascade of the
insulin responsive tissues; liver, skeletal muscle and adipose tissue (314). Fasting serum insulin
concentrations and insulin resistance tend to increase with increasing obesity (315). In clinical
studies  even  a  mild  increase  in  BMI  (2  BMI  units)  increased  the  risk  of  developing  diabetes
threefold, and by 20-fold in subjects with obesity (BMI >30) compared with those being overweight
(BMI >25) (316). However, mechanisms independent of body fat also seem to be involved in the
pathogenesis of type 2 diabetes, because not all obese individuals develop insulin resistance or
metabolic complications of obesity (1, 2), and also lean type 2 diabetic persons can be insulin
resistant (317).
In obesity-related type 2 DM the insulin resistance of the target tissues is combined with insufficient
insulin secretion from the pancreatic β-cells. Excess energy is stored in subcutaneous and visceral
fat depots. When adipose tissue storage capacity is exceeded, FFAs spill over to other tissues (17).
With  accumulating  fat  deposition  FFAs  in  circulation  increase  causing  insulin  resistance  of  the
tissues (33). Elevated amounts of triglycerides in muscle (318), liver (319, 320), and pancreas (321,
322) associate with insulin resistance. A deficit of adiponectin may contribute to the process. To
counterbalance the insulin resistance and prevent hyperglycaemia, pancreatic β-cells secrete more
insulin and plasma insulin levels rise. Ultimately however, for those individuals with genetic
predisposition, the pancreas cannot compensate enough. This leads to β-cell exhaustion and the
development of type 2 diabetes (33). Abnormal insulin sensitivity usually precedes the clinical
diagnosis of diabetes, in some cases even up to 15 years (323). This reduction of insulin sensitivity
in obesity is thought to progress until the pancreatic cells no longer can compensate for it (324).
Hepatic insulin resistance in itself may also contribute to the increases in fasting blood glucose. In
liver steatosis the insulin resistant liver produces glucose by gluconeogenesis despite the increased
circulating insulin concentrations, which should normally suppress the hepatic glucose production
(317, 325). Individuals with NAFLD have been shown to have 20-35% lower suppression of hepatic
glucose production in response to insulin than matched controls (326).
Adipose tissue controls the release of free fatty acids (FFAs), which in excess are suggested to be
one of the major contributors of insulin resistance in other tissues (327, 328). Elevated levels of FFA
for more than a few hours in circulation have been shown to cause insulin resistance, which however
disappears a few hours after the decrease in FFA levels (329, 330). Thus, it has been suggested that
FFAs may have an indirect role by enhancing the accumulation of other metabolites like
diacylglycerol (331). Increased insulin resistance of adipose and of other tissues leads to enhanced
lipolysis and FFA release from adipocytes. This is because in insulin resistant adipose tissue insulin
inadequately suppresses the lipolytic adipose tissue hormone sensitive lipase (HSL), which releases
FFA into circulation.  Obese subjects  fail  to  suppress  the FFA release from adipose tissue after  a
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meal (332). Increased levels of FFA deposition reduce glucose uptake in muscle (327), stimulate
glucose production in liver (330) and insulin secretion from pancreatic β-cells (333). This ectopic
fat deposition has thought to lead to systemic insulin resistance. In the long term however, FFAs
cause lipotoxicity and β-cell exhaustion in the pancreas (334).
In addition to FFAs, branched-chain amino acids have been suggested as mediators of insulin
resistance in obesity. However, some controversy exists and recent studies have proposed that
BCAAs might instead be markers of the insulin resistance of the tissues (167) (discussed in Adipose
oxidative metabolism). In obesity, decreased catabolism of BCAAs in adipose tissue is observed,
followed by an increase in plasma BCAA levels  (167).  The mechanism by which BCAAs could
contribute to insulin resistance may be through the activation of the lipogenic mTORC. Increased
levels of circulating BCAA leucine have been shown to activate the mTORC cascade (167), which
inhibits insulin signaling in the insulin target tissues (335). mTORC positively regulates β-cell mass
and function. However, a sustained activity of mTORC causes insulin resistance in the β-cell islets,
reduces β-cell survival and promotes their apoptosis (336), factors contributing to the development
of type 2 diabetes. The accumulation of BCAAs in obesity is suggested to be either a contributor or
at least a marker of the developing insulin resistance (167).
Low-grade inflammation of adipose tissue is seen as one factor leading to adipose tissue dysfunction
and consequently, whole-body insulin resistance (303). The quantity of macrophages in adipose
tissue correlates with insulin resistance (294). Also, cytokines released by the inflammatory cells
and by adipose tissue, such as TNF-α, IL-6 and IL-8, TGF-β, contribute to the development of
adipose tissue and systemic insulin resistance (303, 337). For instance, increased levels of
inflammatory cytokine TNF-α enhance triglyceride hydrolysis and inhibit the expression of genes
that are essential to insulin signaling and adipocyte differentiation (309), while its knockout leads to
improved insulin sensitivity in rodents (304). Hotamisligil et al have suggested that the inflammatory
cytokine TNF-α may mediate the development of insulin resistance in adipose and other tissues
(301). Adipose tissue secretes also anti-inflammatory factors like adiponectin, the levels of which
however are decreased in obesity. Studies have linked low levels of adiponectin to the development
of diabetes; both to the insulin resistance in the target tissues and to the failure of β-cell insulin
secretion (338). Adiponectin seems to counteract the effects of inflammatory cytokines in pancreatic
cells (338).
2.6. Fat distribution – subcutaneous, visceral, ectopic and liver fat - in the
pathogenesis of metabolic complications of obesity
2.6.1.  Subcutaneous and visceral adipose tissue enlargement
Subcutaneous adipose tissue (SAT) is the largest body fat reserve storing ~80-90% of the total body
fat,  and in total  over  4-5 times larger  than visceral  fat  mass,  which stores  about  10% of body fat
(339). Subcutaneous fat is the main depot for removing triglycerides from circulation. Its expansion
potential has been seen as protective against the metabolic complications of obesity (340). If
subcutaneous fat is missing, like in lipodystrophies, excess fat accumulates to ectopic sites - internal
organs and visceral depots - causing metabolic problems (47, 312). Subcutaneous fat depots have
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increased rates of adipose turnover and new adipocyte formation compared to visceral fat and it is
generally thought that new and ‘younger’ adipocytes are metabolically more healthy (3, 120, 203).
However, despite its protective nature, subcutaneous fat has also been shown to contribute to
obesity-related complications. In a group of both obese nondiabetic (341) and obese diabetic (342)
males, subcutaneous truncal fat played a more important role in the obesity-related insulin resistance
than visceral fat. Goodpaster et al demonstrated a relationship between subcutaneous abdominal fat
and insulin sensitivity (343) and the Amsterdam Growth and Health Longitudinal Study related
subcutaneous fat to arterial stiffness (344).
Visceral  adipose  tissue  (VAT)  is  known  to  be  associated  with  metabolic  syndrome  and
cardiometabolic risk factors (345, 346). It has higher metabolic activity measured by lipogenesis
and lipolysis compared to other fat depots (48). Increased lipolysis, FFA release and inflammatory
secretion from visceral adipose tissue is thought to lead to the accumulation of excess liver, muscle
and pancreatic fat, inducing lipotoxicity and insulin resistance in these organs (347, 348). Men are
often thought to be at more risk for metabolic complications of obesity, because they tend to
accumulate visceral fat while women, despite their higher percentages of body fat compared to men,
tend to accumulate subcutaneous fat (223). With accumulating age, body fat distribution often shifts
from subcutaneous to visceral depots.
However, only a small portion of total body fat (7-18% depending on sex and the individual) resides
in the abdominal cavity (347). Also, visceral fat contributes to only 15% of the total amount of free
fatty acids in the systemic circulation, majority coming from subcutaneous abdominal or other
subcutaneous depots (347, 349). This has raised questions about the actual contribution of visceral
fat to total body insulin sensitivity. Recent studies present that low visceral adiposity in obese people
is associated with an insulin sensitive obese phenotype (12, 13, 15, 350), often also termed as
“metabolically healthy obesity”. Thus, there is an idea that increased visceral fat mass might
represent the inability of patients with insulin-resistant obesity to store enough fat in subcutaneous
adipose tissue, leading to ectopic fat accumulation and metabolic problems (340). In contrast, a study
by Fabbrini et al showed that surgical removal of omental fat did not improve insulin sensitivity in
obese adults (351).
Subcutaneous and visceral adipose tissues have distinct transcriptomic characteristics. In a study by
Poussin et al, a large group of genes required for the interaction between the adipocyte and its tissue
environment were upregulated in both depots in high-fat fed mice, however with different individual
upregulated genes (352). In visceral adipose tissue, these structural changes in tissue matrix were
related to body fat gain, while in subcutaneous adipose tissue no such connection was observed. The
site-specific gene expression profiles of subcutaneous and visceral adipose tissue have also been
shown in humans (353). Many of the identified genes in humans that are different between
subcutaneous and intra-abdominal fat are involved in developmental patterning (354), suggesting
that there may be differences in the regulation of adipose tissue formation between these two depots.
As preadipocytes from a certain compartment maintain their phenotypic site differences when
mature, adipocytes from different depots have proposed to have different origins (355).
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Subcutaneous and visceral adipose tissue produce different amounts of adipokines, hormones and
inflammation markers, including leptin, angiotensinogen, TNF-α, PAI-1 (356), carboxypeptidase
and thrombospondin (357). The expression of angiotensinogen for blood pressure regulation (358),
complement factors (359), insulin receptor, 11β hydroxysteroid dehydrogenase (11β HSD) (360)
and the acylation stimulating protein ASP are higher in visceral fat, while leptin is largely produced
by subcutaneous adipose tissue (358) and TNF-α by both depots (361). In extreme obesity, IL-6 has
been reported to be derived mainly from visceral adipose tissue (361). In the light of this, it seems
plausible that both adipose tissue depots actively contribute to the development of, or protection,
from the obesity-related metabolic complications.
2.6.2.  Ectopic fat accumulation
Excess fat accumulation is thought to provoke a stress reaction in adipocytes, causing the
development of inflammation and insulin resistance in adipose tissue. This results in the inability of
the adipocytes to ingest more glucose to be stored as fat (7). In obesity, there is downregulation of
fatty acid uptake into adipose tissue (18). When adipose tissue storing capacity reaches its limits,
excess fat starts to accumulate in internal organs like liver, pancreas, muscle and visceral depots (47)
causing their insulin resistance, a phenomenon called ectopic fat accumulation and lipotoxicity (312,
362).  Accumulation  of  excess  fat  in  ectopic  non-adipose  tissues  leads  to  cell  dysfunction  or  cell
death (363). Several studies have demonstrated that lipid accumulation increases in pancreas and
myocardium from lean to obese and to type 2 diabetic individuals (364, 365), suggesting that lipid
accumulation precedes other metabolic problems. Interestingly, the correlation between adipose
tissue mass and developing insulin resistance and other metabolic complications of obesity is not
linear – even some very lean persons may develop insulin resistance, while some obese do not (366,
367). This association can even vary in populations, indicating that there may be genetic
determinants behind it. (366). Apart from excess adipose tissue, also the partial or total absence of
fat is associated with insulin resistance and cardiometabolic disturbances. This is a phenomenon
seen in lipodystrophies, where the patients do not have enough adipose tissue to store fat (368). This
notion supports the prevailing idea that when the oxidative capacity and the storage capacity of
adipocytes are compromised, lipids accumulate to ectopic sites with toxic consequences (362).
Adipose tissue expandability may be an important factor in determining if an individual develops
metabolic complications of obesity or not (340). Obesity-associated insulin resistance and metabolic
disturbances might be postponed if the adipose tissue expandability, especially in subcutaneous
depots, is good (340). Until now however, it has not been known if the expanding capacity of adipose
tissue (by increasing adipocyte number with hyperplasia or adipocyte size by hypertrophy) is a
genetic or an acquired phenomenon. The limit of adipose tissue storage capacity may also differ
between individuals. Although mitochondria have been recognized as important in the preadipocyte
generation and hyperplastic capacity of adipose tissue, the genetic versus environmental reasons
behind the differences in adipose tissue expandability have thus far remained unknown.
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2.6.3.  Liver fat accumulation
Liver plays an important role in lipid metabolism. It harvests free fatty acids (FFA) from the
bloodstream, stores them as lipids and exports as lipoproteins. FFAs in the liver can be metabolized
either by hepatocyte mitochondria through oxidation to produce ATP or through esterification to
triglycerides, which are stored as liver fat or secreted into the bloodstream as lipoprotein particles,
mainly VLDL. Fatty acids can also be used for phospholipid synthesis or ketone body production.
Apart from lipids, the main metabolic functions of the liver include storing glucose as glycogen,
generating it by gluconeogenesis, secreting coagulation factors and producing inflammatory
cytokines (369).
In a fasting state, liver releases glucose into circulation by glycogenolysis and gluconeogenesis
(370). This production is enhanced by glucagon (371) and suppressed by insulin. Fatty acids from
adipose tissue are oxidized in the liver mitochondria or synthesized into VLDL (372, 373). In a
caloric excess state in normal healthy subjects, increasing insulin (374) and glucose concentrations
suppress hepatic glucose production (375). Liver stores dietary glucose as glycogen, oxidizes it for
immediate energy needs or converts the excess amounts into fat by hepatic de novo lipogenesis
(376). FFAs are used to fill the hepatic triacylglycerol stores (377).
The prevalence of fatty liver increases with obesity (378, 379). Overfeeding of 4 weeks with a high-
fat high-glucose diet increased weight by 9%, but liver fat content with 2-3 fold in normal healthy
subjects (380). Weight loss in turn decreases liver fat content (381). The relationship of body weight
and the accumulation of liver fat however is not linear (382). Some subjects develop fatty liver at
different obesity stages than others. In accordance with this, metabolically healthier insulin sensitive
obese subjects have been suggested to have less liver fat than their insulin resistant peers (16, 382).
A study on monozygotic twins discordant for obesity has shown that liver fat content is increased in
acquired obesity independent of genetic effects (383). However, it is not known, if liver fat or some
other metabolic measure distinguishes between health and disease in obesity, and if this association
is genetic or acquired.
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Figure 8: Liver fat accumulation
Figure 8: Obesity and excess energy intake cause adipocyte hypertrophy and adipose tissue
enlargement. Excess subcutaneous adipose tissue enlargement stresses the tissue, causing
mitochondrial dysfunction, increased lipolysis, increased inflammatory secretion, altered adipokine
secretion and insulin resistance of the tissue. Inability of the subcutaneous fat to enlarge sufficiently
leads to increased FFA concentrations in the circulation which deposit as ectopic fat in the liver.
Inflammatory cytokines secreted by adipocytes and adipose tissue inflammatory cells together with
the increased fat content contribute to the insulin resistance state of the liver and the whole body.
Increased liver fat accumulation, whole-body inflammation and insulin resistance present as
metabolic syndrome.
Non-alcoholic fatty liver disease (NAFLD) is defined as a state where over 5% of liver content or
weight is fat. Insulin resistance and inflammatory state, caused by obesity and excess triglycerides,
in adipose and other peripheral tissues such as muscle, also contribute to the increase in plasma
glucose and inflammatory secretion to the circulation. These factors in turn contribute to the fatty
acid deposition and development of inflammation and insulin resistance in the liver. In the insulin
resistant, fatty liver, glucose production is not inhibited despite the increased blood glucose
concentrations. Liver produces excess VLDL particles contributing to the hypertriglyceridemia
often seen in obesity, hyperglycemia by glucose production, systemic inflammation by inflammatory
molecule expression and secretion and increased probability of thrombosis by increased thrombotic
factor secretion. Endoplasmic reticulum (ER) stress in adipose tissue and factors secreted by gut
microbiota may contribute to the FFA deposition and insulin resistance of the liver.
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In obesity, continuous accumulation of fatty acids in liver and inflammatory factors secreted by
adipose tissue (384, 385) can lead to a non-alcoholic fatty liver disease (NAFLD). This comprises a
spectrum of disorders from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) and on
to fibrosis and cirrhosis (386). NAFLD is defined as more than 5% fat content of liver volume or
liver weight (387) and histologically when 5% or more of the hepatocytes contain intracellular
visible triglycerides (388). Features of steatohepatitis include hepatocellular injury (ballooning,
apoptosis and necrosis, Mallory's hyaline bodies and giant mitochondria in hepatocytes),
inflammatory milieu and fibrosis (389). Many (390, 391) studies have found that VLDL-particle
secretion from liver is greater in patients with NAFLD than in those with normal hepatic triglyceride
concentrations. However, for some reason the increased secretion is not enough to compensate for
the increased liver fat deposition.
Intra-hepatic triglyceride content has been directly linked to hepatic insulin resistance by many
studies (326, 392, 393) and NAFLD associated with insulin resistance (394, 395) and obesity (392,
395). The relationship of fatty liver and insulin resistance has been suggested to be independent of
total body fat, visceral fat (396) and intramyocellular fat (397). The development of insulin
resistance and inflammation in the liver is thought to happen simultaneously, at the same time during
the increase in liver fat content. Visceral and subcutaneous adipose tissue enlargement produces
both excess FFAs and inflammatory factors, which activate cascades to impair insulin signaling in
the liver (384). FFAs are released and deposited ectopically uninhibited because of the insulin
resistant state in the adipose depots (398). Adipose tissue derived inflammatory factors and impaired
liver function in turn has been evidenced by an increased expression of inflammatory markers in
subcutaneous adipose tissue of obese women with high liver fat content compared with obese
women with normal amounts of liver fat (399). Insulin resistant state in the liver and other tissues
enhance pancreatic β-cell insulin secretion, and NAFLD has been associated with pancreatic β-cell
exhaustion and dysfunction in obese subjects (400, 401).
In the fatty, insulin-resistant liver the insulin clearance from bloodstream is reduced (402). Inhibition
of hepatic glucose production becomes impaired (326) and  the secretion of VLDL lipoprotein
particles is not sufficiently inhibited (391). Liver overproduces both glucose and VLDL, and plasma
glucose and lipoprotein levels rise. Cytokines and coagulation factors are overproduced. The results
of fatty liver - hyperglycemia, hypertriglyceridemia, low HDL cholesterol concentration and
hyperinsulinemia - are commonly, but not always, seen in the obese state. Hepatic triglyceride
accumulation does not necessarily cause insulin resistance, as demonstrated by mouse studies (403,
404). Thus, while those obese that accumulate ectopic fat and have hypertriglyceridemia and
hyperglycemia are known to be at risk for cardiovascular disease and other metabolic complications
of obesity (405), recent discussion has focused on the possibility that liver fat accumulation might
distinguish between the obese developing metabolic complications from those who do not.
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2.7. Metabolically healthy phenomenon in obesity
Studies in the last decades have shown that some obese humans have a better metabolic profile than
what would be expected regarding their adiposity. This ‘metabolically healthy -obesity’ -phenotype
has been described by several groups already in 1980 (406, 407). From then on, characterizing the
metabolically healthy obese (MHO) phenotype and the mechanisms that would protect the obese
individuals from the metabolic complications of obesity has been the subject of many studies (1,
366, 408, 409). However, there has been some disagreement regarding the characterization of MHO
and thus also its prevalence, because some groups have used the term to mean absence of insulin
resistance  and  some  or  all  features  of  metabolic  syndrome  (1,  410).  Samocha-Bonet  et  al  have
suggested that one possibility would be to look at the insulin sensitivity of the subjects only (408).
In general, as presented in the meeting of IASO in 2013 on healthy obesity, the basic metabolic
characteristics of the healthy obese phenotype are thought to be high level of insulin sensitivity, no
hypertension, a favorable blood lipid profile, little inflammation, good hormonal and immune
profiles as well as a low amount of liver fat despite the persons having excessive body fat (1). Most
of the studies have reported two key characteristics of MHO. The MHO individuals present less
visceral and ectopic fat, in particular in their liver, than obese persons with the same parameters of
adiposity and BMI, but with metabolic abnormalities (1, 16, 408). Another key factor seems to be a
lower degree of systemic inflammation (lower plasma high-sensitivity C-reactive protein) in the
MHO persons compared with other unhealthier obese persons (15, 16, 411). MHO has also been
associated with a lower activation of NLRP3 inflammatory cascade in macrophages of visceral
adipose tissue compared with obese unhealthy individuals, as well as a generally more favorable
inflammatory profile in MHO versus the unhealthy obese (412). 15–30% of the obese individuals,
depending on the metabolic parameters involved and the study groups examined, do not develop
alterations in their metabolic health, at least not in short term (2, 413). The reasons behind this have
remained unclear. It is still not known, which factors distinguish the individuals prone to metabolic
complications of obesity from those who are not.
Adipose tissue hypertrophy/hyperplasia has been postulated as one mechanism distinguishing the
metabolically healthy and the unhealthy obese individuals. Metabolically healthy obese appear to
have smaller adipocytes (circa 15% smaller) than the metabolically unhealthy obese (14, 224).
McLaughlin et al showed that metabolically healthy obese compared with unhealthy peers have
increased expression of genes related to adipocyte differentiation (227). Recently, another study
found that adipose tissue extra-cellular matrix remodeling differed between the two metabolic
groups and adipose tissue enlargement could thus be a factor behind the differences in metabolic
health (414). The expansion of adipose tissue needs the expansion of its vasculature and maintenance
of oxygen supply. A study in obese mice has shown that increasing vasculature in adipose tissue
preserved adipose tissue function in obesity (415).
Differences in the visceral versus subcutaneous fat amount as well as ectopic fat accumulation have
been suggested as important factors in the development of either of the phenotypes. However, these
results are not without controversy. Metabolically healthy obese have been reported to have even
50% less visceral adipose tissue than the unhealthy obese (1, 11, 13). It was thus thought that the
healthy obese could be able to store more fat in their subcutaneous depots (2, 11). However, not all
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studies have found differences in the amount of subcutaneous fat between these metabolic groups
(13, 16). However, ectopic fat accumulation in the liver and skeletal muscle has been shown to be
lower in the metabolically unhealthy obese individuals compared with their unhealthy peers (1, 16).
Hepatic fat content has been associated with the metabolically unhealthy obese phenotype and
insulin resistance (416) and suggested as a determinant of the metabolic health (409).
Interestingly, it has been shown that the MHO phenotype may not be a lasting phase in obesity (417-
419). In these three studies, it was noticed, that time (aging) and probably additional weight gain
may turn the previously “healthy” obese to an unhealthy obese state. It may thus be speculated, that
the “metabolically healthy” phenomenon would only be a transient phase before the measureable
metabolic changes and could just depend on the stage when the individual happens to be examined.
2.8. Twin study setting in obesity research
This thesis is based on studies on young healthy obesity-discordant and obesity-concordant
monozygotic  twins.  Monozygotic  (MZ)  twins  are  born  from  a  single  fertilized  ovum  and  are
genetically identical. Dizygotic (DZ) twins are derived from two different ova and thus share
approximately 50% of their genes, as any siblings do. Usually, a twin study compares the similarity
between MZ and DZ twins (420). If the MZ twins are similar in the investigated variable, but the
DZ twins are less so, the difference is taken as evidence of a genetic effect. Twins often share the
same environment in childhood. MZ twin pairs, who are discordant for the investigated trait, are
invaluable study subjects for that trait, because they are perfectly matched for genes, age, gender
and early environmental influences – and often also matched for environment in adulthood.
Comparing MZ trait-discordant and MZ trait-concordant otherwise healthy twins gives a unique
possibility to discern between genetic and environmental etiologies of the investigated trait. The
factors behind the individual response of fat tissue to obesity, and the development of metabolic
disturbances can in this setting be distinguished from genetic effects. The role of mitochondria in
acquired obesity has not yet been studied in twins. The MZ co-twin control setting is ideal for
discerning the factors behind mitochondrial dysfunction that are caused by obesity.
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3. AIMS OF THE STUDY
The overall aim of this thesis was to study the biological pathways in adipose tissue that lead to the
development of metabolic complications in obesity and to detect novel factors associated with
obesity-related diseases.
Specifically the aims were
1) To study the effects of acquired obesity on adipocyte size and number and how these factors
relate to the development of metabolic complications in obesity.
2) To study different fat depots and transcriptional pathways in adipose tissue related to
mechanisms maintaining the “metabolically healthy obesity”, where a subset of obese
individuals stay free from the metabolic complications usually associated with weight gain.
3) To study mitochondrial biogenesis and oxidative metabolism in adipose tissue in acquired
obesity, and the associations of these factors to adipose tissue metabolism and metabolic
complications of obesity.
4) To study the effects of acquired obesity on mitochondrial biogenesis in adipocytes and
compare the gene expression results and other mitochondrial parameters in adipocytes and
adipose tissue.
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4. SUBJECTS
4.1. FinnTwin16 and FinnTwin12 birth cohorts
The studied twins were recruited from two population-based longitudinal birth cohorts: FinnTwin16
and FinnTwin12, all twins living and resident in the country. Originally the twins and their families
were followed up and studied for health behaviors. FinnTwin16 consists of five consecutive birth
cohorts (1975-1979) of Finnish twins and their families, identified from the Central Population
Registry of Finland (421). Data collection was started in 1991 and the baseline questionnaire was
conducted at the twins 16th birthday or in 60 days’ time of it. At baseline, there were 2733 twin pairs.
The respondents were surveyed again at 17 and 18.5 years and at 22-27 years (response rates 83%
to 97%, n = 5,601 at baseline). FinnTwin12 also consists of five birth cohorts (1983-1987) identified
from the Central Population Registry of Finland (421, 422). In FinnTwin12, of all eligible families,
87% completed the family questionnaire and thus around 2800 families were participating at the
baseline. These twins were originally 11-14 years of age at the beginning of the study and were
followed up at regular intervals, 11 to 12, 14, and 17.5 years of age, and a subgroup until young
adulthood (20-25 years) (response rates 74% to 92%, n = 5,184 at baseline).
4.2. Subjects included in the thesis project
For the TwinFat 2008 study and this thesis project, the twins were recruited from both FinnTwin16
1975-1979 (FinnTwin16, n=2 839) and 1983-1987 (FinnTwin12, n=2 578) registries. Together, 26
rare weight-discordant (intra-pair difference (Δ) in BMI 3-10 kg/m2, males n = 9, females n = 17,
aged 29.9 ± 0.6 years) and 14 concordant (ΔBMI 0-2 kg/m2, males n = 9, females n = 5, aged 31.6
± 0.6 years) young healthy adult monozygotic (MZ) twin pairs between the age of 22-36 were
studied. All twins were healthy with no diagnosed diseases, except that one obese co-twin had type
2 diabetes mellitus and used metformin and insulin. Another obese co-twin had an inactive ulcerative
colitis and used mesalazine and azathioprine. All other subjects were healthy, normotensive and did
not take any regular medications except for contraceptives. The twins’ body weights had been stable
for at least 3 months prior to the study. The zygosity of the twins was confirmed by genotyping ten
informative genetic markers (423). Additionally, adipocytes from six obese and seven lean
volunteers were used in study IV. A written consent for the study was obtained from all participants.
The study protocol was designed and performed according to the principles of the Helsinki
Declaration and approved by the Ethical Committee of the Helsinki University Central Hospital.
Subgroups  of  the  twins  for  the  four  studies  in  this  thesis  were  as  follows  (Figure  9):  15  weight-
discordant and five weight-concordant MZ twins were included in study I. Study II included 16
obesity-discordant and 11 concordant twin pairs. In study III, 26 obesity-discordant and 14
concordant twin pairs were used in the transcriptomics analyses, 15 discordant MZ twin pairs in the
laboratory measurements of mtDNA amount and mtDNA transcripts, seven discordant MZ twin
pairs  in  the  OXPHOS  Western  Blot  analysis  and  24  discordant  MZ  twin  pairs  for  epigenetic
analyses. Study IV included 14 discordant and five concordant MZ twin pairs, and additionally seven
lean and six obese individual volunteers for the OXPHOS Western Blot analyses
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Figure 9: Subgroups of the twins in the studies I-IV
4.3. Study design
The twins were studied extensively. Body composition of whole body fat percentage was measured
by DEXA (dual energy x-ray absorptiometry), body fat distribution of subcutaneous and visceral
adipose tissue were measured by MRI (magnetic resonance imaging) and liver fat by MRS (proton
magnetic resonance spectroscopy). Oral glucose tolerance test (OGTT), lipids, adipokines, hs-CRP
and other metabolic measurements were performed. Subcutaneous adipose tissue biopsies under the
umbilicus were taken, the total RNA of adipose tissue and adipocytes extracted and genome-wide
transcriptomics analyses of adipose tissue and adipocytes performed. Differences between the obese
and the lean co-twins in pathways related to adipocyte morphology, metabolic disturbances,
mitochondria-related nuclear and mitochondrial transcription and inflammation in subcutaneous
adipose tissue and adipocytes were analyzed. Adipocytes were photographed and calculated and the
diameters of the cells were measured. Total DNA from adipose tissue samples was extracted and
the amount of mtDNA determined. MtDNA-encoded transcripts were measured. Western blot of
total adipose tissue (twins) and adipocyte (obese and lean individuals) lysates were performed for
OXPHOS complexes I, II, III, IV and V.
53
5. METHODS
5.1. Clinical assessments
Weight and height were measured after a 12-hour overnight fast in light clothing for the calculation
of body mass index (BMI). Body composition was determined by dual-energy X-ray absorptiometry
(Lunar Prodigy, Madison, WI, software version 8.8) (424), the amount of SAT and visceral adipose
tissue (VAT) by MRI and liver fat by MRS with a 1.5 Tesla MRI imager (Avanto, Siemens, Erlangen
Germany) (425). Parental weight, height and age were recorded at the twin age of 16.
5.2. Blood tests and analytical measurements
Concentrations of fasting plasma glucose were measured after a 12 h overnight fast, using the
spectrophotometric hexokinase and glucose-6-phosphate dehydrogenase assay (Gluko-quant
glucose/hexokinase, Roche Diagnostics) with a Hitachi Modular automatic analyser and fasting
serum insulin with time-resolved immunofluorometric assay (Perkin Elmer). A 75 g oral glucose
tolerance test (OGTT) was performed to calculate HOMA-insulin resistance index as [fasting
glucose (mmol/l) x fasting insulin (mU/l)/22.5] (426), Matsuda index (427) and insulinogenic index
(428). The twin with type 2 diabetes was not included in the OGTT analyses. Plasma total
cholesterol, HDL cholesterol and triglyceride concentrations were determined with enzymatic
methods (Roche Diagnostics Hitachi, Hitachi Ltd, Tokyo, Japan). LDL cholesterol was calculated
from the Friedewald formula. Serum high-sensitivity C reactive protein (hs-CRP) was measured by
particle-enhanced immunoturbidimetric assay (Cobas CRP (Latex) HS, Roche Diagnostics) on
Modular automatic analyzer (Hitachi Ltd, Tokyo, Japan) and plasma leptin, adiponectin, adipsin and
resistin by enzyme-linked immunosorbent assay (ELISA) by using DuoSet ELISA, R&D Systems
Europe Ltd, Abindgon, UK.
5.3. Subcutaneous abdominal adipose tissue biopsies
Surgical biopsy samples of abdominal SAT under the umbilicus were obtained under local
anesthesia and snap frozen in liquid nitrogen. Adipocytes were collected from fresh adipose tissue
biopsies by digesting a piece of adipose tissue in 2% collagenase-DMEM/F-12. The reaction was
stopped after 1h by DMEM/F-12 supplemented with 10% NCS, the solution centrifuged to produce
an adipocyte upper layer and adipocytes collected and washed twice with DMEM/F-12. Based on
the  availability  of  sample  material,  the  frozen  tissue  specimens  of  adipose  tissue  or  the  fresh
adipocytes were used for transcriptomics analyses for adipose tissue (Affymetrix, all 26 discordant
and 14 concordant twin pairs) and adipocytes (Affymetrix, 14 discordant and 5 concordant twin
pairs), determination of the mtDNA amount in adipose tissue (15 discordant twin pairs),
determination of mtDNA-encoded transcript levels in adipose tissue (15 discordant twin pairs) and
adipocytes (12 discordant twin pairs) and an OXPHOS protein analysis in adipose tissue (7
discordant twin pairs). Additionally, adipocytes from six obese and seven lean individuals were used
for OXPHOS analysis in article IV. 24 discordant and 11 concordant twin pairs were available for
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DNA methylation analyses in adipose tissue for article III. Clinical characteristics of the selected
and unselected twin pairs were similar.
5.4. Adipose tissue (AT) and adipocyte RNA extraction,
transcriptomics analyses and data validation
Total RNA was extracted from the whole SAT biopsies and from the adipocytes by using the RNeasy
Lipid  Tissue  Mini  Kit  (Qiagen)  with  a  DNase  I  (Qiagen)  step  according  to  the  manufacturer’s
instructions. Gene expression studies in the articles I, II and III of the thesis were done with whole
AT biopsy samples that included stromal vascular fraction cells (SVFC). In article IV of the thesis,
both adipocyte and adipose tissue gene expression data were used in 14 discordant twins. Total RNA
(500  ng)  from  all  twins  in  AT  and  adipocytes  was  used  for  the  gene  expression  analysis  on
Affymetrix U133 Plus 2.0 array. The labeling and hybridization were done according to the
manufacturer's instructions. Pre-processing of the expression data was done using BioConductor
(429) and the GC-RMA algorithm in articles I, III and IV. In article II, the data were normalised
using the GC-RMA algorithm and analyzed by the GeneSpring GX 7.3 software (Agilent
Technologies, Santa Clara, CA, USA).
The AT data were validated with four key genes in adipose tissue in 14 discordant pairs. Individual
transcript levels in adipose tissue were used for leptin (probe 207092_at), adiponectin (207175_at)
and hormone-sensitive lipase (LIPE) (208186_s_at) in article II. Transcript levels of leptin,
adiponectin, LIPE and MCP1 (also known as CCL2) were validated by quantitative PCR (iQ5 Real-
Time PCR Detection System; Bio-Rad, Hercules, CA, USA). Samples were run in triplicate and the
comparative Ct method was applied using four housekeeping genes (B2M, YWHAZ, PPIA and
RPLP0). Spearman correlations between quantitative PCR and Affymetrix were: leptin r =0.82,
adiponectin r =0.71, LIPE r=0.58 and MCP1 r =0.94 (all p <0.002).The transcriptomics data of
adipose tissue was published with article II and the data of adipocytes with article IV.
5.5. Adipocyte morphology
For the measurement and calculation of adipocyte volume and number, part of the adipose tissue
sample was digested in 2% collagenase-DMEM/F-12 media for 1h and then supplemented with 10%
newborn calf serum (NCS) (430). The solution was centrifuged to produce an adipocyte upper layer.
After washing the adipocytes twice with DMEM/F-12 media, photographs of the adipocytes were
taken with a light microscope (Zeiss, Axioplan2) using magnification 50x. Diameters of 200 cells
were measured by image processing and analysis software ImageJ (ImageJ 1.42q/ Java 1. 6.0_10
32-bit) (430). Adipocyte volume and number were calculated as explained below (430) and as
published before (61, 120). Mean adipocyte diameters, volumes and adipocyte number were
calculated for each individual using the following formulas:
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V=cell volume (μm3), d=cell diameter (μm), w=cell weight (μg), n=total adipocyte number, where
m=total  body  fat  mass  (kg)  and  V  (m3)*rho (density, fat) =mean weight of a single adipocyte.
Density of fat cell triglycerides=0.915g/mL (22). Adipocytes were assumed to be spheres.
In the first article of the thesis, the distribution of adipocyte volumes was divided into quartiles with
the lowest 25% quartile representing “small cells” (<160 pL) the mid-quartiles for the “medium”
(160-330 pL) and “large cells” (330-550 pL) and the top 25% quartile for the “extra-large” cells
(550-2 000 pL). The proportions of small, medium, large and extra-large cells were calculated for
each individual.
The twins were also divided into two groups in regard to ‘hyperplastic’ and ‘hypertrophic’ obesity,
where in the hyperplastic group the obese co-twins had responded to obesity with increasing their
cell count and had more cells compared with their leaner co-twins, whereas in the hypertrophic
profile the obese twins had less or a similar amount of cells than their leaner co-twins. However, all
the obese co-twins had larger adipocytes than their lean co-twins. The ‘hypertrophic’ group in this
thesis  means the twin pairs  where the obese co-twins had no hyperplasia  and thus no increase in
their  cell  count  despite  increased fat  mass (relative to their  lean co-twin)  and exhibited relatively
more hypertrophy than the ‘hyperplastic’ group (430).
5.6. Bioinformatics and pathway analyses
In article I of the thesis, the bioinformatics analyses were performed to find associations between
obesity-induced changes in adipocyte size and number and global adipose tissue gene expression.
Log 2 transformed gene expression fold changes (FC) (heavier/leaner co-twins in all pairs) were
paired with log 2 fold changes (heavier/leaner co-twins) in adipocyte size. The correlation limit was
set to 0.6 for both positive and negative correlation. All the resulting correlations were statistically
significant with a correlation p-value less than 0.05. The p-values were then adjusted for multiple
testing by pFDR (431), which results in a q-value. All the q-values were considered significant with
a value of less or equal to 0.25. The computational platform Moksiskaan (432) was used to study if
the identified correlating genes were involved in similar molecular circuits, how they interact with
each other and which signaling pathways they were involved in. Moksiskaan constructs a network
for a list of correlating genes by using literature-driven pathway information from several databases
to identify known regulations between the genes in the list of interest. All the correlating genes with
correlation limit +/-0.6 and p-value < 0.05 were used as an input to Moksiskaan pathway analysis.
A comprehensive network was constructed by using all 206 imported pathways to identify known
regulations between the correlating genes. Connections between the correlating genes were
identified with a maximum of one intermediate gene from the correlating genes list. Orphan genes
with no neighbours were removed from the network. The transcriptomics data analyses were
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performed using the Anduril data analysis framework (433) and R (The R Foundation, R
Development Core Team).
In article II, the bioinformatics analyses were done with GeneSpring GX 7.3 software. Based on the
GO enrichment analysis, six pathways of interest—‘branched-chain amino acid (BCAA)
catabolism’ (gene ontology [GO]: 009083), ‘fatty acid β oxidation’ (GO: 0006635), ‘oxidative
phosphorylation’ (GO: 0006119), ‘triacylglycerol synthesis’ (GO:0019432), ‘white adipose cell
differentiation’ (GO: 0050872) and ‘chronic inflammatory response, CIRP’ (GO: 0002544)—were
selected, for which a mean centroid value (indicating mean activity of the pathway) was calculated.
The mean centroid values for articles II, III and IV were calculated by normalizing the expression
levels  of  the  regulated  genes  in  each  pathway  to  a  mean  of  zero  and  a  variance  of  1  across  all
individuals (262) and by using Affymetrix gene expression data for the genes included in the
pathway.  In  addition,  in  articles  III  and  IV,  the  mean  centroid  values  were  calculated  for  the
expression of the small (MRPS, n = 30 (adipose tissue) /29 (adipocytes) subunits) and large (MRPL,
n = 50 (adipose tissue) /49 (adipocytes) subunits) mitochondrial ribosomal proteins in adipose tissue
and adipocytes respectively.
In articles  III  and IV of  the thesis,  the Limma (434) package of  Bioconductor  (429) was used to
identify differentially expressed genes genome-wide between the obese and the lean co-twins in the
discordant pairs. In the third article, we then looked whether the differentially expressed genes were
found in MitoCarta (75), an online atlas of 1013 human genes, which encode proteins with
mitochondrial localization. Forty-nine of the 1013 Mitocarta protein transcripts were not detectable
by Affymetrix probes, including the 13 mtDNA-encoded OXPHOS transcripts. Identified
mitochondria-related transcripts were further subjected to QIAGEN´s Ingenuity® Pathway Analysis
(IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity) to reveal the pathways and the
upstream regulators of the transcripts. The top 10 significant pathways were selected for further
examination and for calculation of overall pathway activity. In article IV, the significantly
differentially expressed genes between the co-twins in adipocytes and adipose tissue were subjected
to IPA-analysis as above and the 10 top significant pathways and their mean centroids analyzed
from both datasets. In addition, all the significantly differentially expressed genes between the co-
twins that were also consistently up- or downregulated in the heavy co-twin, in at least 12 out of the
altogether 14 discordant twin pairs were analyzed with IPA pathway analysis as above.
5.7. DNA methylation analyses (AT)
DNA methylation values in article III (beta-mixture quantile normalization, BMIQ) of all probes
mapping to the differentially expressed MitoCarta genes and the upstream regulator PGC-1α in SAT
were picked from the Illumina HumanMethylation BeadChip. Differential methylation analysis of
the CpG sites on these genes was performed by using paired moderated t-tests (R Bioconductor)
(429) in the discordant pairs and relationships between methylation in significant CpG sites and the
expression of their associated genes by Spearman correlations in the individual twins.
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5.8. Adipose tissue DNA extraction and qPCR for the measurement of
mtDNA copy-number (AT)
Total DNA from the SAT samples of 15 BMI-discordant twin pairs was extracted with the standard
phenol/chloroform and ethanol precipitation method. The amount of mtDNA was determined by a
quantitative real-time PCR (qPCR). The amplification of mitochondrial cytochrome B (CYTB) gene
was normalized to the amplification profile of nuclear amyloid beta precursor protein (APP) gene.
The qPCR was performed from 25ng of total DNA by SYBR Green PCR Master Mix (iQ Custom
SYBR Green Supermix, Bio-Rad, US) according to the manufacturer´s instructions on CFX96 Real-
Time PCR Detection System (Bio-Rad). The PCR cycling conditions were: 95°C for 5min, followed
by 40 cycles of 95°C for 15s, 60°C for 30s. Q-PCR data were analyzed by comparative ΔΔ Ct with
Bio-Rad CFX Manager v.1.6 software.
5.9. qRT-PCR for the measurement of mtDNA transcripts (AT and
adipocytes), mitochondrial regulator PGC-1α (AT and adipocytes)
and other individual transcript levels (AT)
With AT samples, total extracted RNA (250ng) from SAT of 15 discordant twin pairs was treated
with RQ1 DNase in 20μl of reaction volume (Promega, Madison WI, USA). cDNA was generated
by Maxima synthesis kit (Maxima First Strand cDNA synthesis kit for qRT-PCR, Thermo Scientific)
of DNAse treated RNA, done according to the manufacturer’s instructions.  PCR amplifications of
mtDNA-encoded 12S rRNA (MT-RNR1), 16S rRNA (MT-RNR2), and mRNAs (MT-COX1, MT-
ND5, MT-CYTB) were performed in 1/ 100 cDNA dilution with SYBRgreen PCR Master Mix (iQ
Custom SYBR Green Supermix, Bio-Rad, US) according to the manufacturer´s instructions using
CFX96 Real-Time PCR Detection System (Bio-Rad). The PCR cycling conditions were: 95°C for
5min, followed by 40 cycles of 95°C for 15s, 60°C for 30s. All samples were run in triplicates and
data were analyzed with ΔΔ Ct method. The multicopy nuclear-encoded 18S rRNA gene and the
two-copy GAPDH gene (data not shown) were used as control genes.
In adipocytes, a total of 300 ng of RNA was used to generate cDNA with the iScript cDNA Synthesis
Kit (iScript cDNA Synthesis Kit, 170-8891, Biorad, UK) according to the manufacturer’s
instructions. PCR amplifications of mtDNA-encoded 12S rRNA (MT-RNR1), 16S rRNA (MT-
RNR2), and mRNAs (MT-COX1, MT-ND5, and MT-CYTB) were performed with SYBRgreen
PCR Master Mix according to the manufacturer’s guidelines in the final volume of 20μl (IQ Custom
SYBR Green Supermix 170-8860, Biorad, UK) by CFX96 Real-Time PCR Detection System (Bio-
Rad). The PCR cycling conditions were as described above. The multicopy nuclear-encoded 18S
rRNA gene, the two-copy GAPDH gene, YWHAZ gene and IPO8 gene were used as control genes.
The  qRT-PCR  data  were  analyzed  by  qBASE+  (version  2.6.1,  Biogazelle,  Belgium)  software,
comparing the expression of target genes individually to the expression of all four control genes.
The Affymetrix microarray PGC-1α probes in AT and adipocytes were targeted to 3´UTR region of
the longest mRNA isoform (ENSG00000109819) that is not shared with other protein coding PGC-
1α isoforms.  The  expression  of  PGC-1α was  validated  by  using  iQ  Real-Time  PCR  Detection
58
System (Bio-Rad) and the comparative ΔΔ Ct method with 18S rRNA as a housekeeping gene for
AT  (article  III).  For  adipocytes  (article  IV)  the  data  were  analyzed  by  qBASE+  (version  2.6.1,
Biogazelle, Belgium) software as described above with four individual control genes. The target
genes of PGC1- and other upstream regulators were found in the upstream regulator analysis of
IPA.
5.10. Western Blot for the measurement of OXPHOS protein levels (AT
and adipocytes)
For article III, SAT from seven discordant twin pairs was available for protein extraction. Sample
lysates were obtained by homogenization in 1% n-dodecyl β-D-maltoside (DDM, Cayman) in PBS
with  protease  inhibitors  (Roche).  For  the  Western  Blot,  20μg  of  total  adipose  tissue  lysates  was
separated on 12% SDS-PAGE gels. The primary antibodies used were mouse monoclonal antibodies
against complex I – NDFUA9 (MS111, Mitosciences), complex II 70kDa subunit (MS204,
Mitosciences), complex III core 2 subunit (MS304, Mitosciences), complex IV subunit I (MS404,
Mitosciences), and complex V subunit α (MS507, Mitosciences), The rabbit polyclonal antibodies
were against PORIN (Abcam) and β-TUBULIN (Cell Signaling), and goat polyclonal antibody
against  ACTIN  (I-19,  Santa  Cruz  Biotechnology).  Antibodies  were  diluted  in  1%  BSA/  Tris-
buffered saline and 0.1% Tween 20 (TBST) at 1:2000 (CI), 1:5000 (CII), 1:2500 (CIII), 1:500 (CIV)
and 1:1000 (PORIN, TUBULIN, ACTIN) and incubated at 4°C overnight. Secondary HRP-
conjugated anti-mouse, anti-rabbit and anti-goat antibodies (1:10 000, Molecular Probes) were
incubated with the membranes in 1% milk/ TBST for 1h at room temperature. The proteins were
quantified with Image Lab v3.0 software.
For article IV, adipocytes from six obese and seven lean individual volunteers were used for Western
Blot  analysis.  Protein  lysates  were  obtained  by  homogenization  in  ice-cold  RIPA  buffer  with
protease inhibitors (Roche). For the Western Blot, 10μg of the lysates was separated on 4-20% SDS-
PAGE gels. The primary antibodies used were Total OXPHOS antibody mixture (110411; Abcam);
NDUFB8 (complex I), SDHB (complex II), subunit core 2 (UQCRC2) of complex III, COX2
(complex IV) and ATP5A (complex V). Additionally, individual antibodies were used for complex
III core 2 subunit (MS304) and complex V subunit α (MS507, Mitosciences). Actin (Santa Cruz
Biotechnology), Vinculin (Abcam ab129002) and Porin (Abcam) were used as controls. Antibodies
of Total OXPHOS and Vinculin were incubated in 5% milk/ Tris-buffered saline and 0.1% Tween
20 (TBST) and CIII, CV, Actin and Porin in 1% BSA/TBST at 1:1000 concentrations overnight in
4°C. Vinculin was used at 1:10 000 concentration. Secondary HRP-conjugated anti-mouse (Santa
Cruz), anti-rabbit (Jackson ImmunoResearch) and anti-goat (Calbiochem 401504) (1:2500) were
used in 5% milk/TBST for 1h in room temperature. The proteins were quantified with ImageLab
v3.0 software.
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5.11. Family history and lifestyle factors (diet, alcohol intake, smoking
and physical activity) in the discordant pairs
The dietary intake of the twins was assessed from three-day food records and analyzed by the Diet32
program (Aivo), based on a national Finnish database for food composition (Fineli, www.fineli.fi,
National  Institute  for  Health  and  Welfare,  Nutrition  Unit,  Helsinki,  Finland).  Information  on  the
weekly alcohol intake and smoking habits during the past four weeks before the study (study II) was
obtained by structured questionnaires. Physical activity was assessed by Baecke- questionnaire and
its three sub-compartments (sport-, leisure time and work indexes) (435). The parents were
examined by questionnaires (age, height, weight) when the twins were 16 years of age.
5.12. Statistical analyses
Basic statistical analyses were performed using Stata statistical software (Releases 11.0, 12.0 and
13.0 Stata Corporation, College Station, TX). Results are expressed as mean±SE. Differences
between co-twins were calculated by paired Wilcoxon’s signed rank tests and differences in the
protein levels between lean and obese individuals by Mann Mann–Whitney U -test. Intra-class
correlations were used to analyze the resemblance between the co-twins. To test the frequencies
between two groups, chi-squared distributions were exploited. Within pair differences (Δ) of all
clinical and metabolic parameters were obtained by subtracting the leaner co-twin’s value from the
heavier co-twin’s value. Within-pair differences (Δ) were then correlated using the Spearman
correlations. QRT-PCR and Western Blot results were calculated by paired Wilcoxon’s signed rank
tests for twins. Correlations between metabolic and the investigated variables in all concordant and
discordant twin individuals were calculated using Pearson correlations, corrected for clustered
sampling of co-twins by survey methods (436). Logarithmic corrections (log base 10) were used for
non-normally distributed variables, and the correlation coefficients adjusted for multiple
comparisons. Since the high correlation among the variables made the traditional Bonferroni
correction for multiple testing too conservative, the number of principal components was used to
provide a proper P-value threshold. The variables in the correlation tables presented in the thesis
produced one to five principal components, which explained 79-90% of the variance. Therefore, the
adjusted significance level for analyses in the subsequent correlation tables were P < 0.05 divided
by the number of principal components that were analyzed for each table separately. To test whether
adipocyte volume and size were related to clinical and metabolic measures independent of the within
pair difference in body fat, the ratios of Δadipocyte volume/Δkg fat and Δadipocyte number/Δkg fat
were used in the correlation analyses. Multiple regression analysis was used to test whether
Δadipocyte volume and Δadipocyte number independently associated with metabolic measures.
In article II, the obesity-discordant MZ pairs were divided into two subgroups according to the
amount of their liver fat: those who were discordant - group 2 with high ≥2% within-pair differences
in liver fat (n = 8) - and those who were concordant - group 1 with low <2% delta ∆ liver fat (n = 8).
In group 1 were those obesity-discordant co-twins that were metabolically similar, and in group 2
those co-twins where the obese co-twin had a higher liver fat amount compared to their leaner co-
twins and metabolic disturbances. The Mann–Whitney U test was used to compare differences
between lean in the liver fat group 1 vs group 2, as well as obese in group 1 vs group 2. Sex
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distributions between the groups were tested by the χ2 test. Analyses on leptin were performed with
sex-adjusted values because women had higher circulating and adipose tissue transcript levels of
leptin than men. Multiple regression analyses were performed to detect independent predictors of
Δliver fat.
GO enrichment analysis was used to compute hypothesis-free enrichment of GO terms (molecular
function) in each of the groups in article II (weight-concordant, group 1 discordant and group 2
discordant). Enrichment analysis was done using Fisher’s Exact Test. Fisher’s test compares the
observed frequency of each present GO term to the frequency in a reference gene set (whole gene
array). A GO term is present if some input gene is annotated with the GO term or its descendants.
The p-values were adjusted using the Benjamin and Hochberg FDR. The GO enrichment analysis
was performed using the Anduril data analysis framework (433) and R.
Identical twins are a powerful study setting. Power calculations show that 12 twin pairs is needed to
detect 20% differences with P<0.05 significance level and 0.80 power in insulin resistance and other
studied metabolic measures between the obese and the lean co-twin.
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6. RESULTS
6.1. Characteristics of the twins (I-IV)
Characteristics of the twins are presented in Table 1. In total, the obese (BMI 31.3 ± 1.0 kg/m2) and
the lean (25.3 ± 0.9 kg/m2) co-twins of the discordant pairs (n = 26) had a mean difference of 18 ±
0.5 kg (P <0.001) in body weight. The obese co-twins had significantly more SAT, VAT, and liver
fat; larger adipocytes; higher plasma leptin levels; lower plasma adiponectin levels; lower HDL and
higher LDL cholesterol level as well as higher plasma triglyceride levels, and they were more insulin
resistant than the lean co-twins. The concordant co-twins (n = 14) had similar body composition and
metabolic measures (Table 1) and also did not differ in their mitochondrial parameters.
Table 1: Clinical characteristics of the monozygotic (MZ) twins
Variable Weight-discordant pairs
(ΔBMI >3 kg/m2, n = 26)
Weight-
concordant
pairs (ΔBMI
<3 kg/m2, n =
14)
Leaner co-twin Heavier co-
twin
p-value* Both co-twins
Age (years) 29.9 ± 0.9 29.9 ± 0.9 0.33 31.6 ± 0.6
Weight (kg) 75.4 ± 3.5 93.3 ± 4.0 < 0.0001 79.3 ± 2.5
Height (cm) 171.9 ± 2.0 172.2 ± 1.9 0.38 171.5 ± 2.0
BMI (kg/m2) 25.3 ± 0.9 31.3 ± 1.0 < 0.0001 26.9 ± 0.7
Body fat % 32.3 ± 1.8 41.1 ± 1.3 < 0.0001 29.2 ± 1.7
Fat (kg) 24.9 ± 2.2 38.2 ± 2.1 < 0.0001 23.5 ± 1.7
Fat free mass (kg) 48.0 ± 2.1 52.1 ± 2.5 0.0001 53.4 ± 2.0
Subcutaneous fat (dm3) 3813.7 ± 416.8 6358.9 ± 540.4 < 0.0001 3256.3 ±
261.2
Intra-abdominal fat (dm3) 790.2 ± 178.9 1643.7 ± 247.4 < 0.0001 1065.2 ±
130.0
Liver fat (%) 1.12 ± 0.32 4.52 ± 0.99 < 0.0001 2.87 ± 0.98
Adipocyte volume (pL) 355.6 ± 34 547 ± 59 0.0008 412.0 ± 46.2
Adipocyte number (1013) 8.4 ± 0.74 8.3 ± 0.60 0.95 7.82 ± 0.60
fP-glucose (mmol/L)† 5.1 ± 0.1 5.3 ± 0.1 0.17 5.4 ± 0.1
fP-insulin (mU/L)† 4.9 ± 0.5 8.5 ± 1.2 0.0011 5.5 ± 0.6
HOMA-index† 1.1 ± 0.1 2.1 ± 0.3 0.0010 1.3 ± 0.2
Matsuda-index† 8.6 ± 0.9 6.0 ± 0.7 0.0089 9.9 ± 1.3
AUC Insulin in OGTT
(mU/L)
87.6 ± 8.0 129.3 ± 24.6 0.031 77.5 ± 10.9
Total cholesterol
(mmol/L)
4.4 ± 0.2 4.7 ± 0.2 0.14 4.5 ± 0.2
LDL cholesterol (mmol/L) 2.6 ± 0.1 3.0 ± 0.2 0.034 2.8 ± 0.2
62
HDL cholesterol
(mmol/L)
1.6 ± 0.1 1.3 ± 0.1 0.0004 1.3 ± 0.1
Triglycerides (mmol/L) 0.94 ± 0.1 1.32 ± 0.2 0.014 1.02 ± 0.13
fP-Leptin (mg/mL) 18.9 ± 4.1 34.6 ± 5.5 0.0015 28.4 ± 10.2
fP-Adiponectin (μg/mL) 2.8 ± 0.3 2.2 ± 0.2 0.0023 2.2 ± 0.1
fS-hs-CRP (mg/dL) 2.6 ± 0.7 4.0 ± 1.1 0.065 1.2 ± 0.3
Adipsin (ng/mL) 1190 ± 45 1310 ± 47 0.0063 1070 ± 71
Resistin (ng/mL) 9560 ± 1440 10060 ± 1360 0.0694 7670 ± 4630
Total physical activity 8.9 ± 0.2 8.3 ± 0.2 0.213 8.9 ± 0.3
Sport-index 3.2 ±0.2 2.7 ± 0.2 0.061 3.3 ± 0.2
Leisure-index 2.8 ± 0.1 2.8 ± 0.1 0.837 2.8 ± 0.1
Work-index 2.8 ± 0.1 2.8 ± 0.1 0.466 2.8 ± 0.1
*Wilcoxon’s rank sum test was used to compare values of the leaner versus the heavier co-twin. †n
= 25 obesity-discordant MZ pairs. AUC, area under the curve; fP, fasting plasma; fS, fasting serum;
HOMA, homeostatic model assessment; hs-CRP, high-sensitivity C-reactive protein; OGTT, oral
glucose tolerance test; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue. Data
represent means with SE.
6.2. Adipose hypertrophy and hyperplasia in obesity (I)
6.2.1 Obesity increases adipocyte hypertrophy, but adipocyte number remains the same
due to genetic factors
Adipocyte size is  known to increase in obesity,  but  how this  is  influenced by genetic  factors  has
been debated. Of the total 40 twin pairs included in this thesis, study I involved 20 pairs of MZ twins
(ΔBMI range: 0.86-9.95 kg/m2), of which 15 were defined as discordant for obesity (∆BMI >
3kg/m2, here mean±SE ∆BMI 5.7±0.55) and the other 5 were defined as concordant (∆BMI
<3kg/m2, here mean±SE ∆BMI 1.7±0.37) (Table 1). The concordant MZ pairs were remarkably
similar both for adipocyte number (intra-class correlation between the obese and the lean co-twin
ICC=0.91, p=0.0021, 95%CI 0.77-1.06) and for adipocyte size (ICC=0.92, p=0.0021, 95%CI 0.79-
1.05) (Figure 10). However, for the discordant MZ pairs, the twins resembled each other for
adipocyte number (ICC=0.63, p=0.0041, 95%CI 0.31-0.94) but less so for size (ICC=0.34, p=0.094,
95%CI 0.00-0.80).  Each individual presented with a wide distribution of cell sizes. In the discordant
pairs, the distribution of adipocyte cell size differed significantly between the co-twins (Figure 10).
When compared with the lean co-twins, the obese had significantly fewer small cells (volume<160
pL) (20% vs. 31%, p=0.0046) and more extra-large cells (volume 550-2,000 pL) (29% vs. 21%,
p=0.039). The differences in the proportions of medium-sized (volume 160-330 pL) or large cells
(330-550 pL) were not significant between obese and lean twin pair members (23% vs. 27%, p=0.15,
and 27% vs. 21%, p= 0.075). On average, the cell size was larger in the obese than in the lean co-
twins (61±12%, range -2.9-122%, p=0.0008) (Table 1). All but one of the obese co-twins had larger
mean adipocyte size compared with the lean co-twins.
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Figure 10: Adipocyte volume and number in the discordant and concordant co-twins
Figure 10: In the concordant co-twins the within-pair differences (intra-class correlation, ICC) in
both adipocyte volume (r=0.92, p ≤ 0.01) and number (r=0.91, p<0.01) were linearly correlated
between the co-twins, speaking for a tight regulation of adipocyte number and volume. The
distribution of small and large cells did not differ significantly between the co-twins. In the
discordant pairs, adipocyte number increased linearly (r=0.65, p<0.01) between the twins, but
adipocyte volume less so (r=0.34, p=0.09). During weight gain, adipocyte number seems to be
stable and based on the extreme similarity between the MZ twins, being tightly genetically regulated,
while environmental factors affect adipocyte volume in an excess energy state. In the discordant
pairs, the lean co-twins had significantly more small adipocytes (p=0.0046) and less extra-large
cells (p=0.039) than their obese peers.
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When inspecting the obesity-discordant data as a whole, the total cell numbers did not differ between
the co-twins (Table 1), but in turn, considerable variability between twin pairs could be observed.
In a proportion (7/15) of the discordant twin pairs the obese co-twins had more while in the other
proportion (8/15) they had less adipocytes than their leaner co-twins. The range of ∆adipocyte
number (obese minus lean co-twin) varied from -38% to 53%. This suggested that some twin pairs
seemed to react to obesity with increased adipose cell proliferation and thus hyperplasia, while
others reacted with more pronounced hypertrophy (and hypoplasia). Obese co-twins who had an
increased adipocyte count compared with their lean co-twins (hyperplastic obesity) were
indistinguishable from their lean counterparts in most metabolic measurements (Figure 11). In
contrast, obese co-twins who had a more hypertrophic obesity profile with a decreased cell count
compared with their leaner co-twins had significantly more liver fat, insulin resistance, inflammation
and LDL cholesterol  than the lean twin pair  members (Figure 11).   According to these results  it
would seem that the larger the capacity for hyperplasia in adipose tissue, the better the metabolic
complications of obesity are prevented. The remarkable similarity between the concordant co-twins
suggest that adipocyte phenotype is genetic or due to shared environmental factors.
Figure 11: Hypertrophic and hyperplastic obesity groups
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Figure 11: The 15 obesity-discordant twin pairs could be divided into two metabolically different
subgroups: the “hyperplastic” group (n=7 pairs), where the obese twins had more adipocytes than
their leaner counterparts and the “hypertrophic” or “hypoplastic” group (n=8 pairs), where the
obese co-twins had similar or even smaller total number of adipocytes than their leaner co-twins.
Lean twins= white bars, obese twins= black bars. In the hypertrophic group, the obese twins had
larger adipocyte volume, more liver fat, higher HOMA-index and fasting insulin concentrations as
well as higher LDL cholesterol, hs-CRP and lower HDL cholesterol concentrations than their leaner
co-twins. In the hyperplastic group, despite larger adipocyte volume than their leaner co-twins, the
obese co-twins had similar amounts of liver fat and similar metabolic measurements compared to
their leaner co-twins. Wilcoxon’s rank sum test was used to compare values of the leaner vs. the
heavier co-twin. *P<0.05. Data is presented as mean ± standard error.
6.2.2 Adipocyte size but not number correlates with metabolic measures of obesity and
insulin resistance
∆Adipocyte size (obese minus lean co-twin) correlated positively with many of the metabolic
measurements (Table 2, Article I). The correlations with ∆adipocyte number however were more
modest, and when present, to an opposite direction from those of ∆adipocyte size. ∆Adipocyte
volume correlated positively and ∆cell number negatively with ∆HOMA index, ∆insulin, Δtotal
cholesterol, ∆LDL and ∆leptin and Δadipocyte size negatively with Δadiponectin. When Δadipocyte
volume  and Δadipocyte number were analysed in the same multiple regression model, the following
associations were found for the metabolic measurements: Δadipocyte volume was independently
associated with Δfasting insulin (β=0.017, SE=0.0076, p=0.042), ΔLDL cholesterol (β=0.0018,
SE=0.00081, p=0.043), Δtriglycerides (β=0.019, SE=0.00060, p=0.005), Δleptin   (β=53.0,
SE=21.4, p=0.028), and Δadiponectin (β=-2.6, SE=0.98, p=0.021). Additionally Δadipocyte number
but not Δadipocyte volume was inversely associated with ΔCRP (β=-1.8e-13, SE=5.5e-14,
p=0.006). Results are presented in Table 2, article I. Independent of the degree of body fat difference
between the co-twins, ∆fasting serum insulin was associated with increased Δadipocyte volume/∆kg
fat (r=0.66, p=0.0023) and reduced Δadipocyte number/∆kg fat (r= -0.72, p=0.0005). Also
ΔHOMA-index was associated with increased Δadipocyte volume/∆kg fat (r=0.72, p=0.0005) and
reduced Δadipocyte number/∆kg fat (r= -0.65, p=0.0026). ΔLDL cholesterol correlated positively
with Δadipocyte volume/∆kg fat (r=0.57, p=0.0094) and negatively with Δadipocyte number/∆kg
fat (r=-0.53, p=0.0154) as did also Δtotal cholesterol/Δkg fat (r=0.48, p=0.0326), (r=-0.47,
p=0.0365). Δadipocyte volume/∆kg fat was related to Δleptin/Δkg (r=-0.50, p=0.0471). The other
associations between adipocyte morphology and metabolism were not significant after adjusting for
∆body fat.
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6.2.3 Gene expression associated with increased adipocyte size reveals mitochondria- and
cell death-related pathways, correlating with metabolic measures of the body
To shed light on the genes and pathways behind increased adipocyte hypertrophy, we linked obesity-
associated changes in adipocyte size and number with global adipose tissue gene expression. We set
out to find genes where the gene expression fold changes (heavier/leaner co-twins in all pairs)
correlated most positively with fold change (heavier/leaner co-twins) in adipocyte size. Correlation
limit was set to 0.6 and the FDR-corrected p-Value was 0.25. To find out the networks that would
be behind increased adipocyte size, we generated an interaction map with Moksiskaan analysis of
those genes, that were significantly positively or negatively associated with adipocyte size
(simplified in Figure 12). The genes were clustered into six interconnected entities which we named:
i) mitochondrial function (cluster 1); ii) lipid synthesis and modification of lipid peroxidation
products (cluster 2); iii) aldehyde-, ketone- and steroid metabolism, and modification of the cell
membrane  (e.g.  releasing  arachidonic  acid)  (cluster  3);  iv)  RNA  transcription  as  well  as  DNA
packaging and repair (cluster 4); v) ubiquitination of target proteins, DNA-damage and cell cycle
changes, especially in the G1/S transition phase (cluster 5); and vi) tumour growth factor β (TGF-β)
signaling, programmed cell death, p53 pathway and proapoptosis (cluster 6).
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Figure 12: Interaction map of the genes associating to adipocyte size
Figure 12: Gene networks associated with adipocyte volume within 20 monozygotic twin pairs (fold
change of heavier/leaner co-twins for adipocyte volume and for each gene), generated by
Moksiskaan database analysis. Six gene clusters intertwined to each other emerged in the analysis.
Fold change of genes correlating positively with fold change in adipocyte size are presented as light
grey and fold change of genes correlating negatively with fold change in adipocyte size as dark grey.
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A heatmap of the expressions of the genes in these clusters with clinical phenotypes (Article I, Figure
4) illustrates that transcripts associated with mitochondrial function (cluster 1) correlated
significantly negatively with adipocyte size, subcutaneous, visceral and overall body fat
measurements, fasting insulin and leptin. The same was true for triglyceride synthesis and glycerol
metabolism associated transcripts (cluster 2) except for the gene PPAP2A, for which the correlations
were opposite. Transcripts involved in modifications and oxidoreduction of aldehydes, ketones and
lipids, cell membrane associated genes (cluster 3), genes of DNA repair, and packaging (cluster 4),
cell  cycle  arrest  (cluster  5),  cell  death  and  inflammation  (cluster  6)  correlated  positively  with
adipocyte size, body fat, fasting insulin and leptin.
6.3 Metabolically healthy and unhealthy obesity (II)
6.3.1 Two distinct metabolic groups of obesity-discordant MZ pairs
A completely novel  finding in the second study of  the thesis  was that  the obesity-discordant  MZ
twin pairs could be divided into two distinct metabolic groups according to the amount of their liver
fat. In half of the pairs (group 1, n=8), the obese co-twins had as low liver fat percentages as their
leaner co-twin (Δ liver fat = 8%, p=0.21), whereas in the other group (group 2, n=8) the obese co-
twins had a strikingly increased liver fat content compared with their leaner co-twins (Δ liver fat =
718%, p = 0.012) (Figure 13). These two groups did not differ in the measure overall fatness (weight,
BMI, fat kg, fat %, SAT), but group 2 had increased ΔVAT content compared with group 1 (Figure
15 b, c). In group 1, there were no differences in the insulin or glucose curves during OGTT, and no
differences in HOMA-index, Matsuda-index or circulating lipids (LDL, HDL) between the co-twins.
However in group 2, the obese co-twins had significantly higher AUC for glucose (23%, p = 0.028)
and insulin (78%, p = 0.028) during the OGTT (Figure 14, 119%, p = 0.018), higher HOMA-index
and 55% (p = 0.028) lower Matsuda index (Figure 15 d, e) as well as significantly higher LDL- and
lower HDL-cholesterol levels (Table 1, Article II) than their leaner co-twins.
69
Figure 13: Division of twins into two subgroups of obesity according to the amount of liver fat in
the obese co-twins
Figure 13: The obese and the lean co-twins
could be divided into two subgroups of obesity,
according to the amount of liver fat in the obese
co-twin. In group 1 (n=8 pairs, liver fat % ≤ 2),
the obese co-twins were very similar to their
leaner counterparts in the liver fat measures. In
group 2 (n=8, liver fat % ≥2), the obese co-twins
had significantly increased liver fat amounts
compared to the lean co-twins.
Figure 14: Glucose and insulin during the OGTT (oral glucose tolerance test) in the obese and
lean twins of groups 1 and 2
Figure 14: Glucose (a) and insulin (b) during
the OGTT in group 1. Glucose (c) and insulin
(d) during the OGTT in group 2. Obese twins
in group 2 presented with significantly
augmented responses compared with their
leaner co-twins in both glucose and insulin
during the test.
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Figure 15: Metabolic characteristics of the twins divided in two subgroups on the basis of their
liver fat content
Figure 15: Metabolic characteristics of the BMI-discordant co-twins stratified into two subgroups
according to the amount of liver fat in the obese co-twin. White bars present lean twins and black
bars obese twins. BMI-concordant pairs are presented as reference. ***P<0.001, **P<0.01,
*P<0.05. Data is presented as mean ± SE. In group 1 (n=8 twin pairs) the obese co-twins did not
significantly differ from their leaner counterparts in their metabolic measures. In group 2 (n=8),
the obese twins had more liver fat, subcutaneous and visceral fat, higher hs-CRP levels and were
more insulin resistant than their leaner co-twins.
The mean adipocyte cell size was increased in obese co-twins of both groups, but Δadipocyte
number differed between the groups (p = 0.037). In group 1 the obese co-twins had more adipocytes
than their leaner counterparts (11%, p = 0.069), whereas in group 2, the obese co-twins had even
less adipocytes (8%, p = 0.13) than their lean co-twins. Interestingly, the result of two different
groups of adipocyte hyperplasia or hypertrophy was reported in article I, where the twins divided in
the hyperplastic group had insignificant difference in their liver fat between the obese and the lean
co-twin, while in the hypertrophic group, there was a significant difference in the liver fat profiles
of the co-twins, the heavier co-twins having much more liver fat than their leaner counterparts.
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6.3.2. Distinct gene expression profiles in the two metabolically different obesity groups
When the gene expression profiles of the two groups were compared, in group 2 the obese and the
lean co-twins differed significantly for mitochondrial pathways. ‘Oxidoreductase activity’ (GO:
0016491) (FDR corrected p = 0.045) and ‘Cofactor binding’ (GO: 0048037) (p = 0.0096), the latter
of which also included several mitochondrial genes, were lower in the obese co-twins and restricted
to group 2. In group 1, the obese and lean co-twins differed only for ‘structural constituent of
ribosome’ (GO: 0003735) (FDR corrected p =0.016). Based on these findings, additional pathways
were analyzed and three mitochondrial pathways selected to represent different aspects of energy
handling; oxidative phosphorylation pathway (p = 0.48 in group 1, p = 0.028 in group 2) (Figure
16a); BCAA catabolism pathway (p = 0.48 in group 1, p = 0.018 in group 2) (Figure 16b) and fatty
acid β oxidation pathway (p = 1.0 in group1, p = 0.018 in group 2) (Figure 16c) were all significantly
different and downregulated in the obese co-twins compared with their lean twins in SAT of group
2 but not group 1. Also, the activity of the chronic inflammatory response pathway (CIRP) was
observed to be significantly elevated in the obese co-twins of group 2 (p = 0.028) but not group 1 (p
= 0.31). (Figure 16f) Two pathways representing SAT enlargement were also analyzed
(triacylglycerol synthesis and adipocyte cell differentiation). The triacylglycerol synthesis pathways
did not  differ  between the obese and lean co-twins’  SAT in either  of  the groups (Figure 16e).  In
contrast, the adipocyte differentiation pathway was significantly downregulated in group 2 obese
co-twins (p = 0.004), whereas the expression pathways in group 1 co-twins were similar (p = 0.33),
(Figure 16d).
72
Figure 16: Gene expression profiles of twins from the two metabolically different
subgroups
a) b) c)
d) e) f)
Figure 16: Gene expression profiles of the two metabolically different subgroups in twins, separated
according to the amount of liver fat in the obese co-twin. White bars represent lean twins and black
bars obese twins. BMI-concordant pairs are presented as reference. **P<0.01, *P<0.05.
Expression values represent the mean activation of the pathway by mean centroid values. Error bars
indicate standard error. Oxidative phosphorylation, fatty-acid beta oxidation, BCAA catabolism and
adipose tissue differentiation pathways were downregulated and chronic inflammatory response
pathway (CIRP) upregulated in the obese twins of the group 2 with increased liver fat content in the
obese co-twin.
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6.4 Downregulation of mitochondrial biogenesis in obese adipose tissue
(III)
6.4.1. Downregulation of mitochondria-related transcripts and pathways in obese adipose
tissue and differential methylation between the obese and the lean co-twins
Due to the mitochondria-related results in the previous two articles, in the third article of the thesis
(III) we set out to investigate the transcriptomic profile of adipose tissue by concentrating on the
mitochondria. In this article, we had the full 26 discordant and 14 concordant MZ twin pairs in use
for the transcriptomics data analyses. With these analyses we found that there were many
mitochondria-related genes and pathways in the significantly differentially expressed genes between
the co-twins. We first investigated the within-pair differences in the expression of mitochondrial
proteins in SAT (n = 26 twin pairs) by linking the results from the significantly differentially
expressed genes between the co-twins from transcriptomics data with the genes of MitoCarta.
Among the 2108 significantly differentially expressed genes, 222 genes were listed in MitoCarta
(Supplementary data S1). Most of these transcripts (187 of 222, 84%) were downregulated in the
obese compared with the lean co-twins´ SAT.
We then investigated which functional entities of the mitochondrial proteins the 222 transcripts
represented. We subjected the transcripts to IPA (Ingenuity Pathway Analysis) and found out that
among the most significantly different and downregulated pathways in the obese compared with the
lean co-twins were the key mitochondrial functions: OXPHOS (p < 0.0001), BCAA degradation (p
< 0.0001), ketogenesis/ketolysis (p < 0.0001), the tricarboxylic acid cycle (TCA, p < 0.0001),
glutaryl-CoA degradation (p < 0.0001), and fatty acid β-oxidation (FAO, p < 0.0001; Table 2). We
correlated the calculated mean centroid values (obtained by normalizing the expression levels from
Affymetrix data of the regulated genes in each pathway to a mean of zero and a variance of 1 across
all individuals and thus obtaining a value representing the activity of the pathway) of the most
significant pathways to measures of adiposity (SAT, VAT and liver fat, adipocyte volume), insulin
sensitivity (Matsuda index), insulin resistance (HOMA index), inflammation (adipsin, hs-CRP),
leptin and adiponectin. The mean centroid values of OXPHOS and TCA cycle pathways correlated
negatively with SAT, VAT, liver fat, adipocyte volume, HOMA- index, adipsin and hs-CRP (Table
3) and positively with Matsuda-index and adiponectin. Glutaryl-CoA degradation, ketogenesis, and
tryptophan degradation pathways correlated negatively with all of the selected clinical variables and
positively with Matsuda-index and adiponectin. BCAA degradation (valine-, isoleucine-, and
leucine degradation pathways), FAO, and ketolysis correlated negatively with all clinical variables,
except positively with adiponectin and Matsuda-index.
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Table 2: Pathways significantly changed in the obese compared with the lean co-twin
(IPA analysis of the differentially expressed genes, n = 26 discordant pairs)
Ingenuity canonical pathways P value Regulation
Oxidative phosphorylation < 0.0001 Downregulated
Glutaryl-CoA degradation < 0.0001 Downregulated
Isoleucine degradation I < 0.0001 Downregulated
Ketogenesis < 0.0001 Downregulated
Fatty acid -oxidation I < 0.0001 Downregulated
Tryptophan degradation III (eukaryotic) < 0.0001 Downregulated
Ketolysis < 0.0001 Downregulated
TCA cycle II (eukaryotic) < 0.0001 Downregulated
Leucine degradation I < 0.0001 Downregulated
IPA, Ingenuity Pathway Analysis
Table 3A: Correlations of mitochondrial variables with metabolic measures of individual
MZ twins (n = 80)
Variable SAT VAT Liver fat Cellvolume Matsuda
mtDNA -0.2544 -0.0835 -0.1761 -0.2076 0.2954
Oxidative phosph. -0.367† -0.603‡ -0.420† -0.497† 0.445‡
Fatty acid β-ox -0.622‡ -0.669‡ -0.518‡ -0.584‡ 0.669‡
TCA cycle -0.315† -0.660‡ -0.432† -0.452† 0.483‡
Glutaryl-CoA degr. -0.690‡ -0.644‡ -0.469‡ -0.586‡ 0.634‡
Ketogenesis -0.661‡ -0.652‡ -0.480‡ -0.569‡ 0.623‡
Ketolysis -0.657‡ -0.627‡ -0.478‡ -0.541† 0.626‡
Valine degr. -0.585‡ -0.702‡ -0.559‡ -0.596‡ 0.658‡
Leucine degr. -0.430† -0.649‡ -0.485‡ -0.489† 0.578‡
Isoleucine degr. -0.533‡ -0.641‡ -0.472‡ -0.512‡ 0.602‡
Tryptophan degr. -0.630‡ -0.644‡ -0.469‡ -0.586‡ 0.634‡
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Table 3B: Correlations of mitochondrial variables with metabolic measures of individual
MZ twins (n = 80)
Variable HOMA Leptin
Adipo
hs-CRP Adipsin
nectin
mtDNA -0.4582* -0.2413 -0.0408 -0.0166 -0.4007*
Oxidative phosph. -0.322† -0.191 0.353* -0.384† -0.3402*
Fatty acid β-ox -0.595‡ -0.519‡ 0.378† -0.476‡ -0.4174†
TCA cycle -0.388‡ -0.147 0.456‡ -0.416‡ -0.4241†
Glutaryl-CoA degr. -0.558‡ -0.543‡ 0.330* -0.470‡ -0.4484‡
Ketogenesis -0.570‡ -0.488† 0.358* -0.437† -0.4337‡
Ketolysis -0.587‡ -0.490† 0.387* -0.437† -0.4671‡
Valine degr. -0.638‡ -0.425† 0.524‡ -0.486‡ -0.5377‡
Leucine degr. -0.506‡ -0.306† 0.411† -0.412‡ -0.4003†
Isoleucine degr. -0.581‡ -0.391* 0.486‡ -0.430‡ -0.5187‡
Tryptophan degr. -0.558‡ -0.543‡ 0.330* -0.470‡ -0.4484‡
*P < 0.05, †P < 0.01, ‡P < 0.001. fP, fasting plasma; HOMA, homeostatic model assessment;
hs-CRP, high-sensitivity C-reactive protein; SAT, subcutaneous adipose tissue; TCA,
tricarboxylic acid cycle; VAT, visceral adipose tissue.
6.4.2. Reduced mtDNA amount, mtDNA encoded transcripts, mitochondrial ribosomal
protein subunits and OXPHOS protein levels in the adipose tissue of the obese co-twins
As the mitochondrial transcripts and pathways dominated the above transcriptomics analyses, we
then further investigated the effect of obesity on mitochondrial amount and biogenesis in SAT, by
measuring the amount of mtDNA and the expression of mtDNA-encoded genes (12S rRNA, 16S
rRNA, COX1, ND5, and CYTB, n = 15 discordant pairs) as well as Affymetrix gene expression of
mitochondrial ribosomal proteins that translate the mitochondrial transcripts into proteins. The
mtDNA amount was reduced by ~20% (p = 0.031, Figure 17B) in SAT of the obese compared with
the lean co-twins. Significant negative correlations were observed between the mtDNA amount and
HOMA (insulin resistance) and adipsin (inflammation) (Table 4). Mitochondrial 12S (MT-RNR1, p
= 0.0064) and 16S (MT-RNR2, p = 0.0090) rRNAs,  as  well  as  mRNAs COX1 (p = 0.0064, CIV
subunit), ND5 (p = 0.027, CI subunit), and CYTB (p = 0.0015, CIII subunit, Figure 17C), were
decreased in SAT of the obese co-twins compared with their lean counterparts. We also studied the
expression of 30 nuclear transcripts for the small subunit (MRPS) and 50 nuclear transcripts for the
large subunit (MRPL) of the mitochondrial ribosome using the Affymetrix data (n = 26 discordant
pairs). In line with 12S and 16S rRNA expression, the average value of the total expression (a mean
centroid) of both MRPS (lean 0.03 ± 0.09 AU vs. obese -0.31 ± 0.1 AU, p <0.001) and MRPL (lean
-0.04 ± 0.1 AU vs. obese -0.26 ± 0.1 AU, p = 0.0034) was lower in the obese compared with the
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lean co-twins (Figure 17D). The expression of the main mitochondrial regulator PGC-1α was
reduced in the obese co-twins (qRT-PCR, p = 0.004, Figure 17A).
Finally, we measured mitochondrial content and the level of OXPHOS protein subunits in SAT
lysates of seven discordant pairs by Western blot. Mitochondrial mass per cell (Porin, a
mitochondrial outer membrane protein compared with a cytoskeletal protein beta-tubulin), trended
downwards  in  the  obese  co-twins  (p = 0.09, Figure 17 E, F). Mitochondrial OXPHOS protein
subunits of CIII, CIV and CV were reduced in obesity: the level of CIII-core 2 (CIII subunit, p =
0.018), MT-CO1 (CIV subunit, p = 0.018) and CV-α (CV subunit, p = 0.028), compared with the
levels  of  beta-tubulin,  were all  lower in the obese than in the lean co-twins (Figure 17E).  As the
different complex subunits typically follow the amounts of full holocomplexes, these results support
deficiency of CIII, CIV, and CV. Fully nuclear-encoded CII did not differ between the co-twins.
Furthermore, we analyzed whether the OXPHOS levels were reduced per mitochondria in obesity.
Thus, we normalized the OXPHOS protein signals against the mitochondrial protein Porin. The
amount of CI (p = 0.063) trended downwards, and complexes CIII (p = 0.018) and CIV (p = 0.028)
were reduced in the obese co-twins (Figure 17F). Overall, the protein results suggested a trend of
lower mitochondrial mass (Porin), and a decrease of OXPHOS levels per cell and per mitochondria
as a downstream effect of the reduced mtDNA amount.
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Figure 17: Reduction of PGC-1α, mtDNA amount, mtDNA transcripts, MRPS/MRPL and
OXPHOS protein amounts in SAT of obese MZ twins.
Figure 17: A. Reduced expression of the main mitochondrial regulator PGC-1α (qRT-PCR) in SAT
of the obese co-twins (n=15 discordant pairs). White bars represent lean twins and black bars obese
twins. ***P<0.001, **P<0.01, *P<0.05, paired Wilcoxon signed rank test. Error bars indicate
mean ± standard error. B. Relative mtDNA amount measured by qPCR and C. mtDNA transcripts
measured by qRT-PCR in SAT of the MZ obese compared with the lean co-twins (n = 15 discordant
pairs). D: The mean centroid values of MRPS and MRPL in the SAT of the obese compared with the
lean co-twins (n = 26 discordant pairs). E and F. Relative amount of OXPHOS proteins in the SAT
(n = 7 discordant pairs). Western blot signals were normalized against cytosolic β-tubulin (E) and
mitochondrial membrane protein Porin (F).
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Figure 18: Representative Western Blot bands from three twin pairs
Figure 18: Western Blot bands from three twin pairs. CI-CV: complexes 1-5. Actin, Porin and
Tubulin were used as controls.
6.5. Obese adipocytes show distinct reduced transcripts related to
mitochondrial genes and proteins (IV)
6.5.1 Significantly differentially expressed genes between the co-twins in adipocytes
revealed mitochondrial downregulation and an inflammatory pattern
Our previous studies on adipose tissue raised an interesting question of whether the changes in gene
expression and worsening of the metabolic profile in the obese co-twins in acquired obesity were
derived from adipocytes or from other cells in the adipose tissue. In addition to adipocytes, adipose
tissue includes a population of stromal vascular fraction cells, including immune cells. In study IV,
we wanted to investigate the transcript profiles of obese adipocytes and the similarities or differences
between their abundance in adipocytes and those of adipose tissue. We started with the genes and
pathways that were significantly changed between the 14 discordant co-twins. The transcriptomics
analyses of the adipocytes revealed that these significantly differentially expressed genes between
the co-twins were related to oxidative phosphorylation, glutaryl-CoA degradation, mTOR-signaling
as well as BCAA catabolism (valine- and isoleucine degradation) and, which were all downregulated
in the heavier co-twins (p < 0.05 all, Table 4). Glucocorticoid-receptor signaling and IL-8 signaling
were upregulated in the heavier co-twins (p < 0.05 all, Table 4).
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To see whether these downregulated pathways had any clinical implication for the obese co-twins,
the top ten pathways of both adipocytes and adipose tissue were correlated with metabolic measures
of the body. For IL-8 receptor signaling and glucocorticoid receptor signaling in adipocytes, the
correlations were opposite to the above mentioned mitochondrial pathways. Mitochondria-related
pathways of oxidative phosphorylation, valine, isoleucine degradation and glutaryl-CoA
degradation correlated negatively with many adiposity and insulin resistance measure, hs-CRP and
adipsin and positively with Matsuda-index and adiponectin (Table 5 A and B). For IL-8 receptor
signaling and glucocorticoid receptor signaling, the correlations were opposite to the above
mentioned mitochondrial pathways. JAK2 signaling, NRF2-mediated oxidative stress response and
EIF4 signaling did not correlate with clinical measures (Table 5 A and B).
To detect transcripts that regulate the observed genes and pathways, we did an IPA upstream
regulator analysis for the significantly differentially expressed genes. This analysis revealed
SREBF1, CEBPA and MYC as  top  significant  regulators.  However,  when  compared  with  a  t-test
none of these transcripts were significantly different between the co-twins. We then combined the
significantly different genes with the Mitocarta gene list to detect specifically mitochondria-related
regulators. Here, SREBF1, MYC and PGC-1α emerged as top three regulators. PGC-1α was the only
transcription factor significantly reduced in the heavier (3.9±0.3) compared with the leaner (4.3±0.3
Affymetrix units (AU), p = 0.0157) co-twins and this result was confirmed by qRT-PCR (heavier
2.6±0.6, leaner 4.1±1.0, p = 0.0414, Figure 19A).
We then did a consistency analysis, where we looked at all the genes which were both significantly
different between the co-twins but also consistently up- or downregulated in the heavier co-twin.
The  consistency  limit  was  set  to  at  least  12  out  of  14  twin  pairs.  This  analysis  revealed that
adipocytes had 454 consistently upregulated and 538 consistently downregulated transcripts in the
heavier co-twins. The downregulated genes were related to mitochondria-related pathways
(oxidative phosphorylation, fatty acid β-oxidation, AMPK signaling, glutaryl-CoA degradation,
TCA cycle II; p < 0.001 all), while the upregulated pathways displayed an inflammatory pattern (IL-
10 signaling, granulocyte adhesion, IL-8 signaling, recognition of bacteria and viruses, HMGB1
signaling and cytokine production; p < 0.001 all).
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Table 4: Top 10 pathways in adipocytes of the heavier compared with the leaner co-twins (IPA
analysis of the significantly differentially expressed genes, n = 14 discordant twin pairs)
Ingenuity canonical pathways Ttest P-value Regulation
Oxidative phosphorylation 0.0019 Downregulated
Valine degradation I 0.0035 Downregulated
Glucocorticoid Receptor Signaling 0.0029 Upregulated
IL-8 Signaling 0.0012 Upregulated
mTOR Signaling 0.0043 Downregulated
Role of JAK2 in Hormone-like Cytokine Signaling 0.9750 Not changed
Isoleucine Degradation I 0.0012 Downregulated
Glutaryl-CoA Degradation 0.0012 Downregulated
NRF2-mediated Oxidative Stress Response 0.0736 Not changed
IPA, Ingenuity Pathway Analysis
Table 5A: Correlations of top 10 pathways with metabolic measures in adipocytes in individual
MZ twins (n = 36 twins)
Pathway Fat kg SAT VAT Liver fat Adipocytevolume Insulin
Oxidative Phosphorylation  -0.51*  -0.42  -0.70***  -0.55**  -0.51  -0.49
Valine Degradation  -0.56**  -0.48*  -0.66***  -0.61***  -0.57  -0.53**
Glucocorticoid Receptor
Signaling  0.48*  0.44  0.67***  0.58**  0.42   0.38
IL-8 Signaling  0.64***  0.61**  0.84***  0.64***  0.59*  0.53**
mTOR Signaling  -0.39*  -0.42**  -0.46**  -0.41*  -0.51**  -0.33
JAK2 in Hormone-like Cytokine
Signaling  0.33  0.25   0.16   0.25  0.32  -0.02
Isoleucine Degradation I  -0.55**  -0.43  -0.62**  -0.62**  -0.55  -0.52**
Glutaryl-CoA Degradation  -0.62**  -0.54**  -0.72***  -0.65***  -0.66**  -0.55**
NRF2-mediated Oxidative
Stress Response  0.23  0.18  0.25  0.09  0.11  0.16
EIF4 and p70S6K Signaling  -0.37  -0.38  -0.44  -0.39   -0.46   -0.34
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Table 5B: Correlations of top 10 pathways with metabolic measures in adipocytes in individual
MZ twins (n = 36 twins)
Pathway HOMA Matsuda Leptin Adiponectin hs-CRP Adipsin
Oxidative Phosphorylation  -0.51  0.61**  -0.24  0.48***  -0.41  0.19
Valine Degradation  -0.54**  0.68***  -0.38   0.50*  -0.46*  0.04
Glucocorticoid Receptor Signaling  0.37  -0.61**  0.31  -0.49**  0.49*  0.38
IL-8 Signaling  0.54**  -0.70***  0.40*  -0.44**  0.57**  0.07
mTOR Signaling  -0.32   0.39*  -0.31**  0.14  -0.28  0.26
JAK2 in Hormone-like Cytokine
Signaling  -0.01  -0.12  0.24  -0.04  0.26  -0.43*
Isoleucine Degradation I  -0.52**  0.65***  -0.35  0.56**  -0.46  -0.50*
Glutaryl-CoA Degradation  -0.55**  0.70***  -0.44*  0.50**  -0.47  -0.45
NRF2-mediated Oxidative Stress
Response  0.16  -0.20  0.13  -0.43**  0.09  -0.26
EIF4 and p70S6K Signaling  -0.36  0.35  -0.20  0.07  -0.18  0.08
6.5.2 Reduction of mtDNA transcripts, PGC-1α (qRT-PCR) and mitochondrial ribosomal
protein subunits (Affymetrix units) in adipocytes of the heavier co-twins
To further investigate specifically the transcripts of mitochondrial genes that are not detectable with
Affymetrix  array,  we  did  a  qRT-PCR  of  mtDNA-encoded  rRNAs  12S,  16S  RNA  and  mRNAs
COX1, ND5 and CYTB. Mitochondrial 12S (MT-RNR1, p = 0.0022) and 16S (MT-RNR2, p = 0.0186)
rRNAs, as well as mRNAs COX1 (p = 0.0047, CIV subunit), ND5 (p = 0.0186, CI subunit), and
CYTB (p = 0.0047, CIII subunit) were all significantly downregulated in adipocytes of the heavier
as compared with the leaner co-twins (Figure 19B).
The mitochondrial mRNAs are translated on mitochondrial ribosomes into proteins which form parts
of the OXPHOS complexes. To shed light on the level of the nuclear transcripts encoding subunits
of these ribosomes we calculated mean centroids (an average mean) for the transcripts of small
(MRPS) and large (MRPL) mitochondrial ribosomal protein subunits in adipocytes for n=29
(MRPS) and n=49 (MRPL) Affymetrix transcripts. This analysis showed a downregulation of
mitochondrial ribosomal protein subunits in the heavier co-twins (MRPS: heavier -0.24 ± 0.18 vs.
leaner 0.23 ± 0.18 AU, arbitrary Affymetrix units, p = 0.0092; MRPL: heavier -0.17 ± 0.18 vs. leaner
0.18 ± 0.17 AU, p = 0.0157, Figure 19C).
In upstream regulator analyses, when combining the significantly differentially expressed genes
with Mitocarta gene list of mitochondria-related transcripts, the top regulators detected were
SREBF1, MYC and PGC-1α. PGC-1α being one of the master regulators of mitochondrial biogenesis
and found to be the only transcription factor significantly reduced in the heavier (3.9±0.3) compared
with leaner (4.3±0.3 Affymetrix units (AU), p = 0.0157) co-twins, we then verified the result in a
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qRT-PCR of PGC-1α in adipocytes with the heavier co-twin having reduced levels of this transcript
(heavier 2.6± 0.6, lean 4.1±1.0, p = 0.0414, Figure 19A).
6.5.3. Reduction of OXPHOS protein amounts in obese versus lean individuals
In seven lean and six obese individuals the Western Blot analysis of mitochondrial OXPHOS protein
subunit levels of CI, CII, CIII, CIV and CV were studied: the levels of CI subunit NDUFB8  (p =
0.0176) and CIII-core 2 subunit (CIII, p = 0.0455) were reduced in the obese compared with the lean
individuals and COX2 (CIV subunit, p = 0.253) and ATP5A (CV subunit, p = 0.254), were lower
but non-significant in the obese compared with the lean individuals (Figure 19D). The nuclear-
encoded CII  subunit  SDHB did not  differ  between the obese and the lean (p = 0.361). When the
OXPHOS protein signals were normalized against the mitochondrial protein porin, complex CI
subunit NDUFB8 (p = 0.0106) was significantly reduced in the obese compared with the leaner
individuals, suggesting a decrease of OXPHOS CI levels per mitochondria. CIV (p = 0.086) trended
downwards and CII (p = 0.988), CIII (p = 0.199), and CV (p = 0.775) were non-significant in the
obese compared with the lean individuals (Figure 19E).
Figure 19: Reduction of PGC-1α, mtDNA transcripts and MRPS/MRPL expression in adipocytes
of the heavier MZ twins. Reduction of OXPHOS protein amounts in obese individuals.
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Figure 19: A) Reduced expression of the main mitochondrial regulator PGC-1α (qRT-PCR) in
adipocytes of the heavier co-twins (n=12 discordant pairs). White bars represent lean twins and
black bars heavier twins in the figures A-C. ***P<0.001, **P<0.01, *P<0.05, paired Wilcoxon
signed rank test. Error bars indicate mean ± standard error. B) mtDNA transcripts measured by
qRT-PCR in adipocytes of the MZ heavier compared with the lean co-twins (n = 12 discordant
pairs). C) The mean centroid values of mitochondrial ribosomal protein small (MRPS) and large
(MRPL) subunits in the SAT of the obese compared with the lean co-twins (n = 15 discordant pairs).
D and E) Relative amount of OXPHOS proteins in adipocytes (n = 4 obese and n=4 lean
individuals). Western blot signals were normalized against cytosolic Actin (D) and mitochondrial
membrane protein Porin (E).
Figure 20: Western Blot bands from two pairs of lean and obese individuals
Figure 20: Western Blot bands from two lean and two obese individuals. C5: complex V, C3:
complex III, C2: complex II, C4: complex IV, C1: complex I. Actin, Porin and Vinculin were used
as control proteins.
6.5.4. Adipose tissue transcriptomics in 14 discordant twins mimicked those of the adipocytes
The same transcriptomic analyses of the 14 discordant co-twins in adipose tissue revealed a total of
2135 transcripts that were differentially expressed between the co-twins (nominal P value <0.05).
As in adipocytes, the top 10 upregulated genes in the heavier co-twins (Study IV, Supplementary
Data in figshare repository, https://dx.doi.org/10.6084/m9.figshare.3806286.v1) were associated
with immune reactions and cellular stress and the top 10 downregulated transcripts (Study
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IV,supplementary data in figshare repository) with mitochondria, fatty acid synthesis and β-
oxidation. Analyses according to the fold change between the co-twins revealed chemokines and
inflammatory genes among the top upregulated list as in adipocytes. Also, the pathway-analyses in
adipose tissue mimicked those of adipocytes, with oxidative phosphorylation, valine and lysine
degradation, glutaryl-CoA degradation, acetate conversion to Acetyl-CoA, fatty-acid β-oxidation,
triacylglycerol synthesis and ketone body production and breakdown among top 10 pathways, all
downregulated in the heavy co-twins (p < 0.05 all). Strong negative correlations were found for the
top 10 pathways and adiposity, including adipocyte size, leptin, insulin resistance, hs-CRP and
adipsin and positive correlations with Matsuda-index and adiponectin. Triacylglycerol synthesis was
an exception correlating only with intra-abdominal and liver fat and adipsin. The mitochondrial top
three upstream regulators in adipose tissue were SREBF1, PGC-1α and EIF2A of which PGC-1α
(3.8±0.3 vs. 4.9±0.3 AU, p = 0.0019) and EIF2A (11.2±0.04 vs. 11.4±0.1 AU, p = 0.0029) transcript
levels were reduced in the heavier co-twins.
In consistency-analyses the top significantly downregulated pathways included CHK proteins in cell
cycle control, DNA modifications, cysteine degradation, mTOR signaling, cholesterol biosynthesis,
dopamine signaling, and upregulated pathways 14-3-3-signaling, NF-ᴋB activation, immune cell
cytokine communication, lipid antigen presentation, CD40-signaling, androgen signaling and
GABA receptor signaling (p < 0.001 all).
When repeating the transcriptomics analyses on mitochondrial ribosomal protein subunits, both
MRPS (-0.24±0.19 vs. 0.11±0.14 AU, p < 0.01) and MRPL (-0.21±0.2 vs. 0.01±0.15 AU, p < 0.05)
were downregulated in the heavier co-twins as in adipocytes.
6.6. Sex, onset of obesity-discordance, family history and lifestyle factors
(diet, alcohol intake, smoking and physical activity) in the
discordant twin pairs (I-IV)
Although the differences between sexes in body composition and fat distribution are well known,
there were no within-pair differences in the measures of adiposity and metabolism or in the measures
of mitochondrial activity in males and females. The onset of obesity-discordance in all 26 discordant
twin pairs was 22.6 ± 0.6 years (437) in the early adulthood of the twins, and the length of the
discordance on average 6.3 ± 0.3 years. Self-reported reasons for the weight gain for the heavier co-
twins were behavioral: eating unhealthier and exercising less than their leaner counterparts (438). In
the family history of the twins, of the total 44 parents of the discordant pairs, for whom data was
available, 15.9% were obese (4/23 of the mothers, mean age 42.2 ± 0.7 years and 3/21 of the fathers,
mean age 45.4 ± 0.8 years), including one twin pair where both parents were obese. Physical activity
of the twins was measured by Baecke-index and its three sub-components (sport, leisure time and
work indexes) from the twin questionnaires. There were no significant differences in total- as well
as sport- or leisure-time physical activity indexes between the co-twins. In study II, the metabolically
different groups 1 and 2 were similar with regards to age, sex, smoking habits, alcohol intake, total
physical activity and mean daily energy intake. In group 2, sports activity was lower and alcohol
intake tended to be higher in the obese than in the lean co-twins.
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7. DISCUSSION
7.1. Summary of the main findings
This thesis shows that mitochondrial biogenesis is reduced in obese adipose tissue and adipocytes,
both at the transcript level as well as at the protein level. This reduced biogenesis is associated with
the metabolic abnormalities of obesity. Adipocyte hypertrophy with little hyperplasia is related to
worsening of the metabolic profile in obesity. The hyperplastic capacity of adipose tissue in an
individual may be genetically determined. We show in twins that there are two metabolically distinct
subgroups of obesity, which can be separated according to the amount of liver fat relative to their
leaner co-twin. The “metabolically unhealthy” group had increased liver fat amount compared to
their leaner co-twin. This group also presented with low capacity for adipocyte hyperplasia in their
adipose tissue. The two groups had the most distinct differences in mitochondria- and inflammation-
related genetic pathways. Mitochondria-related transcriptomics pathways as well as mitochondrial
DNA transcripts and mitochondrial OXPHOS protein subunits were downregulated in the obese co-
twins, suggesting a general reduction of mitochondrial biogenesis in obesity. The mitochondrial
transcriptomics pathways also correlated negatively with the metabolic measures of obesity,
suggesting that their reduced activity is related to a worsening of the metabolic profile. In our results
the downregulation of the essential functions of mitochondria in adipose tissue in obesity was not
only a phenomenon of adipose tissue, but strongly influenced by the adipocyte cells.
A general assumption is that at a certain level of adipocyte hypertrophy, a critical threshold emerges,
at which the cells cannot ingest more fat and begin exhibiting signs of stress. At this point the lipid
flux  to  ectopic  tissues  increases  causing  toxic  effects  like  insulin  resistance  and  apoptosis.  Low
mitochondrial function, adipocyte membrane stress, adipose tissue hypoxia, increased influx of
FFAs, altered adipokines and increased inflammatory cytokines are some of the factors suggested
to lie behind the adipocyte stress reaction. The correlation between fat mass and metabolic problems
however is not linear. The reasons for this have thus far remained unknown. In this thesis, we suggest
that increased adipocyte size but low capacity to hyperplasia is a factor directly related to metabolic
abnormalities in adipose tissue and in the whole body and also discerning individuals who are prone
to the metabolic complications of obesity. In addition to high hyperplastic capacity and small
adipocyte size, “metabolically healthy” obesity was distinguished by low liver fat content in the
obese twins and a decrease in mitochondrial activity by fatty-acid and BCAA oxidation and absence
of inflammation in their adipose tissue. These results backed up the hypothesis that if subcutaneous
adipose tissue expandability is good, metabolic problems are better prevented. Finally, we linked
the metabolic dysfunction in obesity to low mitochondrial amount and biogenesis in adipose tissue.
We also suggest that at the transcript level, the downregulation of mitochondrial pathways is
connected especially to the metabolically unhealthy obesity, but not to the healthy phenotype. The
same changes of acquired obesity were seen both in adipose tissue and adipocyte cells.
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7.2. Adipocyte hypertrophy, hyperplasia and metabolic health in
acquired obesity
In this thesis, we have associated adipocyte volume to a worsening of metabolic profile in obesity
in study I (430). Based on the hypertrophy of the adipocytes and the hyperplastic capacity of adipose
tissue in the obese twins, the twins could be divided into two metabolically different groups (430).
In study II,  the twins who were characterized as  metabolically unhealthy with increased liver  fat
content compared with their leaner co-twins and worsened metabolic measures compared with the
metabolically healthy obese in group 1, also had hypertrophied adipocytes and less hyperplasia in
their subcutaneous adipose tissue. We have also presented negative correlations between
mitochondrial oxidative pathways and adipocyte volume in study III (437) in twins. These findings
support the idea of adipocyte volume and adipocyte morphology (as measured by adipocyte
volume/hypertrophy and adipocyte number/hyperplasia in an individual) as an important factor in
obesity-related complications. Also, when correcting against kg body fat, negative correlations
between adipocyte volume and metabolic measures in obese twins remained, suggesting an
independent effect of total body fat in metabolic complications.
In study I we noticed that although adipocyte volume increased with increasing obesity, adipocyte
number between the co-twins remained same, both in MZ discordant and concordant co-twins. Our
results suggest that subcutaneous adipocyte morphology is under genetic control, as evidenced by
the remarkably similar adipocyte cell number and size (ICC 0.91-0.92) in weight-concordant MZ
co-twins. In weight-discordant pairs, the responses to obesity varied: some obese co-twins reacting
through hypertrophy and others through hyperplasia combined with a milder hypertrophy in their
adipocytes. In the hypertrophic obesity group, the obese co-twins had a lower adipocyte count,
higher liver fat, and disturbances in their insulin sensitivity as well as several other metabolic
parameters compared with their lean co-twins. In contrast, hyperplastic obese co-twins in the latter
group were as healthy as their lean twin pair members. The increase in adipocyte cell size within the
twin pairs was associated with decreased expression of mitochondrial genes as well as with increased
expression of genes regulating cell death and inflammation.
Obesity is known to be highly heritable. Study I of the thesis suggests that this may also hold true
for the adipocyte size and number. Consistent with our results, the seminal overfeeding studies in
MZ twins have showed that the members of weight-concordant pairs resembled each other
significantly for fat cell size and fat cell lipolytic activities (439). In the present study the obesity-
discordant MZ pairs were less similar for fat cell size (intra-class correlation ICC=0.34) than for fat
cell number (ICC=0.63), which suggests that acquired obesity significantly influences adipocyte
volume, whereas the control of cell count could be more genetic. This is in line with studies in rats
where adipocyte size was increased by high-fat feeding independent of genetic factors, whereas
increase in adipocyte number was enhanced by high-fat diet only in certain strains (440). Several
genetic causes of human lipodystrophies have been discovered in the past years, also proposing that
the presence of genetic factors underlie adipogenic capacity (5).
Spalding et al 2008 reported that neither adipocyte death rate nor adipocyte generation rate were
altered in obese compared with lean unrelated individuals, speaking for a tight regulation of
adipocyte number in adulthood, even in the obese state (120). Although absolute fat cell production
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was higher in obese than in the lean individuals, the rate of adipocyte generation was same in both
groups. Because the fat mass in the lean and in the obese both stayed at the same level, this suggests
that the difference in the number of adipocytes in obese versus lean individuals occurs already before
adulthood (120). Hyperplasia however seems to correlate with the severity of obesity. Morbidly
obese individuals show more evident hyperplasia than obese or lean individuals (441). In obese
(442) and type 2 diabetic subjects (443), a lower differentiation potential and reduced generation of
preadipocytes has been proposed, but individual differences in the differentiation capacity of
preadipocytes in obesity had not been assessed before. The similarity of MZ concordant co-twins in
our study suggested a strong genetic component in the regulation of adipocyte number in adulthood.
In the hypertrophic obesity group of our study, even as the discordant twins acquired more fat, their
total adipocyte number stayed in a comparative level or even decreased compared with their leaner
co-twins, but in the hyperplastic group, the obese co-twins had acquired more cells than their leaner
counterparts. Our study thus proposes that some individuals are able to respond to long-term energy
excess with hyperplasia, while others predominantly react by hypertrophy. This difference could be
a factor behind different metabolic outcomes of obesity. Acquired obesity in the present study was
characterized in particular by a reduction in small adipocytes. Although it is generally regarded that
small adipocytes are more insulin sensitive, data on their decreased amount or causal role in the
development of metabolic derangements in obesity is controversial (227).
Regarding the metabolically healthy-obesity phenotype, smaller adipocytes have been reported in
omental adipose tissue of morbidly obese but insulin sensitive individuals (14) as well as in
individuals characterized as “metabolically healthy” obese (224), without insulin resistance or any
other features of metabolic syndrome (410). Adipocyte size distribution in these studies was
measured in visceral and subcutaneous abdominal surgery samples (14, 410). McLaughlin et al. have
reported larger mean adipocyte size in subcutaneous adipose tissue of both overweight and obese
insulin-sensitive and insulin-resistant humans, challenging the idea of the relationship between
adipocyte volume and insulin resistance. Contrary to the expectations, the small-to-large adipocyte
ratio was higher in the insulin-resistance group, suggesting that the insulin resistant obese had more
small cells than the insulin sensitive obese individuals (227). The study also presented with 2–3-fold
increase in the expression of genes encoding markers of adipocyte differentiation. Together, the
findings could suggest an impaired adipocyte differentiation by the arrest of development in the very
small adipocytes toward fully mature cells in insulin resistant obese individuals, explaining the
larger ratio of small cells in insulin resistant individuals (227). It could be thus postulated that the
insulin sensitive obese individuals who have better adipocyte differentiation from very small cells
to mature ones and thus adipose tissue storage capacity, would be protected from the adverse effects
of ectopic fat accumulation. However, in study I of this thesis, based on the extreme similarity of
MZ twins in their total adipocyte cell count even in the obese state, the adipocyte differentiation
capacity seems to be determined by genes. Thus, the obese who develop insulin resistance may not
have enough preadipocytes for differentiation to start with, or the differentiation capacity of the cells
may be lower than in the more healthy subjects, and these factors may be determined by genes. Our
study did not assess the large and small fat cell pools in relation to insulin sensitivity or
mitochondrial function, but a significant general correlation was observed between these variables.
In article I, increased adipocyte volume in the obese twins was associated with an impaired
mitochondrial function and downregulation of gene expression pathways in lipid handling and
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steroid metabolism, structural changes in the cell membranes, DNA damage as well as higher cell
death and inflammation. These features associated with the development of metabolic disturbances
in obesity. Our hypothesis, based on the results of the pathway-analyses in study I of this thesis and
backed up by the other three studies is that downregulation of mitochondrial biogenesis is associated
with disturbances in adipocyte lipid handling and fatty acid oxidation. Increased lipid load by obesity
and the decreased fatty acid oxidation in mitochondria lead to the accumulation of unoxidized FFA
and intermediary metabolites like monomethyl BCAAs in adipocytes (444). Disruptions in the
adipocyte mitochondrial function have indeed been shown to lead to enhanced lipid deposition in
the cell (445) in such amounts that the ROS production was increased, leading to ER stress and
increased FFA spillover to ectopic sites (65, 243, 256). In line with these studies our results suggest
that the stressed mitochondria release more ROS, which leads to adipocyte stress and the expression
of inflammatory genes and the secretion of inflammatory cytokines. Apart from nuclear-related
changes in the adipocyte membrane plasticity, mitochondria control the synthesis of the
phospholipids of the cell surface (153), a process which can be influenced by low mitochondrial
function. The cell membrane changes result in the recruitment of macrophages into adipose tissue
(19) and finally to the crown-like inflammatory structures around extra-large cells, adipose tissue
cell death and enhanced inflammation. Inflammatory cytokines in turn can harm mitochondria,
decrease mitochondrial biogenesis and the function of the OXPHOS system. Thus, once initiated,
the changes seen in obese dysfunctional adipose tissue may be a vicious circle.
Indeed, already previously a study from our group has associated obesity with membrane lipid
alterations in adipocytes and suggested that these alterations trigger the recruitment of inflammatory
cells to the adipose tissue (19). We have also shown that inflammatory pathways were upregulated
and mitochondrial BCAA-catabolism, cell differentiation and energy metabolism pathways
downregulated in obesity in twins (262). These findings are also in line with a previous study of an
inflammatory profile in large adipocytes (231). Certain individual interesting genes also emerged.
We (430), and previously others (231) observed that adipocyte hypertrophy was linked to the
increased expression of palladin (PALLD), which is a cytoskeletal protein working in adhesion and
migration of the cells. Another gene, the function of which was related to cell-to cell interactions,
membrane modifications and actin cytoskeleton organization (446), was moesin (MSN). Indeed, it
has been proposed that in obesity, there is an active reorganization of the adipose tissue structure,
specifically visible in its gene expression patterns (352). Moesin was also important for apoptosis
(447) and oxidative stress (448). We also found PUMA (BBC3), which induces mitochondrial
membrane permeabilization and thus apoptosis in the cell (449). Inflammatory genes were well
presented with MIF, PKAR2B, RNF125 and PLA2G4A correlating strongest with the adipocyte
volume. We also observed downregulation of CIDEA, an important mediator of lipolysis (450) and
triglyceride deposition in the adipocytes (451). The downregulation of CIDEA in adipose tissue has
been suggested to contribute to the ectopic lipid accumulation (451).
In study III (437), the main finding was that adipocyte hypertrophy was negatively correlated to the
expression of various oxidative and metabolic-related pathways in mitochondria, speaking for an
important assocciation of adipocyte size to mitochondrial function in the cell. Our study on reduced
expression of oxidative pathways and reduced levels of the subunits of the OXPHOS system verified
a general downregulation of OXPHOS subunits in obesity, correlating with general adipocyte size.
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However, we did not assess the reduction of mitochondria-related pathways and OXPHOS protein
levels separately in the small or large adipocytes of the tissue. A study of Yin et al 2014 found no
differences between the obese and lean individuals in the respiratory capacities of small and large
adipocytes (10). Fisher et al 2015 suggested that small and large adipocytes would not be different
in their  oxidative capacity per  se,  but  generally all  adipocytes  from an obese or  a  lean individual
would have the same oxidative profile, the metabolic profile affected by obesity itself (235). This
would suggest that adipocyte volume as a single measure might not be an independent marker of the
oxidative status of the cell. Based on the controversial findings, the relationship of adipocyte
hypertrophy and mitochondrial respiratory activity will probably need more studies.
As adipocyte size has been linked to adipocyte cell death (208) rather than overall obesity, and
suggested to be the main factor contributing to the inflammatory macrophage infiltration in adipose
tissue in mice (208), it could be plausible that adipocyte volume is a marker of the dysfunction of
the  tissue,  at  least  in  mice.  In  humans,  adipocyte  hypertrophy  has  been  linked  to  the  increased
secretion of inflammatory proteins, enhanced lipolysis in adipose tissue and decreased insulin-
induced glucose uptake (452), all factors that are related to the development of insulin resistance.
Transcriptomic profiles of separated adipocytes demonstrated that large adipocytes express higher
levels of inflammatory genes than small adipocytes (231). Adipocyte volume as a measure is
however  always  linked  to  the  accumulation  of  total  body  fat  and  is  also  affected  by  sex  (223).
Adipogenic capacity is affected by sex and adipose tissue depot. Adipose precursor cells have
distinct patterns of gene expression, differentiation potential, and response to environmental effects
depending on their depot and the sex of the individual (220). Arner et al showed that in the obese
range of the adipocyte size, adipocyte volume may also be a biased measure. The relationship
between adipocyte size and body fat mass is curvilinear and reaches a plateau at certain fat cell sizes
in both men and women (453). When adipocyte volume reaches its maximal size, the excess fat
starts to accumulate to ectopic sites. Near the maximal volume of the cell the adipocyte size does
not anymore increase linearly, but approaches a plateau, and the volume thus no longer presents the
real metabolic state of the tissue (441). There may also be differences between men and women in
reaching this adipocyte hypertrophy plateau and thus difference in adipocyte hyperplastic capacity,
as suggested in the meta-analysis by Laforest et al 2015. In their study, it was noted that men are
more prone to hypertrophy of adipocytes, reaching the adipocyte size plateau at lower BMI values
(25kg/m2) than women (35kg/m2). Also omental adipocyte size has been shown to be 20% smaller
than subcutaneous adipocyte size in women, while in men there is no difference in these measures
(454). Arner et al were also able to show, that subjects with larger adipocyte volume than predicted
by the curve of increasing adipocyte hypertrophy, had lower rates of adipogenesis and that
adipogenesis correlated negatively to adipocyte hypertrophy, when adjusted with the predicted
volume at a given body fat mass (453). Despite all this, it has still been unclear, to which extent an
individual can acquire additional fat cells in adulthood. Most studies done related to adipocyte
hypertrophy and hyperplasia are cross-sectional, and in short-term weight increase, no significant
increase in adipocyte number has been observed (455). However, it seems that fat cell number at
least does not decrease in adulthood, even following long-term weight loss (120).
While definitive cause and consequence- determinations have not been made, a general assumption
is  that  problems in adipose tissue in obesity precede the metabolic  problems in other  organs and
whole body. It is interesting however, that the relationship of adipocyte size and the development of
the metabolic problems of obesity doesn’t seem to be linear either. Different individuals develop
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metabolic complications of obesity at different adipocyte hypertrophy levels. Taking into account
both adipocyte volume and hyperplasia – a morphology value, suggested by Arner et al (453) ─
could indeed be a better predictor of metabolic problems. It has been suggested that individuals with
adipocyte hypertrophy are less capable of storing fat in their adipocytes than individuals with
capacity to adipocyte hyperplasia (362) and that the reduced adipose tissue storing capacity in
hypertrophic, but not in hyperplastic obesity would enhance ectopic lipid accumulation and related
problems (362). In humans, adipose tissue cellularity has been connected to the inflammatory and
metabolic status of adipose tissue (46). Metabolically normal obese individuals have been shown to
have elevated levels of proadipogenic factors such as Wnt signaling regulator Dapper (456) and
increased lipid droplet protein levels (Perilipin, Cidea, FSP27), suggesting an improved adipose
tissue hyperplastic capacity and function compared to metabolically compromised individuals. In a
recent study, adipocyte morphology predicted the outcomes of improvement in insulin sensitivity in
weight loss, distinguishing the individuals that had the largest improvements in their insulin
sensitivity – those with the hypertrophic but not hyperplastic obesity phenotype (457). Interestingly,
adipocyte morphology in this study was not associated with the amount of weight loss but rather to
its outcomes. The calculation of morphology might be important in determining, which patients are
at highest risk of problems related to obesity and would best benefit from weight reduction therapies
(457).
In study I of this thesis, we showed that based on adipocyte size and number in whole body, twins
could be divided into hyperplastic and hypertrophic groups - a form of morphology value – where
hypertrophic twins clearly had a worsened metabolic profile compared to the hyperplastic group.
Early detection of individuals that are most prone to obesity-related complications would be a great
health benefit. No differences in adipocyte number between the obese and the lean MZ concordant
co-twins, but an increase in the number of cells in the obese co-twins of the hyperplastic group,
suggested that the adipocyte number and thus possibly also the hyperplastic capacity is genetically
determined. This raises questions on an early detection of different adipose tissue cellularity
phenotypes in obesity. However, if the genetic background predisposes an individual to a certain
adipose tissue hypertrophic and hyperplastic capacity, the increase in adipocyte volume and the
metabolic complications that arise after excessive fat accumulation seem to be caused by acquired
obesity, confirmed by comparing the obese and the lean co-twins in our study.
It  is  interesting,  however,  that  while  many  studies  have  used  the  mean  fat  cell  diameter  in  their
analyses, this approach may miss the very small and the very large adipocytes and the
subpopulations of the cells, because by conventional collagenase digestion and imaging methods,
very small adipocytes may not be recognized and large adipocytes may break before analysis. Cell
flux analyzers and an osmium staining are some alternatives for this. An interesting question for
future analyses is, if adipose tissue expansion leads to different subpopulations or different small-to
large cell ratios and if these factors have an effect on the metabolic profile of adipose tissue.
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7.3. Liver fat content as determinant of metabolic health in acquired
obesity
In study II we showed that liver fat content and adipose tissue hyperplastic capacity may distinguish
the obese individuals prone to the metabolic complications of obesity. The twin-setting gave the
study the possibility of discerning acquired influences behind the metabolically healthy obesity
(MHO) –phenomenon. In this study, it became evident that the twins could be divided into two
metabolically different groups according to the amount of their liver fat. In group 2, in which the
obese co-twins had significantly elevated liver fat content compared with their leaner counterparts,
the obese twins exhibited a typical response to obesity - marked insulin resistance, dyslipidaemia,
disturbed responses to OGTT, higher blood pressure, downregulated mitochondrial and upregulated
inflammatory transcript pathways in SAT compared with the obese twins of the healthier group 1.
Adipocyte size increased in both groups, but more in the metabolically unhealthy group 2. The
groups 1 and 2 did not differ for overall fatness. What was remarkable in the study was that all the
clinical values in twins were still within the normal range. This suggests that the changes seen in
metabolically unhealthy obesity occur already early, before clinically observed complications, and
that increase in the liver fat content is a central marker in this aspect.
Already some years previously it was noticed that not all obese individuals develop the metabolic
and inflammatory changes normally seen in obesity. It was thus suggested that the fat distribution
in body composition and the individual function of adipose tissue might be more important
determinants of metabolic well-being than body fat mass (2, 14, 16). Earlier studies had established
a relationship with excess liver fat and worsening of the metabolic profile (16, 397), especially the
increase in insulin resistance (397, 458). Fatty liver had also been associated with the features of
metabolic syndrome independent of obesity (459) and suggested to explain why some but not all
obese individuals were prone to insulin resistance and the metabolic complications of obesity – and
also why even some lean individuals develop these problems (382). Fittingly, in our present study,
particularly the AUC during OGTT in the obese twins in the “metabolically unhealthy” group 2 was
affected. Also, the obese twins in the group 2 had significantly more intra-abdominal fat, liver fat
and larger adipocyte volume, as well as increased circulating hs-CRP levels and decreased
adiponectin levels. On gene expression level an increase in chronic inflammatory response pathway,
decrease in adipogenesis and decrease in mitochondrial oxidative functions were recorded. We had
previously associated increased inflammation and decreased expression of mitochondrial pathways
to acquired obesity (262, 460), but in this new study, we show that these changes are especially
related to the obese with increased liver fat in group 2. The increased response of insulin secretion,
other worsened metabolic parameters, as well as the transcriptional changes already at the early
stages of obesity in young otherwise healthy twins, indicated that the metabolic problems caused by
acquired  obesity  are  detectable  already  much  before  the  clinically  significant  type  2  DM  or
metabolic disease criteria are filled.
Overfeeding with a high-fat high-glucose diet increased weight by 9%, but liver fat content with 2-
3 fold in normal healthy subjects (380).Weight loss in turn decreases liver fat amount (381).  Study
II of this thesis however demonstrated, with MZ obesity-discordant twins, that the accumulation of
liver fat varies among obese individuals, independent of genetic effects. Indeed, it is interesting that
an increase in the amount of liver fat (382), as well as the increase in adipocyte size (441) is not
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linearly related to increases in body fat mass. Furthermore, in lipodystrophies individuals with little
subcutaneous fat exhibit fatty liver (461). These notions back up the hypothesis, that compromised
expandability of subcutaneous adipose tissue leads to visceral, liver and ectopic fat accumulation
and to metabolic problems (17, 18, 462). Our study suggests that decreased mitochondrial fat and
amino acid oxidation in SAT are associated with increased liver fat accumulation and that these
associations are caused by acquired obesity. Also in study II, the adipocyte differentiation pathway
was downregulated and adipocyte number decreased in the obese co-twins of group 2. As
mitochondria are vital in adipocyte differentiation (463), these two phenomena may be linked.  Thus,
we suggest that the reduction in mitochondrial biogenesis in addition to the low level of the
remodeling capacity of SAT enhance liver fat accumulation. Accumulating liver fat distinguishes
between metabolic health and disease in obesity. Moreover, adipocyte size may play a role in this.
21% of known variation in liver fat could be explained by adipocyte size alone and increased
adipocyte size was associated with the liver fat accumulation independent of other causes (464). The
interesting results in study I of the thesis, where the metabolically unhealthier twins with disturbed
metabolic parameters and increased liver fat content were present in the group that had increased
adipocyte volume but only little hyperplasia in their tissue, also backs up the hypothesis that the
adipose tissue expandability and liver fat amount are central markers for the metabolic well-being
in obesity.
Studies have shown that the levels of Acetyl-CoA and ATP, the main substrates for lipolysis (157)
and de novo lipogenesis (252) in adipocytes, are reduced if mitochondrial metabolism is
compromised.  In  our  study,  the  subjects  were  measured  after  an  overnight  fast,  in  a  state  with
preferential lipolysis. As expected, we did not observe differences in the transcripts of the
triacylglycerol synthesis pathway. The situation however might be different postprandially. It has
also been demonstrated that increased capacity in adipose tissue for lipogenesis might protect the
metabolically unhealthy obese from the problems related to weight gain (465), also speaking for the
importance of adipose tissue remodeling capacity in obesity.
Generally  it  has  been  thought  that  at  least  increased  visceral  fat  is  metabolically  harmful  for  the
body, and some studies have shown that insulin sensitive obese individuals have only little visceral
fat (12, 350). In contrast, a study by Magkos, Fabbrini et al reported that increased total adiposity
without increase in liver fat is not associated with metabolic problems of obesity (466) and also that
intrahepatic fat, but not visceral fat, is linked to the metabolic abnormalities of obesity (396). This
notion was supported by another study from the same laboratory, where surgical removal of omental
fat did not improve insulin sensitivity in obese adults (351). However, in another study both intra-
abdominal and liver fat independently of each other explained variation in serum TG, HDL
cholesterol, insulin concentrations and hepatic insulin sensitivity, supporting the idea that both fat
depots are important predictors for the components of the metabolic syndrome. (467). It may be
possible that both visceral and liver fat indeed do contribute to the metabolic dysfunction state in
obesity, and this needs more studies.
In most, but not all obese subjects, obesity is associated with marked changes in the secretory profile
of adipose tissue and its macrophages with a resulting low-grade inflammatory state (299).
Samocha-Bonet et al presented in a review that one hallmark of the metabolically healthy obesity is
a favourable plasma inflammatory profile compared with the metabolically unhealthy individuals
(408). In our study, inflammatory pathways in SAT were upregulated and also circulatory
93
inflammation markers elevated in the obese twins of the unhealthier group 2 compared with the
obese in the healthy group 1. On the one hand, macrophage infiltration in visceral adipose tissue has
been found to be significantly increased in insulin-resistant versus insulin-sensitive obese
individuals, with no differences in SAT macrophage amounts (14). In another study on the other
hand, obese women with high liver fat content had increased levels of inflammatory transcription
factors in their SAT and higher circulating plasma lipid levels than their obese peers without liver
fat (399). An intriguing fact is that also subjects with rapid weight loss after bariatric surgery (468)
can have inflammatory monocytes in their circulation. This would suggest that rapid changes in
either direction in body fat content may support an inflammatory response. It is still not known if
individuals with rapid onset of obesity are more prone to inflammation in their adipose tissue.
Our hypothesis was that low mitochondrial biogenesis and function precedes complications like
increased cell death and inflammation in obese subcutaneous adipose tissue. The low adipogenic-
and expandability capacity of the tissue may be genetic, but the causality between this and the low
mitochondrial function is not yet known. However, both decreased mitochondrial function and low
hyperplastic  capacity  of  SAT  are  thought  to  lead  to  liver  fat  accumulation  and  to  a  worsened
metabolic profile in obesity. The process may however be a vicious circle. A study by Vernochet et
al showed that inducing decreased expression and enzymatic activity of complex I, III, and IV
proteins of the electron transport chain in mice, led to adipocyte death and inflammation in white
adipose tissue (469), backing up the idea of mitochondria behind the inflammatory changes in
adipose tissue. While it is still not established whether inflammation or mitochondrial function are
first compromised in unhealthy obesity, our study, in line with previous studies (262) suggests that
these two may be interconnected in a way that mitochondrial dysfunction may lead to decreased
energy levels in the cell, apoptosis, cell death and in consequence, to the development of the
inflammatory milieu. This inflammatory milieu in turn may also affect mitochondrial biogenesis. In
humans, use of anti-inflammatory medications has been reported to improve glycaemic control in
type 2 diabetes and obesity (470). Future treatments for the metabolically unhealthy obese might
thus include agents that improve mitochondrial function, reduce or inhibit the formation of
inflammation in adipose tissue or enhance the differentiation or expansion potential of preadipocytes
in adipose tissue.
Interestingly, it is possible that the MHO stage may not be a lasting phenotype, but will change with
age or with advanced obesity (418, 419). The hyperplastic capacity of adipose tissue has been shown
to be reduced with age (471-473) and this might be one factor behind the change. In our study
however, the two metabolically distinct groups were of the same age and had similar age of onset of
obesity discordance. Weight differences between the groups were similar. An interesting fact
however is that a given weight difference may have different metabolic effects depending on where
in the distribution of the BMI a twin pair is located. A 5 unit increase from the BMI of 23 may have
different metabolic effects than a 5 unit increase from the BMI 27. However, it may be speculated
that in different individuals, depending on their adipose tissue buffering capacity, the metabolically
unhealthy obesity is reached at different levels and/or different ages of obesity. In the general
population a liver fat percentage of 5% has been considered a cutoff for “normal” liver fat content.
All of the lean twins in our healthy MZ twin cohort do fall below this 5% cutoff. However, while
the difference in liver fat content between the obese and the lean co-twins in group 2 is striking, not
all “obese” co-twins have liver fat values exceeding 5%. It is of note that the differences between
the co-twins are significant and consistent, suggesting that even in obesity that has lasted for a
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relatively short time (6±years), the early changes of unwanted metabolism are striking, especially in
the metabolically unhealthy obesity group.
Based on our findings, we conclude that the MHO phenotype was characterised by the maintenance
of mitochondrial function and absence of inflammation in SAT. The metabolically unhealthy obese
in turn had fatty livers and the hallmarks of the metabolic syndrome, impaired glucose tolerance and
dyslipidaemia. Also, fitting to study I, the adipose tissue of the MHO individuals was characterised
by the capability for both hypertrophy and hyperplasia of adipocytes with increasing BMI.
7.4. Mitochondrial oxidative pathway downregulation in acquired
obesity in adipose tissue and adipocytes and the metabolic
complications in whole body
The novel findings in studies III and IV were the downregulation of mitochondria-related pathways,
their upstream regulators, mtDNA amount, mtDNA transcripts and OXPHOS protein subunit levels.
Downregulation was shown in a wide spectrum in many analyses of mitochondria in adipose tissue
in article III, and the transcriptional downregulation confirmed in adipocytes in article IV. Many of
the differentially expressed transcripts were also differentially methylated between the co-twins in
adipose tissue and the methylation in general inversely correlated with the expression of the gene,
possibly suggesting a role of epigenetic modification in the reduction of mitochondrial biogenesis
in obesity.  Reduction of the mitochondrial oxidative metabolism in SAT correlated with whole body
insulin resistance and inflammation in adipose tissue and adipocytes. We were also among the first
to show a downregulation of OXPHOS subunits of complexes I and IV in obese adipose tissue, a
finding which was then published also by Fischer et al 2015. We also confirmed reduced levels of
mitochondrial encoded subunits of complexes and III and V, as well as nuclear-encoded complex
II. We used a unique study design of rare young and clinically healthy MZ weight-discordant twin
pairs, which enabled us to control for sex, age, and genetic background between the lean and the
obese groups. Thus, we could establish these mitochondria-related changes as a consequence of
acquired obesity, not genetic influence. Our findings provided evidence that a substantial
insufficiency of mitochondrial biogenesis in SAT in acquired obesity occurs already prior to the
onset of clinical metabolic complications.
The mitochondrial OXPHOS system is unique because it is encoded by both the nuclear and the
mitochondrial genomes. In study III we showed that mtDNA amount, its transcript levels, OXPHOS
subunit levels as well as nuclear genes encoding OXPHOS protein subunits are reduced in the obese
co-twins suggesting a major downregulation in mitochondrial oxidative ATP production and
catabolic functions in SAT in acquired obesity. Previous studies by us (262) and by others (251)
have found similar reduction of mtDNA amount in SAT in obesity, but the generalized reduction of
mitochondrial protein subunit levels and the downregulation of oxidative metabolism have not been
reported previously. The OXPHOS complexes partially encoded by mtDNA were downregulated
without significant decrease of mitochondrial mass (shown by the ratio of mitochondrial membrane
protein porin to cytosolic β-tubulin), showing that the mitochondrial OXPHOS subunit levels are
reduced in SAT both within the cell and within the mitochondria in the obese co-twins. The
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translation machinery of mitochondria was shown to be downregulated by both the nuclear-encoded
and the mitochondrial-encoded genes as the rRNAs and MRPs were both downregulated in the obese
co-twins.  Our  findings  are  in  agreement  with  earlier  studies  on  the  subject,  where  in  two  mouse
models of obesity and type 2 diabetes a low abundance of MRP transcripts and reduced
mitochondrial biogenesis in inguinal adipose tissue was observed (67), as well as in a rat model for
late-onset obesity, where a truncation of MRPS26 was associated with the accumulation of visceral
fat and insulin sensitivity (474).
Pathway analysis of nuclear-encoded mitochondrial transcripts revealed reduced expression of
mitochondrial oxidative pathways, including FAO, TCA cycle, ketogenesis, ketolysis, and BCAA
degradation in the obese co-twins. These mitochondrial pathways correlated negatively with several
clinical parameters including all adiposity measurements, insulin resistance and inflammation, and
positively with adiponectin levels. Mitochondrial metabolism and the development of type 2
diabetes have been thought to be linked (475). Studies in adipocytes or adipose tissue in human
subjects are however few. 3T3-L1 mouse preadipocytes have been exposed to high glucose and fatty
acids, resulting in signs of mitochondrial dysfunction by decreased mitochondrial size, membrane
potential and downregulation of the master regulator PGC-1α (476). High-fat feeding has resulted
in decrease of PGC-1α expression, impaired glucose homeostasis and reduced mtDNA content in
rats (105). However, another study on mouse adipocytes did not register a relationship between
mitochondrial biogenesis and glucose homeostasis (477). In studies III and IV we however confirm
that reduced mitochondrial biogenesis, at least at the transcript level, is related to disturbances in
insulin sensitivity both in human adipocytes and adipose tissue. What was remarkable was that the
observed changes occurred already at a relatively young age, in twins that were clinically healthy,
but where still a slight but significant worsening in the metabolic parameters in the obese co-twins
could be observed.
We have previously reported downregulation of transcripts related to BCAA catabolism in SAT in
obesity (262). Also in studies III and IV we observed the downregulation of BCAA catabolism in
obesity and in study II  of  this  thesis  for  the first  time showed it  to  be restricted to the unhealthy
group 2, with increased liver fat and other metabolic abnormalities. This was a new and important
finding. BCAAs, especially leucine, stimulate adipocyte growth and differentiation through mTOR
pathway (478).  Decreased adipose BCAA catabolism has been shown to lead to a  rise  in  plasma
BCAA levels in obesity (165) and associated with the development of type 2 diabetes (264).
However, it is still controversial if the observed rise in plasma BCAAs is a cause or a marker of the
development of insulin resistance and metabolic complications of obesity (167). A study by Su et al
showed that the intermediary metabolites of BCAAs (monomethyl BCAAs) accumulate in adipose
tissue in obesity, and that this accumulation is linked to the obesity-related insulin resistance (444).
The accumulation of the metabolites occurs if adipose tissue mitochondrial oxidation is impaired.
Weight loss after gastric bypass has shown to increase the levels of BCAA oxidation enzymes in
adipose tissue and as a result, the circulating BCAA levels decline (166). In our study of MZ twins,
plasma levels of BCAAs were indeed elevated, while the pathway analyses indicated a decreased
catabolism of BCAAs in mitochondria (479). Adipose tissue however is not the only site of BCAA
catabolism, and also temporal differences in the catabolism rate are not known. The elevation of the
circulating BCAAs in obesity has been known since the 1960s, but the results (262) from recent
years for the first time link this to the decreased catabolism of BCAAs in mitochondria of obese
individuals. In study II of the thesis, a significant decrease in the expression of the genes required
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for this BCAA catabolism was present only in the adipose tissue of the obese twins of group 2, with
increased amounts of liver fat and with metabolic impairments.
While mitochondria are essential in adipogenesis (6) and the same transcription factors are needed
for both mitochondrial biogenesis and adipogenesis (133, 145), it is reasonable to think that defects
in each of these factors might affect the other. Indeed, while both reduced hyperplastic capacity and
reduced mitochondrial function of adipose tissue seem to be linked to the metabolic problems of
obesity, the dysfunction and low amount of mitochondria in adipocytes could be suggested to be one
factor behind the hyperplastic capacity itself. This could play a role in determining at which stage
the adipose tissue dysfunction in obesity emerges and whom it concerns at the individual level,
possibly distinguishing the metabolically healthy and unhealthy obese persons from each other. It is
not known if the mitochondrial oxidative capacity is genetic and the hyperplastic capacity of adipose
tissue  thus  also  genetic,  or  the  other  way  around.  Based  on  study  I,  we  showed  that  at  least  the
regulation of adipocyte number in twins seems to be genetic. Concerning the analyses in this issue
of the metabolically healthy and unhealthy obesity, the protein level analyses on 7 twin pairs and
transcriptomics in 12 twin pairs was not sufficient to separate metabolically healthy or unhealthy
twin pairs, because not enough samples were available from the unhealthy pairs. The reduction in
mitochondrial oxidative metabolism in adipose tissue and adipocytes seems to be caused by the
acquired obesity, based on the difference in mitochondrial biogenesis between the obese and the
lean identical co-twins. For future analyses an interesting question to consider is: are there
interindividual differences in the oxidative metabolism of mitochondria in an energy overload state,
prompting some obese persons to develop complications and “the metabolically unhealthy obesity”
earlier than others?
An interesting new finding in article III was the relationship of DNA-methylation to mitochondrial
biogenesis. Our data showed that 74 out of the 222 differentially expressed genes targeting
mitochondria were differentially methylated between the co-twins, and in general inversely
correlated with gene expression. We also showed that three CpG sites in the body of mitochondrial
regulator PGC-1α were hypermethylated in the obese co-twins. This hypermethylation correlated
negatively with gene expression, suggesting that methylation may reduce the transcription of the
gene. Previously it has been reported that compared with the lean controls, obese patients with type
2 diabetes have a PGC-1α promotor hypermethylation in SAT (480). Thus, it is possible that
epigenetic modifications in certain nuclear genes associate with the decrease in mitochondrial
biogenesis in SAT in acquired obesity. In obesity-discordant MZ twins, such an effect seems to be
acquired, independent of the genetic background.
In article IV the downregulation of mitochondria-related pathways and upregulation of
inflammatory pathways was observed in two independent analyses, both in examining the most
significantly differentially expressed genes and their pathways between the co-twins as well as by
comparing the genes that were consistently up- or downregulated between the co-twins. The small
number of twins in article IV could however be a reason for the smaller amount of significant
transcripts in adipocytes after multiple correction than was observed in article III for adipose tissue.
Our results however reinforce the idea that the transcriptional changes seen in obesity are both
consistent and involving many networks and many cells, most importantly the adipocytes
themselves. We could also demonstrate the reduction of the mitochondrial mtDNA transcripts in
adipocytes as well as a reduction in the expression of the main mitochondrial regulator PGC-1α. In
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unrelated individuals, Western Blot of OXPHOS proteins subunit levels were reduced in the obese
individuals in complexes CI (NDUFB8) and CIII (CIII-core 2 subunit) compared to cytoskeletal
actin.  The levels  of  complex IV and V subunits  were lower but  non-significantly so in the obese
individuals. The low significance in the results was probably due to the very small sample size.
Compared to mitochondrial membrane protein porin, CI subunit NDUFB8 was shown to be reduced
in the obese individuals and levels of CIV subunit COX2 tended to be reduced. According to these
data it seems plausible that in adipocytes and adipose tissue there is a shutdown of mitochondrial
biogenesis and/or reduction of the levels of mitochondrial components in the obese state and that
similar  pathways are responsible  for  this.  However,  the studies  on protein levels  may need to be
confirmed with larger data. It remains to be established whether there is a difference in the
mitochondrial component levels, function and biogenesis in the small and large cells from obese
compared with lean persons. Pre-adipocytes differentiated from human subcutaneous adipose tissue
of obese persons have been shown to have lower oxygen consumption rates after beta-adrenergic
stimulation compared with pre-adipocytes from lean subjects (68). However, in other studies no
difference has been found between the oxidative capacities of small and large adipocytes (10, 235).
Further studies on cultured adipocytes seem to be a relevant approach to clarify this issue.
Strong upregulated inflammatory gene expression emerged both in adipocytes and adipose tissue of
the obese co-twins. Obese adipose tissue is characterized by accumulation of macrophages and other
immune cells (228, 481). The current literature however seems to be controversial whether or not
the inflammatory component seen in obese adipose tissue originates from the inflammatory cells of
the tissue or adipocytes themselves. Some studies suggest that SVF cells and infiltrating
macrophages are responsible for the cytokine secretion in adipose tissue (310, 482). Adipocytes are
known secretors of IL-6, IL-8, TNF-α and other inflammatory adipokines (311), and exhibit immune
cell-like functions that trigger CD4 T cell inflammation in the tissue, independent of infiltrating
macrophages (483). Macrophage-derived TNF-α has also been shown to upregulate the expression
of inflammatory genes like ICAM-1, IL-6 and MCP-1 in adipocytes (299, 309) and in obese
adipocytes, inflammatory gene expression is shown to be increased (231). Adipocytes also express
high levels of inflammatory CD14 as well as other previously thought to be macrophage-markers
such as CD68 (484) on their surfaces, speaking for their role in the mediation of inflammation. The
disagreement seems to be whether or not the adipocyte-derived factors have clinical significance
compared to the macrophage and other inflammatory cell-derived ones. A study involving
arteriovenous examination of TNF-α flow from human subcutaneous adipose tissue showed that
TNF-α is not secreted and mobilized systemically, but IL-6 instead is (485). However, the technique
used in the study may not have been able to detect low levels of TNF-α. Also, the amount of
macrophage-derived or adipocyte-derived inflammatory factors may differ. The upregulation of
inflammatory genes and pathways in adipocytes of the obese co-twins of our study IV suggests that
adipocytes do contribute to the inflammatory milieu of obese adipose tissue, and that obesity induces
changes also in the adipocyte-derived inflammatory component of obesity.
One hypothesis behind the observed changes could be that in an excess energy state, the cell shuts
down its mitochondria while producing energy more easily and effectively in cytoplasm by
anaerobic glycolysis. The mitochondria of adipocytes however may be stressed from excess free
fatty acids and energy substrates, releasing more free radicals that derange the cell metabolism,
enhance inflammation and mitochondrial function and finally, the rate of oxidative energy
production further declines. How the mitochondrial respiration is affected in the metabolically
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healthy and unhealthy subjects  will  be an interesting issue of  future studies.  Adipose tissue is  an
especially challenging research material because there are few mitochondria in adipocytes and thus
a low mitochondrial yield in white adipose tissue. The same is true for adipose tissue protein yield,
RNA yield and many other methods. This could be one reason behind such few publications in the
issue.
In summary, in articles III and IV we observed strong evidence for association between acquired
obesity and downregulation of mitochondrial biogenesis both in adipose tissue and adipocytes. In
adipose tissue, the genes important for mitochondria may also be epigenetically regulated.
Importantly, we showed that the downregulation of mitochondrial biogenesis and oxidative
metabolic pathways in subcutaneous adipose tissue and adipocytes is a phenomenon in obesity that
on transcript level is associated with mild metabolic alterations, insulin resistance, and low-grade
inflammation.
Figure 21
Figure 21A: Adipose tissue dysfunction and reduced mitochondrial biogenesis in obesity
Figure 21A: Excess energy intake leads to hypertrophied adipocytes. This is thought to lead to the
accumulation of inflammatory cells in the tissue. However, the mechanisms have been unclear.
Increased secretion of inflammatory markers and increased FFA release from hypertrophied
adipocytes prevents preadipocyte recruitment and impairs lipid and glucose metabolism in adipose
tissue and consequently, in the whole body. Intestines and other organs like liver, muscle and
pancreas accumulate lipids and this leads to their impaired function and insulin resistance.
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Figure 21B: Adipocyte dysfunction in obesity
Figure 21B: Excess FFA and adipocyte stress -> reduced mitochondrial biogenesis? Hypertrophied
adipocyte lipid droplet may endorse endoplasmic reticulum stress, oxidative stress and stress for
the adipocyte cell membrane. Adipocytes secrete increased levels of inflammatory markers. The
changes in the adipocyte membrane structure due to cell stress and expansion recruit the
macrophages and other inflammatory cells in the tissue. When adipocyte is not able to store all the
incoming fat, part of the fat is flown to ectopic sites. FFA release from the cell increases contributing
to hyperlipidemia in obesity. In mitochondria, fatty acid oxidation and BCAA oxidation become
impaired with the overflow of FFAs. Increased amounts of FFAs that cannot be oxidized are also
released as intermediary metabolites that can disturb the function of the cell. Markers of oxidative
stress and ROS production from mitochondria increase. This in turn increases the adipocyte stress
reaction. Nuclear expression of mitochondria-related regulator genes and pathways is
downregulated. Whether this is due to the adipocyte stress reaction or the cell shuts down its
mitochondria in favor of oxygen-independent metabolism of FFAs, or from other reasons, is still
unknown and may be a vicious circle.
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Figure 21C: Reduced mitochondrial biogenesis in adipose tissue and adipocytes in
obesity
Figure 21C: Reduced expression of the main mitochondrial regulator PGC-1α (qRT-PCR) and
reduced expression of the main mitochondrial pathways; oxidative phosphorylation (OXPHOS),
fatty acid β-oxidation (FAO), branched-chain amino acid oxidation (BCAA) in adipose tissue and
adipocytes. Reduced levels of mitochondrial mtDNA (adipose tissue), mtDNA transcripts (rRNAs
and mRNAs), the nuclear expression of mitochondrial ribosomal protein subunits (MRPS, MRPL)
and levels of oxidative phosphorylation (OXPHOS) protein subunits in obesity (Western Blot) in
adipose tissue and adipocytes.
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7.5. Methodological considerations
Because of the extreme rarity of the MZ twin pairs, the study samples were small. A different amount
of twin pairs were available for the four sub-studies and their laboratory experiments. Also, our
sample of concordant pairs in studies I and IV (n=5) is also small. Study IV included 14 discordant
twin pairs, from which enough sample for adipocyte extraction was available. Results obtained from
them may thus be interpreted with caution. Further, there was a small but statistically significant
difference in the BMI of  the weight-concordant  pairs  in  articles  I  and IV.  We also did not  report
results on DZ pairs, and formal calculations of heritability cannot therefore be performed. Analyses
on adipose tissue included also stromal vascular fraction (SVF) cells, which contribute to the results.
Adipocyte extraction and purification protocol for separating adipocytes from the tissue matrix is a
common and widely used protocol, but the exact level of adipocyte purification from SVF cells
could not be assessed. Assessing the cell size was done by calculating the cell diameters with a light
microscope, by which the populations of very small cells may have remained undetected. Thus, a
lower limit for the adipocyte cell size (20 μm) was set and the populations of very small cells were
not addressed in these studies. Transcriptomic data may not fully reflect the real protein levels and
further their activity in the tissue and thus additional studies on protein level may be needed to
confirm  part  of  the  results.  Data  analyses  and  the  analysis  of  PCR  experiments  were  done  with
different methods between the sub-studies, however all yielding biologically significant and
consistent results. Because of the cross-sectional nature of the study, we cannot make cause and
effect conclusions. The nature of the study data is also associative. However, our findings were in
line with many previous studies on obesity and adipose tissue.
7.6. Future prospects
The results  of  the thesis  as  a  whole suggest  that  the metabolic  complications of  obesity could be
reduced by enhancing mitochondrial amount or function in white adipose tissue and that this might
improve whole-body insulin sensitivity. Also, diminishing inflammation or enhancing the
preadipocyte capacity for differentiation in subcutaneous adipose tissue might prove to be beneficial.
Some pharmacological interventions that have already been tested to treat insulin resistance might
be of use also in obesity. Thiazolidinediones (TZDs), which are PPARγ agonists, have been used to
treat patients with type 2 diabetes, because they improve the insulin sensitivity of the white adipose
tissue. However, there is evidence that TZDs also increase mitochondrial biogenesis, function and
content. Furthermore, TZDs improve palmitate-stimulated oxidative capacity in adipocytes in mice,
and upregulate mitochondria-associated genes and PGC-1α, one of the main mitochondrial
regulators (66, 142). In humans, evidence of this connection has also been shown in vitro (103) as
well as in vivo where treatment with pioglitazone improved mitochondrial biogenesis in diabetic
patients by stimulating the expression of genes important for fatty acid oxidation and PGC-1α, as
well as by increased mitochondrial copy number (486). Thus, increasing mitochondrial biogenesis
by thiazolidinediones might be of use in obesity too. However, for example rosiglitazone from the
same group of compounds has caused cardiovascular problems like heart failure and death - reasons
why it was withdrawn from use. In humans, mitochondrial antioxidant treatment with vitamin D
(487), vitamin E (488), vitamin C, N-acetylcysteine, glutathione and coenzyme Q10, may improve
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insulin sensitivity in diabetic patients (489). R-alpha-lipoic acid (LA) and acetyl-L-carnitine (ALC)
have been shown to enhance mitochondrial function in cultured mouse adipocytes (490). However,
other good-quality human studies have failed to show the association between antioxidants and
improved metabolism (491, 492). Chemical uncouplers that dissipate the energy produced by
mitochondria as heat (493) have been tried as dietary drugs. Weight losses were recorded (494), but
this uncontrolled thermogenesis also lead to fatal increases in body temperature (495) and the idea
was discontinued. So far, exercise and caloric restriction remain established improvers of
mitochondrial biogenesis and function. NAD+-dependent deacetylase sirtuin 1 (SIRT1) is suggested
to be the principal modulator of caloric restriction (496, 497). Resveratrol and other small molecule
compounds that activate SIRT1 have increased mitochondrial respiration as well as produced an
improvement in insulin sensitivity in mouse studies (498, 499).
In rodent studies, knocking out inflammatory genes prevented the development of type 2 diabetes
(304, 500) and in humans, the use of anti-inflammatory medications improves glycaemic control in
type 2 diabetes and obesity (470). Thus, preventing inflammation in adipose tissue might prove to
be beneficial in treating and preventing obesity-associated disorders. Inflammation in adipose tissue
has been targeted for example by amlexanox, an inhibitor of the innate immune system, which
improves insulin sensitivity, promotes weight loss and reduces WAT inflammation and hepatic
steatosis in mice (501). Amlexanox has also been in phase II clinical trials for obese patients with
type 2 diabetes (US National Library of Medicine, ClinicalTrials.gov,
http://www.clinicaltrials.gov/ct2/show/NCT01842282, 2013) and an improvement in HOMA–index
has been preliminary reported (502). Other ways of targeting inflammation have included for
example immunoneutralization of TNF with etanercept, which lowered systemic inflammatory
markers in obese diabetic patients (503), and interventions that block macrophage chemotaxis into
WAT, which had insulin-sensitizing effects (504). Treatment of mice with an inhibitor of the pro-
inflammatory eicosanoid leukotriene B4 (LTB4) resulted in an anti-inflammatory phenotype and
increased insulin sensitivity as well as decreased hepatic steatosis (505). Of all the compounds
mentioned, the LTB4-targeted compound has been validated in one human clinical trial in healthy
males (506); however, not in the context of obesity and type 2 diabetes.
Some of the newest discoveries in adipose tissue-related diseases suggest that in addition to
increasing mitochondrial biogenesis and function or decreasing inflammation, novel therapeutic
approaches may include adipokine-based therapies, promotion of white fat beiging (browning), and
modulation of fibrosis and the oxidative state of the adipose tissue. Adipokine-related therapies like
administration of leptin-recombinants or activation of adipokine receptors have recently harboured
some new discoveries. Fibroblast growth factor 21 (FGF21), bone morphogenic protein 7 (BMP7)
and interleukin 1 beta (IL-1 β) are under research for their use in the treatment of obesity. Brown fat
activation and white adipose tissue “beiging” might also prove beneficial, because BAT is important
in cold- and diet-induced thermogenesis and dissipates energy to generate heat by uncoupling
mitochondrial respiration (507). Beige cells, mingled in white adipose tissue, have been in mouse
studies shown to have potential to be activated and their amount increased by cold exposure, exercise
training and possibly by specific pharmacological compounds (508). However, the compounds tried
for BAT activation and WAT browning have suffered from various side effects like hypertension
and cardiovascular effects (44). In mice studies, hypoxia-inducible factor HIF1α inhibitors have
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increased energy expenditure and reduced body weight as well as adipose tissue fibrosis and
inflammation (509). Angiogenesis inhibitors in obese adipose tissue have also reduced body weight
(510) or prevented the development of obesity in mice (511, 512). However, healthy angiogenesis
is also needed for energy expenditure (280, 284) and it is thus unclear if increasing or decreasing
adipose tissue angiogenesis has beneficial effects on treating obesity.
Obesity is a multisystemic and multifactorial disease. Personalized therapies will be needed to treat
obese with different metabolic status and to administrer drugs locally (44). Our data supports the
findings that increasing mitochondrial metabolism, decreasing inflammation and enhancing
preadipocyte differentiation capacity in adipose tissue will have beneficial effects in the treatment
of obesity.
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8. SUMMARY AND CONCLUSIONS
Background and aims
Obesity with its overload of adipose tissue is a health risk predisposing to many chronic diseases
such as type 2 diabetes, cardiovascular diseases and cancers. Positive energy balance leading to
accumulation of excess body fat and its complications often arises from a complex interplay of
hereditary and environmental factors. Disentangling these two is difficult. The aim of this thesis was
to study, in a unique group of young weight-discordant MZ-twins allowing the control of genetic
factors, the biological pathways in adipose tissue that lead to the development of metabolic
complications in obesity. We studied adipose tissue enlargement, one of the primary features in
acquired obesity, by assessing adipocyte hypertrophy and hyperplasia and their effects on adipose
tissue and whole body metabolic health. We investigated the mechanisms and pathways maintaining
the “metabolically healthy obesity” phenomenon, where despite increased fat mass, certain obese
individuals stay free from the metabolic complications of obesity. Based on the mitochondria-related
findings we further concentrated on mitochondrial biogenesis in obese adipose tissue and its
relationship to metabolic health in adipose tissue and in whole body by assessing the expression of
mitochondria-related nuclear-encoded transcripts, mitochondrial DNA amount, mitochondrial DNA
transcript levels and mitochondrial respiratory chain protein levels in obese adipose tissue and their
associations with adipose tissue metabolism. Finally, we aimed at clarifying the status of
mitochondrial biogenesis in purified adipocyte cells of the obese co-twins.
Subjects and methods
Altogether 26 rare BMI-discordant (intra-pair difference (Δ) in BMI 3-10 kg/m2 and 14 concordant
(ΔBMI 0-2 kg/m2) young healthy adult (22-36 years) monozygotic (MZ) twin pairs were studied.
The subjects were recruited from FinnTwin16 1975-1979 (FinnTwin16, n=2 839) and FinnTwin12
1983-1987 (FinnTwin12, n=2 578) registries. The twins underwent an extensive study protocol with
measurements of body composition, body fat distribution of subcutaneous and visceral adipose
tissue and liver fat, oral glucose tolerance test (OGTT), lipids, adipokines, hs-CRP and other
metabolic measurements from blood samples, adipose tissue biopsies under the umbilicus and many
questionnaires and interviews. Total RNA from both adipose tissue and adipocytes was extracted
and transcriptomics analyses of fat in whole human genome were performed. Differences between
the obese and the lean co-twins in pathways related to adipocyte morphology, metabolic
disturbances, mitochondrial function and inflammation in subcutaneous adipose tissue were
analysed.  Adipocytes  were  photographed  and  calculated  and  the  diameters  of  the  cells  were
measured. Total DNA from adipose tissue samples was extracted and the amount of mitochondrial
mtDNA determined. MtDNA-encoded transcript levels were measured in adipose tissue and
adipocytes. Western blot of total adipose tissue and adipocyte lysates were done for oxidative
phosphorylation (OXPHOS) complexes I, II, III, IV and V. Clinical measures and blood sample data
were correlated with gene expression results.
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Results
In  the  BMI-discordant MZ pairs, the obese co-twins had significantly more fat mass in their
subcutaneous, visceral and liver fat depots and larger adipocytes, higher hs-CRP and plasma leptin
levels, lower plasma adiponectin levels and presented with more insulin resistance than their leaner
co-twins. However, the discordant twins resembled each other for adipocyte number, speaking for a
tight genetic regulation of this measure. The BMI-concordant MZ pairs were similar in their body
composition, fat distribution, as well as adipocyte size and number. In the discordant pairs, increased
adipocyte size (hypertrophy) was related to downregulation of mitochondria-related gene expression
pathways and increased cell death. Obese co-twins who had a more hypertrophic obesity profile
(larger adipocytes in their adipose tissue) with a decreased cell count had, compared with their leaner
co-twins, significantly more liver fat, insulin resistance, inflammation and LDL cholesterol. In
contrast, obese co-twins who had less hypertrophy but an increased adipocyte count compared with
their lean co-twins (hyperplastic obesity) were indistinguishable from their leaner counterparts in
most metabolic measures. This indicates that the hypertrophic vs. hyperplastic obesity are
metabolically different.
We were also able to divide the BMI-discordant twin pairs into two metabolic groups based on the
amount of their liver fat. In half of the pairs the obese co-twins had as low liver fat percentages as
their leaner co-twin, whereas in the other group the obese co-twins had a strikingly increased liver
fat content compared with their leaner co-twins. The obese in the latter group were metabolically
unhealthier than their peers in the first group despite the fact that these two groups did not differ in
overall fatness. Gene expression analyses in adipose tissue revealed that the expression of
mitochondrial pathways and chronic inflammatory response were increased, and adipocyte
differentiation downregulated in the obese compared with the lean co-twin in the high liver fat group
with metabolic problems, but not in the low-liver fat group.
Further analyses on mitochondrial biogenesis using adipose tissue of the twins revealed that a
significant proportion of the genes that were significantly differentially expressed between the co-
twins were related to mitochondria. Mitochondria-related pathways were downregulated in the
obese co-twins, both for nuclear-encoded mitochondria-related genes gas well as for mitochondria-
encoded transcripts. The subunit levels of mitochondrial oxidative phosphorylation (OXPHOS)
protein complexes were reduced in the obese co-twins´ adipose tissue indicating a reduction of
mitochondrial oxidative metabolism. In adipocytes of the obese co-twins, we observed similar
transcriptional downregulation of mitochondrial biogenesis as in the whole adipose tissue.
Conclusions
Studies  I  and  II  of  this  thesis  revealed  two  distinct  metabolic  groups  of  obesity,  independent  of
genetic effects, with adipocyte hypertrophy/reduced hyperplasia and increased liver fat
distinguishing the metabolically high risk group from the “healthy obese” group. While adipocyte
number  in  the  body  seemed  to  have  a  strong  genetic  component,  it  may  be  postulated  that  the
capacity to adipoce hyperplasia may be genetically determined. Increased adipocyte size and
decreased number associated with the worsening of the metabolic profile in obesity with gene
expression changes indicating downregulation of mitochondrial pathways.
106
We further found that, independent of genetic effects, there were distinct differences in the gene
expression profiles between the obese and the lean MZ co-twins, with downregulation of
mitochondrial biogenesis and up-regulation of inflammatory pathways playing central roles in the
metabolic complications of acquired obesity. In study II these changes associated specifically to the
obese twins with high liver fat content.
In study III the mitochondrial downregulation was evidenced by reduced expression of nuclear-
encoded mitochondria-related genes and pathways, their upstream regulators, mitochondrial copy-
number, mtDNA transcripts and finally on reduced OXPHOS protein levels. The same pattern of
downregulation of mitochondrial gene expression pathways and genes and upregulation of
inflammation was observed also in isolated adipocyte cells. In both studies, the mitochondrial
downregulation associated with the metabolic disturbances of obesity.
The transcriptional changes observed in acquired obesity and their associations to whole-body
metabolism could already be seen at  a  young age in clinically healthy twins with relatively short
history of obesity, emphasizing the need for early detection and intervention of this disease and the
detection of persons most vulnerable to the complications of obesity. According to the study, liver
fat content and the capacity of adipose tissue to hyperplasia seem to be clear determinants of
metabolic  health  in  acquired  obesity.  The  results  of  my  thesis  as  a  whole  suggest  that  obesity-
associated metabolic disturbances might be halted by improving mitochondrial activity in adipose
tissue. While medications to stimulate mitochondria in humans are still lacking, caloric restriction
and exercise thus far seem to be the only ways to improve mitochondrial function in adipose tissue,
according to literature. Changes in lifestyle benefit all obese persons, because it is not know if the
observed “healthy” obesity can over time turn to unhealthy obesity.
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9. YHTEENVETO JA JOHTOPÄÄTÖKSET (in Finnish)
Tausta ja tavoitteet
Lihavuus eli liiallinen rasvakudos on merkittävä terveysriski ja aiheuttaa monia aineenvaihdunnan
häiriöitä, kuten insuliiniresistenssiä, tyypin 2 diabetesta, sydänsairauksia, hyperlipidemiaa ja
syöpää. Lihomiseen ja rasvakudoksen laajentumiseen liittyvät metaboliset ongelmat johtuvat usein
geenien ja ympäristötekijöiden monimutkaisesta yhteisvaikutuksesta. Näiden tekijöiden erottaminen
toisistaan on vaikeaa. Lihavuuden syistä ei ole edelleenkään kokonaisvaltaista ymmärrystä. Viime
vuosina on kuitenkin huomattu, että rasvakudos ja erityisesti sen solujen energiatehtaiden eli
mitokondrioiden toiminta on keskeisessä asemassa koko kehon aineenvaihdunnassa ja mahdollisesti
myös lihavuuden kehittymisessä. Väitöskirjassani tutkin nuorten terveiden identtisten kaksosten
rasvakudoksen varhaisia aineenvaihduntamuutoksia ja insuliiniresistenssiä hankitussa lihavuudessa.
Tässä asetelmassa voidaan ainutlaatuisesti erottaa geeneistä ja ympäristötekijöistä johtuvat
lihavuuden seuraukset.
Rasvakudos laajenee joko kasvattaen rasvasolujensa kokoa tai niiden lukumäärää. Väitöskirjassani
tutkin, miten rasvasolujen koko ja määrä muuttuvat lihotessa ja mikä on näiden muutosten yhteys
kehon koostumukseen, aineenvaihduntaan ja rasvakudoksen geenien ilmenemiseen.
Tarkastelemme, mitkä geenien ilmenemisreitit ja muut kehon aineenvaihdunnan muutokset
erottavat aineenvaihdunnaltaan terveitä lihavia sairaista lihavista. Saatujen tulosten pohjalta
tutkimme tarkemmin rasvakudoksen mitokondrioiden ja niiden hengitysketjun toimintaa ja tämän
yhteyttä kehon aineenvaihduntaan sekä selvitimme, millainen on mitokondrioiden toiminta
rasvakudoksen rasvasoluissa.
Aineisto ja menetelmät
Tutkimuksen aineistona käytettiin identtisiä, mutta eripainoisia suomalaisia kaksosia. Aineisto on
harvinainen, sillä geeneiltään identtisiä mutta painoiltaan erilaisia kaksospareja on vähän.
Tutkimukseen osallistui yhteensä 26 diskordanttia eli eripainoista (ΔBMI 3-10 kg/m2)  ja  14
konkordanttia eli samanpainoista (ΔBMI 0-2 kg/m2) nuorta suomalaista identtistä kaksosparia (ikä
22–36 vuotta). Tutkittavat kaksoset olivat FinnTwin16- 1975–1979 (FinnTwin16, n=2 839) ja
FinnTwin 12- 1983–1987 (FinnTwin12, n=2 578) kohorteista löydettyjä vapaaehtoisia.
Kaksosparien kehonkoostumus, kehon rasvajakauma ja maksan rasva mitattiin. Veren paastosokeri,
insuliini, rasvat, adipokiinit ja tulehdusmerkkiaineet määritettiin. Vatsan alueen ihonalaiskudoksesta
kerättiin näytteet rasvakudoksesta. Rasvakudosnäytteistä sekä niiden rasvasoluista eristettiin RNA
ja DNA. Kaksosparin geenien ilmentymistä ja sen eroja tutkittiin koko genomin laajuisesti (20 000
geeniä, Affymetrix U133 Plus 2.0 sirut) ja analysoitiin geenireittejä liittyen lihavuudessa
havaittuihin metabolisiin häiriöihin, mitokondriotoimintaan, rasvasolujen määrään, kokoon ja
rasvakudoksen tulehdukseen. Rasvakudoksen mitokondrio-DNA ja sen kopiolukumäärä
määritettiin. Mitokondrion oman genomin ilmentymisen tasoja mitattiin qRT-PCR:llä ja
mitokondrion hengitysketjun proteiinien tasot määritettiin Western Blotilla. Rasvakudosnäytteiden
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rasvasolut valokuvattiin ja niiden koot ja muoto määritettiin. Useat kyselyt ja haastattelut kuuluivat
lisäksi kaksosten perustutkimuksiin.
Tulokset
Eripainoisten kaksosparien lihavilla kaksosilla oli huomattavasti enemmän rasvamassaa, ihonalais-
ja sisäelinrasvaa sekä maksan rasvaa kuin laihoilla kaksosilla. Lihavat olivat metabolisesti
epäterveempiä; heidän insuliinitasonsa ja veren rasvatasonsa olivat korkeammat, rasvasolun
kokonsa suurempi ja tulehdusmerkkiaineensa korkeammalla tasolla kuin laihoilla kaksosilla.
Lihavien kaksosten kehon rasvasolumäärä ei kuitenkaan eronnut laihojen kaksosten vastaavasta,
viitaten siihen, että rasvakudoksen solumäärä on vahvasti geneettistä perua. Verrokkipareina
toimineilla konkordanteilla eli samanpainoisilla kaksosilla kaikki aineenvaihdunnan mitat ja veren
tulehdus- ja muiden merkkiaineiden pitoisuudet olivat toistensa kaltaisia. Näyttää siis, että havaitut
lihotessa tapahtuvat muutokset rasvasolujen lukumäärää mukaan lukematta ovat lihavuuden ja
ympäristötekijöiden aikaansaamia, eivät geneettistä perua.
Suuri rasvasolukoko ja toisaalta koko kehon pieni rasvasolumäärä yhdistyivät lihavuuden
aiheuttamiin aineenvaihdunnan ongelmiin, insuliiniresistenssiin ja geenireitteihin, jotka liittyivät
heikentyneeseen mitokondrioiden toimintaan ja lisääntyneeseen rasvakudoksen solukuolemaan.
Kaksoset voitiin jakaa kahteen eri ryhmään sen perusteella, oliko heidän rasvasolujensa lukumäärä
laihaan kaksososapuoleen suhteutettuna suurempi vai pienempi tai yhtä suuri. Ne lihavat kaksoset,
joiden rasvasolumäärä laihaan pariinsa verraten oli suurempi (hyperplastinen eli rasvasolumäärää
lisäävä lihavuus) olivat metabolisesti selvästi terveempiä kuin ne parit, joilla lihavalla
kokonaisrasvasolumäärä oli pieni (hypertrofinen eli rasvasolun kokoa kasvattava lihavuus).
Totesimme myös, että maksan rasvapitoisuuden perusteella oli mahdollista erottaa kaksi
metabolisesti erilaista lihavuustyyppiä, joissa toisessa lihavat eivät näyttäneen kärsivän lihavuuden
liitännäisongelmista. Tässä ”metabolisesti terveen” lihavuuden – ryhmässä lihavilla maksan
rasvapitoisuus oli pieni ja yhdistyi mitokondrioiden korkeaan aktiivisuuteen ja vähäiseen
rasvakudoksen tulehdukseen. Kolmannessa väitöskirjan osatyössä näytimme, että lihavuuteen
liittyvä mitokondrioiden huono toiminta ilmenee niin solun tuman koodaamien mitokondrioon
liittyvien geenien luennan vähentymisenä, mitokondrion kopiolukumäärän pienenemisenä kuin
mitokondrion itsensä koodaamien geenien luennan ja mitokondrion hengitysketjun proteiinien
vähentyneinä määrinä. Nämä tulokset yhdistyivät koko kehon insuliiniresistenssiin ja matalan tason
tulehdukseen. Väitöskirjan neljännessä osatyössä samanlainen mitokondriotoiminnan
vähentyminen oli nähtävissä rasvakudoksen rasvasoluissa.
Johtopäätökset
Väitöskirjani tuloksissa voitiin sekä rasvasolujen suuren koon ja pienen määrän (artikkeli I) että
maksan rasvan (artikkeli II) avulla erottaa kaksi lihavuuden ryhmää, jossa alhaisen maksan
rasvapitoisuuden ja hyvän rasvakudoksen laajentumiskapasiteetin omaavat lihavat näyttivät olevan
suojatumpia rasvan kertymisen aiheuttamilta komplikaatioilta. Nuorten terveiden ja identtisten
mutta eripainoisten kaksosten rasvakudoksen geenien ilmentymisessä todettiin lihavalla kaksosella
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mitokondrioiden toiminnan vähentyminen ja tulehduksen lisääntyminen. Nämä tulokset yhdistyivät
koko kehon huonontuneeseen aineenvaihduntaan ja insuliiniresistenssiin.
Mitokondrioiden vähentynyt toiminta näkyi rasvakudoksessa sekä tuman geenien että mitokondrion
omien geenien luennassa ja todettiin myös mitokondrion hengitysketjun proteiinien vähentyneinä
määrinä artikkelissa III. Artikkelissa IV sama mitokondriotoiminnan väheneminen, tulehduksen
lisääntyminen sekä mitokondrion hengitysketjun proteiinien vähentyneet määrät osoitettiin myös
rasvasoluissa. Tulosten perusteella rasvakudos ja sen rasvasolut sekä rasvasolujen mitokondrioiden
toiminta näyttävät olevan tärkeä tekijä lihavuuden aiheuttamien ongelmien synnyssä.
Merkittävää tutkimuksessa oli, että geenien ilmentymisen muutokset olivat näkyvissä jo lihavuuden
kestettyä vasta verrattain lyhyen aikaa kliinisesti terveillä nuorilla kaksosilla. Koska hankitun
lihavuuden aiheuttamat haitalliset muutokset kehon geenien luennassa ja aineenvaihdunnassa
ilmenevät nähtävästi jo hyvin aikaisin, on tärkeää pyrkiä tunnistamaan muutokset ja epäterveelle
lihavuudelle alttiit henkilöt jo varhain. Maksan rasvapitoisuuden perusteella voidaan mahdollisesti
erottaa lihavat, jotka ovat alttiita lihomisen aiheuttamille komplikaatioille ja insuliiniresistenssille.
Väitöskirjani tuloksien perusteella lihavuuteen yhdistyviä metabolisia häiriöitä voitaisiin
todennäköisesti estää lisäämällä ja parantamalla mitokondrioiden toimintaa rasvakudoksessa. Koska
mitokondrioiden toimintaa lisäävien lääkkeiden kehitys on vasta varhaisvaiheessa, liikunta ja
energiansaannin rajoittaminen ovat tähän mennessä kirjallisuuden perusteella ainoita toimivia
keinoja parantaa mitokondrioiden toimintaa rasvakudoksessa. Elämäntapamuutokset hyödyttävät
kaikkia lihavuudesta kärsiviä, sillä tutkimuksessa havaittu ”terve” lihavuus saattaa myös ajan myötä
kehittyä epäterveeksi lihavuudeksi.
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